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Riassunto 
 
Sviluppo di nano-piattaforme a base di peptidi per il trasporto di farmaci 
antitumorali 
Il cancro è la seconda causa di morte nel mondo. Negli Stati Uniti, la mortalità per 
cancro è superata solo da quella per patologie cardiache, ed è la causa di circa 1 
morte su 4. Il cancro quindi costituisce un enorme onere economico per le autorità 
sanitarie e per la società. Inoltre, notevoli sforzi sono dedicati al miglioramento dei 
trattamenti clinici al fine di alleviare le sofferenze del paziente. 
Le nanotecnologie offrono importanti opportunità per il trattamento e la diagnosi di 
numerose patologie ad elevato impatto sociale tra cui il cancro. La nanomedicina 
costituisce una delle più importanti applicazioni e dei più promettenti sviluppi delle 
nanotecnologie. Essa si propone, infatti, l'obiettivo di realizzare un monitoraggio 
completo e continuo dell'organismo umano e di contribuire alla tutela della salute, 
lavorando a livello molecolare per ottenere benefici medici e clinici mediante l'utilizzo 
di nanostrutture. L’utilizzo delle nanostrutture presenta, infatti, notevoli vantaggi in 
quanto i volumi ridotti e le aumentate superfici di contatto, permettono un 
miglioramento delle interazioni fra i nanomateriali e le cellule. Attualmente, le 
applicazioni più promettenti riguardano: l'ottimizzazione delle tecnologie già esistenti; 
lo sviluppo di nuovi sistemi multifunzionali per la diagnosi delle malattie e la 
somministrazione mirata dei farmaci; e la produzione di materiali sempre più 
affidabili, specializzati e riproducibili, che permettono un aumento dell'efficacia e una 
riduzione dei costi. 
In tale contesto, l'internalizzazione di molecole attive e/o farmaci costituisce un 
problema importante della “teranostica”. Il termine “teranostica” è stato recentemente 
introdotto per descrivere composti con la capacità di svolgere contemporaneamente 
un'azione diagnostica e terapeutica, che, quindi, possano essere applicati in 
medicina per entrambi gli scopi al fine di ottenere terapie personalizzate.  
La membrana plasmatica rappresenta il principale ostacolo per l’internalizzazione dei 
farmaci, in quanto costituisce una barriera tra l’ambiente intracellulare ed 
extracellulare. Il successo delle nuove strategie per la teranostica si basa sullo 
sviluppo di nanosistemi (come liposomi, nanoparticelle e dendrimeri) in grado di 
migliorare l'indice terapeutico di molecole biologicamente attive favorendone 
l’internalizzazione. 
La produzione e la caratterizzazione di nanosistemi, che possano agire da vettori 
efficienti per la distribuzione mirata dei farmaci, è fondamentale al fine di 
circoscrivere l’effetto biologico della terapia a una determinata tipologia di cellule, 
migliorandone l’efficacia e riducendone la tossicità sistemica. 
L’obiettivo di questo progetto di tesi consiste nello sviluppo di nuove nano-
piattaforme di natura peptidica, che mediano il trasporto specifico alla cellula 
tumorale e il rilascio intracellulare di molecole bioattive, utilizzabili sia nel settore 
diagnostico che terapeutico. Quest’obiettivo è stato raggiunto, modificando la 
superficie di diversi nanosistemi con peptidi per il trasporto e per il targeting. I peptidi 
per il trasporto hanno la funzione di aumentare l’internalizzazione favorendo 
meccanismi di internalizzazione diversi dall’endocitosi. I peptidi per il targeting 
hanno la funzione di direzionare il nanosistema al sito desiderato sfruttando la loro 
capacità di legarsi a specifici recettori espressi maggiormente sulla superficie delle 
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cellule tumorali.  
I peptidi per il trasporto svolgono un ruolo chiave nel processo di internalizzazione 
perché, le membrane biologiche costituiscono un ostacolo fondamentale dal 
momento che questa barriera è difficilmente attraversabile da parte di molte 
molecole farmacologicamente attive. I Cell Penetrating Peptides (CPPs) sono 
peptidi carichi positivamente in grado di trasportare macromolecole attraverso la 
membrana plasmatica in modo efficiente ed il loro utilizzo si è notevolmente diffuso 
negli ultimi anni. Il loro principale problema è costituito dal meccanismo di 
traslocazione che implica essenzialmente un processo di endocitosi. Quindi, solo 
una piccola quantità della molecola cargo è in grado di sfuggire agli endosomi, dove 
avvengono le comuni reazioni di degradazione intracellulare e di raggiungere il sito 
di azione. È, quindi, necessario lo sviluppo di nuovi CPPs che utilizzino solo 
parzialmente il meccanismo endocitico, migliorando così le proprietà 
farmacocinetiche e farmacodinamiche, la distribuzione e localizzazione intracellulare 
e di conseguenza l’attività sito-specifica dei farmaci. 
In tale ambito, il gruppo di ricerca che mi ha seguito nel progetto di dottorato, ha 
identificato un peptide di origine virale (gH625) che deriva dalla glicoproteina gH 
presente sull’envelope del virus Herpes simplex di tipo I ed è in grado di attraversare 
le membrane cellulari. In particolare, gH625 interagisce con le membrane biologiche 
ed è coinvolto nel processo di fusione con la membrana della cellula bersaglio. Il 
peptide è ricco in residui idrofobici quali glicine, leucine ed alanine e residui 
aromatici quali triptofano e tirosine, che svolgono un ruolo cruciale per l’interazione e 
la destabilizzazione delle membrane. Il peptide assume una struttura ad elica 
anfipatica dove tutti i residui idrofobici sono localizzati su una faccia e quelli idrofilici 
sull’altra. La faccia idrofobica della molecola svolge un ruolo attivo nel processo di 
interazione e fusione con le membrane. L’interazione peptide-lipide è probabilmente 
mediata, inizialmente, dall’arginina presente all’estremità C-terminale, infatti quando 
tale residuo è mutato l’attività fusogenica del peptide risulta fortemente alterata. Il 
dominio idrofobico è coinvolto nelle fasi iniziali di perturbazione di membrana 
caratteristiche anche dell’infezione virale. L’internalizzazione di gH625 è 
probabilmente associata alla sua capacità di interagire con i fosfolipidi di membrana 
e di formare una struttura α-elica transiente che destabilizza temporaneamente la 
membrana facilitandone l’inserzione e la traslocazione. Studi di internalizzazione 
hanno evidenziato che il peptide gH625 attraversa la membrana cellulare utilizzando 
in maniera preponderante meccanismi di traslocazione passiva, mostrando solo una 
parziale co-localizzazione con vescicole endosomiali, risultando quindi un ottimo 
candidato per il trasporto intracellulare di molecole bioattive.  
L’ostacolo principale all’utilizzo di nanosistemi funzionalizzati con gH625 è la 
mancanza di specificità. Per tale motivo in questo lavoro di tesi abbiamo associato i 
vantaggi dell’utilizzo di gH625 con i benefici derivanti dalla strategia di targeting 
attivo. Questa strategia si basa sul riconoscimento molecolare di marcatori tumorali 
sovra-espressi sulle cellule tumorali; in particolare, è stato scelto il recettore del 
fattore di crescita epidermico, sovra-espresso in diversi tipi di tumori. Abbiamo 
utilizzato il peptide legante il recettore del fattore di crescita epidermico (EGBP), 
precedentemente identificato.  
Lo scopo del progetto di dottorato è stato lo sviluppo di una nuova nano-piattaforma 
opportunamente funzionalizzata con gH625 e il peptide EGB, che possa essere 
utilizzata come sistema innovativo nel campo della teranostica. In particolare, il 
lavoro di tesi è stato incentrato sulla coniugazione dei peptidi a nanostrutture di 
diversa natura, sulla loro caratterizzazione chimico-fisica (dimensioni, potenziale 
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zeta, efficienza di caricamento del farmaco e cinetica di rilascio) e sull’analisi 
dell’attività biologica (citotossicità, attività antitumorale, internalizzazione e destino 
intracellulare). I nanosistemi utilizzati sono: liposomi, nanoparticelle magnetiche e 
nanoparticelle di polistirene. La sfida di questo progetto è stata quella di unire i 
benefici chimici di questi nanosistemi al vantaggio associato all’utilizzo di peptidi per 
il delivery e peptidi per il targeting. 
Nanosistema: liposomi 
I liposomi sono nanostrutture vescicolari cave formate da uno o più doppi strati 
lipidici che delimitano all’interno un core idrofilico in cui possono essere 
disciolti/dispersi vari farmaci. Non sono tossici, né immunogenici, sono 
biodegradabili e di diametro compreso tra 50-500 nm. Più in dettaglio, possono 
trasportare diverse molecole, sia molecole idrosolubili, che si posizionano nel core 
idrofilico, sia molecole liposolubili, che si posizionano nel doppio strato fosfolipidico. I 
liposomi sono in grado di veicolare i farmaci all'interno delle cellule, riducendone la 
tossicità, modificandone la farmacocinetica e la biodistribuzione. Per questo motivo 
sono degli ottimi candidati per la veicolazione intracellulare di farmaci 
antineoplastici.  
La superficie dei liposomi può essere inoltre funzionalizzata con peptidi, che 
possono migliorarne l’internalizzazione, il targeting e quindi l’efficacia antitumorale 
del farmaco trasportato. La strategia sintetica utilizzata per funzionalizzare la 
superficie di liposomi con peptidi dipende dalla natura chimico-fisica dei peptidi. Per 
quelli idrofobici, quali gH625, è necessario effettuare il legame del peptide al 
liposoma preformato. Infatti, gH625 è un peptide idrofobico con elevata tendenza a 
localizzarsi nella porzione lipofilica; pertanto, per la preparazione dei liposomi 
funzionalizzati con gH625, il peptide è stato legato alla superficie dei liposomi 
preformati utilizzando la click-chemistry. L’ottenimento di liposomi bifunzionalizzati 
costituisce una sfida ancora maggiore, in quanto al fine di ottenere un nanosistema 
riproducibile, è necessario avere un preciso controllo sul rapporto molare tra i due 
peptidi utilizzati. A tale scopo il peptide targeting (EGBP) è stato derivatizzato con 
una componente lipidica in modo da poterlo utilizzare direttamente come 
componente nella preparazione dei liposomi.  
La caratterizzazione in vitro dei nanosistemi è stata effettuata parzialmente in 
Francia nei laboratori del Prof. Chourpa, e parzialmente a Napoli nei laboratori della 
Microtech della Dott.ssa Bonelli e nei laboratori della SUN del Prof. Caraglia. 
Durante la permanenza nei laboratori del Prof. Chourpa dell'Università di Tours, 
abbiamo preparato liposomi (costituiti da DOPG/DSPE-PEG), decorati sulla 
superficie con gH625 e caricati con il farmaco antitumorale mitoxantrone (MTX) al 
fine di analizzarne il meccanismo di internalizzazione. Abbiamo effettuato studi di 
citotossicità del nanosistema liposomiale e studi di uptake mediante tecniche di 
microscopia confocale, quali Confocal Spectral Imaging (CSI). 
La tecnica CSI permette di evidenziare anche piccolissime variazioni di fluorescenza 
del farmaco (nel nostro caso l’MTX) dovuti ai diversi micro-ambienti intracellulari in 
cui si viene a trovare. I risultati ottenuti mostrano chiaramente che la presenza di 
gH625 sulla superficie dei liposomi ne favorisce l’internalizzazione in cellule HeLa. 
Questo si correla bene con i dati di citotossicità; infatti, entro 4 ore, il liposoma 
funzionalizzato con gH625 (LMTX-gH625) è più attivo rispetto a quello non 
funzionalizzato (LMTX). Il peptide gH625 probabilmente induce una maggiore e più 
rapida internalizzazione, che potrebbe contribuire alla maggiore citotossicità di 
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LMTX-gH625 rispetto al LMTX. gH625 modifica, quindi, l’internalizzazione dei 
liposomi e di conseguenza il trasporto del farmaco alle cellule. 
Il successo dei trattamenti farmacologici è spesso ostacolato dalla comparsa della 
resistenza ai farmaci. La resistenza ai farmaci (MDR) rappresenta il principale 
meccanismo attraverso il quale molti tumori sviluppano resistenza al trattamento 
chemioterapico, e costituisce un notevole problema per il successo clinico. È, quindi, 
molto importante individuare strategie alternative per utilizzare i farmaci attualmente 
in commercio contro i tumori che sviluppano resistenza. A tale scopo, in 
collaborazione con la Microtech e con la SUN, abbiamo sviluppato liposomi con 
maggiori caratteristiche biomimetiche costituiti da fosfolipidi derivanti dalla soia, 
funzionalizzati con il PEG sulla superficie esterna e caricati con la doxorubicina 
(Doxo). Tali liposomi sono stati funzionalizzati con gH625 al fine di migliorarne 
l'efficacia antitumorale e superare i meccanismi di resistenza ai farmaci. Sono stati 
inizialmente effettuati studi di caratterizzazione chimico-fisica, successivamente 
studi di citotossicità e studi di internalizzazione mediante microscopia confocale. Gli 
studi di caratterizzazione chimico-fisica del nanosistema hanno rivelato un diametro 
di 140 nm con una distribuzione uniforme. Gli studi di inibizione della crescita sono 
stati effettuati sia su linee cellulari di carcinoma polmonare (A549) che sullo stesso 
tipo di cellule che però avevano sviluppato una doxo-resistenza (A549 Dx). Tali studi 
hanno evidenziato che la presenza di gH625 sulla superficie dei liposomi favorisce 
la loro azione su entrambe le linee cellulari con un aumento dell’inibizione della 
crescita cellulare specialmente nel caso delle cellule doxo-resistenti. Gli studi di 
internalizzazione mediante microscopia confocale dimostrano che la Doxo 
incapsulata nei liposomi funzionalizzati con gH625 entra nei nuclei delle cellule 
tumorali A549-Dx; questo risultato ci ha fatto ipotizzare che il peptide gH625 induce 
una maggiore e più rapida internalizzazione anche nelle cellule resistenti. Tale 
risultato è di fondamentale importanza perché gH625 potrebbe essere utilizzato per 
superare la resistenza ai farmaci.  
Infine, gH625 sebbene sia molto efficace nell’aumentare l’internalizzazione di diversi 
cargo, non presenta specificità, quindi parte del progetto è stata dedicata alla 
funzionalizzazione dei liposomi anche con il peptide per il targeting. In questo studio, 
ci siamo spostatidall’ultilizzo di liposomi non specifici funzionalizzati con gH625 a 
liposomi specifici diretti contro le cellule tumorali, coniugando sulla superficie dei 
liposomi il peptide EGB, specifico per il recettore del fattore di crescita epidermico 
(EGFR). Al fine di ottimizzare l'interazione del peptide EGB con il suo recettore, 
abbiamo utilizzato due diversi linker per coniugare il peptide al liposoma. Infatti, 
abbiamo sintetizzato l’EGBP con un piccolo distanziatore costituito da tre glicine e 
con una piccola porzione idrofilica costituita da PEG. L’EGBP è stato poi legato al 
colesterolo formando un componente lipidico che è stato utilizzato direttamente nella 
preparazione dei liposomi. 
La posizione del peptide sulla superficie dei liposomi è stata determinata mediante 
fluorescenza. In particolare, lo spettro di fluorescenza del triptofano presente sia nel 
peptide gH625 che nel peptide EGBP, ci ha permesso di ipotizzare la posizione 
relativa dei due peptidi sul liposoma. Infatti, il confronto tra l'intensità di fluorescenza 
dei liposomi funzionalizzati solo con gH625 e dei liposomi doppiamente 
funzionalizzati ha mostrato un aumento di intensità, che potrebbe essere attribuito 
all'esposizione dei triptofani sia di gH625 che dell’EGBP. Il confronto tra i due 
liposomi doppiamente funzionalizzati ha mostrato poi un aumento di intensità per 
quella con il linker idrofilico, indicando che, come previsto, il triptofano è più esposto 
e quindi il peptide è più disponibile per l’interazione con il recettore. L’analisi 
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dell’accumulo della Doxo contenuta nei liposomi bifunzionalizzati in cellule KB, che 
sovra-esprimono il recettore EGFR, mediante citometria a flusso, ha dimostrato un 
aumento di accumulo della doxorubicina rispetto al nanosistema senza il peptide 
targeting. Sono in corso ulteriori studi sull'attività e l’internalizzazione. 
In conclusione, sono stati evidenziati ulteriori dettagli sul meccanismo di 
internalizzazione promosso da gH625 che indicano chiaramente le potenzialità di 
gH625 per lo sviluppo di una nano-piattaforma da utilizzare per la terapia 
antitumorale, utile anche nel caso di tumori che sviluppano resistenza alla 
chemioterapia. 
Nanosistema: nanoparticelle supermagnetiche di ossido di ferro 
Un altro nanosistema di particolare interesse in campo teranostico, è costituito dalle 
nanoparticelle supermagnetiche di ossido di ferro (SPIONs). Le SPIONs offrono la 
possibilità di effettuare contemporaneamente diagnosi (agenti di contrasto nella 
risonanza magnetica nucleare) e terapia (se coniugate a farmaci). Dopo la 
somministrazione endovenosa, le SPIONs possono essere dirette in maniera 
specifica al sito tumorale grazie all’uso, anche combinato,dei seguenti meccanismi: 
I) applicazione di un campo magnetico al sito tumorale; II) sfruttamento dell’effetto di 
maggiore permeabilità e ritenzione (EPR), che si basa sulla maggiore permeabilità 
della vascolarizzazione tumorale e la mancanza di un efficace drenaggio da parte 
del sistema linfatico; III) internalizzazione delle nanoparticelle all'interno delle cellule 
tumorali. L’obiettivo di questo progetto è stato quello di sintetizzare nanoparticelle 
magnetiche e di funzionalizzarle con il peptide gH625 in modo da aumentarne 
l’internalizzazione. Ci siamo dedicati maggiormente alla messa a punto della 
strategia di funzionalizzazione con i CPPs, al fine di trovare il giusto compromesso 
tra la stabilità colloidale del nanosistema, la sua emivita nel sangue e l’efficace 
internalizzazione cellulare. Infatti, poco si conosce sulla densità/quantità ottimale di 
CPPs sulla superficie delle SPIONs necessaria per il trasporto attraverso le 
membrane delle cellule tumorali. Particolari difficoltà si riscontrano con sequenze 
peptidiche idrofobiche, come gH625, infatti un eccesso di peptide sulla superficie del 
nanosistema potrebbe ridurne la stabilità colloidale in mezzi acquosi e l’emivita in 
circolo. Per questo motivo, abbiamo posto la nostra attenzione sulla corretta 
concentrazione di gH625 con cui funzionalizzare il nanosistema. Abbiamo, 
successivamente effettuato misure di Dicroismo Circolare al fine di valutare la sua 
struttura secondaria quando è legato alle nanoparticelle. Dai dati si evince che la 
struttura elicoidale del peptide, alla concentrazione di 8x10-6 M, non è disturbata dal 
legame con le SPIONs. Un eccesso di peptide sulla superficie del nanosistema 
riduce la sua stabilità colloidale in mezzi acquosi e l’emivita in circolo. Così, è stato 
necessario ottimizzare diversi parametri importanti quali la concentrazione di gH625 
sulle SPIONs. Sono ora in corso ulteriori studi di caratterizzazione chimico-fisica del 
nanosistema funzionalizzato con gH625 e studi per valutare la capacità di gH625 di 
promuovere l’internalizzazione delle nanoparticelle magnetiche.  
Nanosistema: nanoparticelle di polistirene 
L’utilizzo di farmaci per le patologie neurologiche attualmente in via di 
sperimentazione, sono limitate dall’incapacità dell’agente terapeutico di attraversare 
efficientemente la barriera emato-encefalica (BBB). La BBB è una barriera dinamica 
e selettiva che protegge il sistema nervoso dall’invasione di sostanze e organismi 
indesiderati; ma rappresenta anche un notevole ostacolo da un punto di vista 
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terapeutico in quanto limita l’attraversamento e il rilascio dei farmaci nel loro sito di 
azione. Per questo motivo è fondamentale identificare e sviluppare un sistema che 
permetta un migliore rilascio del farmaco nei compartimenti del sistema nervoso. La 
maggior parte delle strategie in fase di sperimentazione che hanno avuto un grosso 
impatto terapeutico, come la microiniezione diretta, risultano troppo invasive in 
quanto danneggiano in maniera irreversibile la BBB. Particolare interesse è stato 
rivolto allo studio delle nanoparticelle di polistirene (NPs), funzionalizzate, per 
utilizzarle come sistemi modello per il trasporto di farmaci attraverso la barriera 
emato-encefalica. 
Sono stati condotti esperimenti di internalizzazione delle NPs, di diametro di 100 nm, 
opportunamente funzionalizzate con la sequenza gH625, su cellule dell’endotelio 
cerebrale (bEnd3). I risultati ottenuti dimostrano che la presenza, sulla superficie 
delle NPs di gH625 ne migliora ed in particolare ne modifica il meccanismo di 
internalizzazione. Infatti, le gH625-NPs sono poco presenti nei lisosomi in confronto 
a quelle non funzionalizzate. Inoltre, il loro movimento intracitoplasmatico risulta di 
tipo casuale e non direzionale, indicando una maggiore capacità di movimento 
perché non intrappolate nelle vescicole lisosomiali. Questi dati sono indicativi di un 
meccanismo passivo di internalizzazione e dimostrano che il nostro sistema, 
presenta delle caratteristiche ottimali, per il trasporto di molecole attraverso la 
barriera emato-encefalica e potrebbe essere utilizzato per la cura delle patologie del 
sistema nervoso centrale. 
Conclusioni 
In conclusione, abbiamo sviluppato una nano-piattaforma molto versatile 
caratterizzata dalla presenza di un nanosistema (liposoma, nanoparticelle 
magnetiche, nanoparticelle di polistirene), di un peptide per il delivery, di un peptide 
per il targeting e di un farmaco, che può essere sfruttata per ottenere specifiche 
terapie a seconda del peptide targeting e del farmaco utilizzati. 
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Summary 
 
Peptide Based Platforms for Cancer Drug Delivery 
Cancer remains one of main causes of death in humans, accounting for 8.2 milion 
deaths worldwide in 2012 [1]. Chemotherapy, the most widely used cancer therapy, 
is the most effective and potent strategy to treat malignant tumors, but has the 
disadvantage of not delivering the therapeutic agents only to tumor sites. In fact, 
current cancer treatments kill also normal cells and cause several cytotoxic effects in 
healthy tissues. Nanomedicine may allow the controlled release of drugs by 
biodegradation and self-regulation of nanomaterials in vitro and in vivo. 
Nanotechnologies are potentially effective for drug encapsulation, controllable self-
assembly, specificity and biocompatibility; moreover, they have the potential to 
overcome current chemotherapeutic barriers in cancer treatment, because of the 
unique nanoscale size and their distinctive bioeffects.  
The goal of this PhD project was to create a delivery tool, that transports the drug to 
the target cells not only with high efficacy, but also with minimal toxicity against 
normal cells and avoiding its degradation and entrapment in endosomes. The first 
part of this thesis was focused on the design of the strategies for the achievement of 
a toolbox easily to functionalize and on its obtainment. The second phase was the 
physico-chemical characterization of each selected nanosystem with particular 
attention to the size, zeta potential and drug loading and release. The third phase 
was to analyze in vitro the subcellular fate of the vectorized drug and the effect on 
the cells. 
Several nanosystems (liposomes, magnetic nanoparticles, polystyrene 
nanoparticles) were selected and functionalized with peptides both to enhance tumor 
targeting and facilitate intracellular uptake. 
In particular, we used a novel Cell Penetrating Peptide (namely, gH625) which is 
able to overcome the known limits of classic CPPs. In fact, gH625 is able to 
efficiently traverse biological membranes, promoting lipid-membrane reorganizing 
processes, such as fusion or pore formation and involving temporary membrane 
destabilization and subsequent reorganization; it is able to circumvent the 
endosomal entrapment either favouring the escape from the endosome or by directly 
translocating the drug across the membrane. 
In order to make the nanosystem cell and tissue specific, we have further 
functionalized the surface of the nanosystem with a targeting peptide. We exploited 
the EGB peptide, which recognizes the epidermal growth factor receptor (EGFR), a 
tyrosine kinase receptor overexpressed in several solid tumors. 
The first nanoplatform is liposome based. In collaboration with Prof Igor Chourpa of 
Tours University, we prepared liposomes decorated with gH625 and carrying the 
drug mitoxantrone (MTX) to analyze the internalization mechanism. The purpose of 
this study was to explore the possibility of using liposomes decorated on their 
external surface with gH625 to change the uptake mechanism and enhance the 
internalization of MTX. To analyze the uptake mechanism, we used Confocal 
Spectral Imaging (CSI) which allows to distinguish very fine modifications of MTX 
intrinsic fluorescence within different intracellular microenvironments. The obtained 
results clearly show that the presence of gH625 on the surface of liposomes is 
favouring their uptake in HeLa cells.  
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To enhance the antitumor efficacy of liposomes encapsulating anti-cancer agents 
and to circumvent drug resistance, in collaboration with Dr. Bonelli of Microtech and 
Prof. Caraglia of SUN we used liposomes with enhanced biomimetics characteristics 
(phospholipids derived by soy), carrying on their external surface PEG and modified 
with gH625. We have evaluated the growth inhibition on either wild type (A549) or 
doxorubicin-resistant (A549 Dx) human lung adenocarcinoma cell lines. The 
presence of gH625 on the surface of liposomes is favouring their uptake in both 
sensitive and drug-resistant tumor cell lines allowing an increase of cell growth 
inhibition: in fact, a greater quantity of Doxo from functionalized liposomes is 
accumulated into cells. Doxo encapsulated in functionalized liposomes was able to 
enter in the nuclei of Doxo-resistant cancer cells indicating that the peptide gH625 
was probably inducing a greater and more rapid internalization also in resistant cells, 
which could contribute to overcome drug resistance [2]. 
Moreover, we wanted to develop a nanoplatform based on dual decorated 
liposomes, both for the uptake and the targeting. We have also evaluated the Doxo 
accumulation of the dual decorated liposomes in KB cells by Fluorescence Activated 
Cell Sorting analysis. The conjugation of liposomes with the homing peptide 
increased the retention of doxorubicin into cells, overexpressing epidermal growth 
factor receptor. Further works is under way to characterize the uptake mechanism of 
dual fuctionalized liposomes in vitro.  
The second nanoplatform is based on multifunctional magnetic nanoparticles 
(SPIONs). Our goal was to verify if we could also enhance the cellular uptake of this 
kind of cargo. We focused on optimization of the gH625 conjugation strategy, in 
order to find the best compromise between the colloidal stability of nanosystems, 
their half-life in blood and their efficient translocation into cells. We optimized several 
important parameters such as the concentration of gH625 on the polymeric surface 
of SPIONs and characterized the obtained nanosystem by Circular Dichroism (CD). 
Data confirmed that gH625 retains its helical structure when bound to the 
nanoparticle surface, suggesting that the secondary structure of the peptide was not 
disturbed by attachment to SPIONs. We are now working on the physico-chemical, 
characterization of the nanosystem and the eventual ability of gH625 to increase the 
nanoparticle uptake by cancer cells.  
The third nanoplatform is based on polystyrene nanoparticles (NPs). We explored 
the possibility of using NPs functionalized with gH625 to deliver a drug across the 
Blood Brain Barrier (BBB). The uptake of NPs with gH625 by brain endothelial cells is 
greater than that of the NPs without the peptide. Moreover, gH625 plays a key role in 
controlling the uptake mechanism. In fact, most trajectories of blank NP resulted in 
pearls-on-a-string walk, indicative of motor protein facilitated transport, mediated by 
endocytic vesicles. Conversely, in presence of peptide functionalization, we 
observed that most trajectories showed a random walk behaviour with a very low 
percentage of pearls-on-a-string trajectories, suggesting a translocation across the 
bilayer. These studies clearly indicate that gH625 is able to change the mechanism 
of uptake of the cargo and it is able to cross the BBB. 
In summary, these results establish that gH625 may represent a good choice for the 
design of promising carriers to deliver drugs for the treatment of human diseases and 
we have developed a nanoplatform for targeted drug delivery to be used for several 
pathologies. 
Peptide Based Platforms for Cancer Drug Delivery 
 
 
9 
 
1. Introduction 
Cancer remains one of main causes of death in humans, accounting for 8.2 milion 
deaths worldwide in 2012 [1] (Table 1). 
Over the past several decades, remarkable breakthroughs have been made in 
advancing the understanding of how cancer originates and develops, which has in 
turn led to better methods for both diagnosis and treatment [3]. Chemotherapy, the 
most widely used type of cancer therapy, is the most effective and potent strategy to 
treat malignant tumors. However, the inability to delivery therapeutic agents only to 
tumor sites constitutes a significant impediment to successful chemotherapy. An 
additional obstacle is the resistance of cancer cells to the drugs. Current cancer 
treatments kill normal cells and cause several cytotoxic effects in healthy tissues. 
Therefore, it would be desirable to develop highly efficient therapeutics, that can 
overcome biological barriers and distinguish between malignant and benign cells, 
selectively targeting the cancerous tissues [4]. Nanomedicine allows the release of 
drugs by biodegradation and self-regulation of nanomaterials in vitro and in vivo. 
Nanotechnologies are potentially effective for drug encapsulation, controllable self-
assembly, specificity and biocompatibility; moreover, they have the potential to 
overcome current chemotherapeutic barriers in cancer treatment, because of the 
unique nanoscale size and distinctive bioeffects of nanomaterials. Nanotechnology 
may thus help to solve the problems associated with traditional chemotherapy and 
multidrug resistance.  
 
 
Estimated number (thousands) Men Women 
 Cases Deaths Cases Deaths 
World 6629 4225 6038 3345 
More developed regions 2975 1528 2584 1223 
Less developed regions 3653 2697 3453 2122 
WHO Africa regions 253 209 318 226 
WHO Americas regions 1276 611 1233 568 
WHO East mediterranean regions 214 169 214 144 
WHO Europe regions 1823 1044 1604 823 
WHO South-East Asia regions 742 566 909 564 
WHO western Pacific regions 2316 1621 1755 1016 
United State of America 745 294 692 271 
European Union 1332 693 1114 539 
 
Table 1. Summary of cancer (excluding melanoma skin cancer) incidences and mortality worldwide in 
2008. 
 
1.1 Cancer 
Cancer is the second leading cause of death in the world, being second only to 
coronary diseases. It is estimated that within the next 30 years, it will become the 
main reason for death. This bothersome statistic is not correlated to an increase in 
incidences of cancer, but to the reduction to nearly half of heart disease deaths, 
while the number of cancer-related deaths remains about the same. Cancer, which 
was once considered to be a disease of the westernized, industrialized countries, 
has now become a common disease also of low- and medium-resource countries 
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[1]. Cancer is caused by abnormalities in the genetic material of the transformed 
cells [5]. These abnormalities are due to mutations in the DNA of a normal cell, 
changing them to transformed cells or “mutants”. Mutations are mainly caused by 
exposure to carcinogens; such as tobacco smoke, radiation, chemicals, or infectious 
agents [6]. Other cancer enhancing genetic abnormalities may occur randomly due 
to errors in DNA replication, or are inherited [7]. The heritability of cancers is usually 
determined by complex interactions between carcinogens and the host genome with 
cancer-enhancing genetic abnormalities present in cells from birth. Although much 
progress has been made in cataloging the environmental causes and cellular and 
molecular biological basis for this dreaded disease, we still do not have a precise 
understanding of the differences between a cancer cell and its normal counterpart. 
Cancer development occurs when cells in a part of the body begin an out-of-control 
growth of abnormal cells, and instead of dying, they outlive normal cells and 
continue to form new abnormal cells. Cancer cells acquire autonomy from growth 
signals, evasion of growth inhibitor signals, evasion of apoptotic cell death, unlimited 
replication potential, angiogenesis, and invasion and metastasis, all of which are 
essential for carcinogenesis. Cancer cells rapidly reproduce and divide 
uncontrollably and their growth rate is not restricted by space, nutrients etc. Cancer 
cells are usually different in shapes as compared to healthy cells, which do not 
perform biological functions properly, and they can spread into many areas of the 
body.  
1.2 Obstacles to cancer treatment and the potential of nanotechnology 
1.2.1 Conventional therapies for treatment of cancer 
The established strategies for cancer treatment, include surgery, radiation, and 
chemotherapy or combined strategies of these treatments. These are supplemented 
by some more specialized therapies such as immunotherapy or hormone therapy 
which can be applied only to some tumor types [8]. 
The oldest form of cancer treatment is surgery. It provides the greatest chance of 
cure, mainly for solid tumors; especially those which have not yet metastasized to 
other parts of the body. Radiotherapy is the second major weapon against cancer. 
Radiation therapy involves use of high-energy particle beams or waves (radiation), 
such as X-rays, gamma rays, neutrons for treating cancer [9]. Radiation is more 
harmful for cancerous cells than for normal cells because cancerous cells are more 
unstable and thus more vulnerable to the damaging radiations. Moreover, the 
cellular repair mechanism is also not prominently active in the highly dividing cells 
like cancer cells; while due to proper functionally active cellular repair mechanism 
normal cells can recover from the effects of radiation more easily. One of the major 
drawbacks of radiotherapy is selectivity, in fact it is impossible to treat only tumor 
cells, without affecting the surrounding healthy cells. Chemotherapy uses chemicals 
to treat cancer, especially suitable for those cancers that have been spread out 
(metastasized) and cannot be treated any longer by localized methods such as 
surgery and radiation. One common characteristic of most cancer cells is their rapid 
rate of cell division. Anticancer drugs like taxol (interferes with the depolarization of 
microtubules and hyperstabilized their structure), doxorubicin (is thought to 
intercalate in DNA) or daunorubicin (intercalates with its daunosamine residue 
directed toward the minor groove), all adversely affect the process of cell division; 
thus, they are aimed to destroy aggressive cancers. Nevertheless, 
chemotherapeutics have the same disadvantage as radio-therapeutics. They are 
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unspecific and therefore do not distinguish between healthy and cancerous cell and 
hence damage also healthy cells. The clinical use of most conventional 
chemotherapeutics is often limited due to inadequate delivery of therapeutic drug 
concentrations to the tumor target tissue or due to severe and harmful toxic effects 
on normal organs. In addition, cancer cells can be resistant to chemiotherapeutic 
agents in the clinic. These drug-resistant cancer cells, remaining alive after 
chemiotherapy, are responsible for the re-appearance of tumors and the poor 
prognosis for patients. Multidrug resistance (MDR) is a major problem encountered 
in chemotherapy that negatively impacts the treatment efficacy of 
chemotherapeutics [10]. A number of mechanisms have been reported for MDR, 
including increased efflux pumping of drugs by the overexpressed ATP-binding 
cassette (ABC) transporters, reduced intracellular accumulation of drugs by non-
ABC drug transporters, blocked apoptosis, repair of drug-induced DNA damage, 
metabolic modification, and detoxification by drug-metabolizing enzymes [11]. 
Among these mechanisms, the overexpression of plasma membrane P-glycoprotein 
(P-gp, or ABCB1), a member of the ABC superfamily, is one of the most common 
causes of MDR. A strategy suggested for overcoming MDR is association of the 
drug with drug delivery tools [12]. Nanotechnology has the potential to overcome 
current obstacles to chemotherapy, because of the unique properties of 
nanoparticles, in fact the encapsulation of drugs in nanometric scaled biocompatible 
materials is a potential strategy to improve the accumulation of the drugs in the 
tumor tissues. 
1.2.2 Nanomedicines and drug delivery 
The advent of nanotechnology brought the promise to revolutionize cancer treatment 
both for diagnosis and therapy. In recent years, nanotechnology has been 
successfully utilized to create novel drug delivery systems, which allow the reduction 
of unwanted side effects of systemic delivery, while increasing drug accumulation in 
tumours and improving the therapeutic efficacy. A delivery tool should transport the 
drug to the target cells not only with high efficacy, but also with minimal toxicity 
against healthy cells and immune response avoiding its degradation and entrapment 
in endosomes. The most critical issue for the design of a successful nanoplatform is 
quick clearance in the systemic circulation.  
The nanoparticles used for drug delivery can be readily fabricated from either soft 
(organic and polymeric) or hard (inorganic) materials, with the sizes and 
compositions/structures controlled, typically in the range of 1–100 nm, and loaded 
with anticancer drugs [13,14]. The physico-chemical properties of the nanoparticles 
can also be finely controlled by adjusting their chemical compositions, sizes, shapes, 
structures, morphologies and properties of the surface [3,15]. Compared with 
traditional chemotherapeutics, the delivery of anticancer drugs through a 
nanoparticle-based platform presents many challenges, including: 1) improved 
delivery of drugs that are poorly soluble in water and delivery of a therapeutic agent 
into cancerous cells at a high dose; 2) better protection of a drug from harsh 
environments (e.g., the highly acidic environment in the stomach or the lysosomes of 
a cell, and the high levels of proteases or other enzymes in the blood stream) before 
they can reach the targets, leading to an extended plasma half-life of the drug in the 
systemic circulation; 3) targeted delivery of drugs in a cell or tissue in order to 
maximize the treatment efficacy while systemic side effects are alleviated; 4) 
controlled release of drugs over a manageable period of time at precise doses and 
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realization of on-demand release using a more sophisticated, stimuli-responsive 
system. [16,17,18]  
1.3 Drug delivery systems 
Many of the current “nano” drug delivery systems, are in the nanometer range, such 
as liposomes, polymeric micelles, nanoparticles and dendrimers. Liposomes were 
first prepared in 1960’s; nanoparticles and dendrimers in 1970’s and colloidal gold 
particles in nanometer sizes were first prepared by Michael Faraday more than 150 
years ago, but were never referred to or associated with nanoparticles or 
nanotechnology until recently. Subsequently, as illustrated in Figure 1, a variety of 
other organic and inorganic biomaterials for drug delivery were developed. Only a 
few nanomedicines are approved for use in the treatment of cancer (Table 2). 
 
 
 
 
Figure 1. Biomaterials for drug delivery. 
 
 
 
The first controlled release polymer system for delivery of macromolecules was 
described in 1976. More complex drug delivery systems capable of responding to 
changes in pH which trigger drug release, as well as the first example of cell-specific 
targeting of liposomes, were first described in 1980 [19,20]. The first long-circulating 
liposome was described in 1987, and the concept was later named “stealth 
liposomes” [21]. The use of polyethylene glycol (PEG) was shown to increase 
circulation times of liposomes [22] and polymeric nanoparticles [23] in 1990 and 
1994, respectively, paving the road for the development and subsequent approval of 
Doxil (doxorubicin liposome) in 1995, for the treatment of AIDS-associated Kaposi’s 
Sarcoma. 
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Name Formulation Bioactive 
coupound 
Indication Status 
DaunoXome
® 
Non-PEGylated 
liposomes 
Daunorubicin Kaposi’s sarcoma Approved 
Myocet
®
 Non-PEGylated 
liposomes 
Doxorubicin Breast cancer Approved 
Doxil
®
/Caelyx
®
 PEGylated 
liposomes 
Doxorubicin Breast and ovarian 
cancer, Kaposi’s 
sarcoma 
Approved 
NL CPT PEGylated 
liposomes 
Irinotecan Glioma Phase I 
Genexol-PM
®
 PEG-poly(lactic acid) 
nanoparticles 
Paclitaxel Breast cancer, lung 
cancer, ovarian cancer 
Phase II 
Opaxio™ PGA-paclitaxel Paclitaxel Lung cancer, ovarian 
cancer 
Phase III 
NC-6004 PEG-poly(glutamic 
acid) 
Cisplatin Pancreatic cancer Phase II 
Paclical® 
 
Micellar retinoid-
derived 
 
Paclitaxel 
 
Ovarian cancer 
 
Phase III 
 
Oncaspar® 
 
PEG-L-asparaginase 
 
Asparagine 
specific enzyme 
 
Acute lymphoblastic 
leukemia 
 
Approved 
 
Table 2. Examples of nanosystems in clinic use for anticancer therapy 
1.3.1 Liposomes 
Liposomes are small lipid vesicles within the range of 50 to 1000 nm [24]. They are 
the oldest and probably most investigated drug delivery system. Their main 
advantage derives from the amphiphilic nature of phospholipids, allowing to 
encapsulate hydrophilic molecules in the liposome inner aqueous compartment, 
while hydrophobic molecules are spread into the bilayer [25]. They also have low 
toxicity and can be functionalized to improve their circulation time and to provide site-
specific targeting. [26,27]. Depending upon their size and number of bilayers, 
liposomes can be classified into three categories: multi-lamellar vesicles (MLV); large 
uni-lamellar vesicles (LUV); and small uni-lamellar vesicles (SUV). The major 
problems associated with liposomes are their stability, their relatively fast clearance, 
which demonstrates a pronounced dependence on size, and their tendency to 
localize in the tissues of the mononuclear phagocyte system (MPS), particularly in 
the liver and spleen. The nanoformulation available in the market are Doxil (liposomal 
doxorubicin), DaunoXome (liposomal daunorubicin), and Visudyne (liposomal 
verteporfin) [28]. 
Liposomes are the simplest form of nanovector and their utility is based on the 
significant difference in endothelial structures defined as fenestrations between 
normal vasculature and tumor-associated vessels. The increase in fenestrations in 
tumor neovasculature allows the preferential concentration of liposome-
encapsulated anti-tumor agent in close proximity to the local tumor site, a 
phenomenon defined as enhanced penetration and retention (EPR), which is 
considered to be a characteristic of passive targeting of tumors. 
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1.3.2 Quantum Dots 
Semiconductor quantum dots (QDs) are rapidly emerging as popular luminescence 
probes for many biological and biomedical applications owing to their extremely small 
size (approximately 10 nm in diameter), high photostability, tunable optical 
properties, and multimodality [18,29]. Such inorganic–organic composite 
nanomaterials have shown extreme efficiency in cancer diagnosis in vivo, with their 
small size which facilitates unimpeded systemic circulation and attached targeting 
molecules [30,31]. Similar to other nanoparticles, QDs can be modifyed via 
conjugation of various surface molecules for targeted delivery [32,33] and also 
provide sufficient surface area to attach therapeutic agents for simultaneous drug 
delivery and in vivo imaging [34].  
In a recent study, Bagalkot et al. [35] used QD–aptamer (Apt) doxorubicin (Doxo) 
conjugate for targeted cancer therapy, imaging, and sensing. It was shown that this 
multifunctional nanoparticle system can deliver doxorubicin to the targeted prostate 
cancer cells and sense the delivery of doxorubicin by activating the fluorescence of 
QDs, while allowing for simultaneous imaging of cancer cells. QDs also found 
application in the near infrared (NIR) imaging (700–1000 nm) [36]. The use of NIR-
QDs can maximize the depth of tissue penetration, allowing for more accurate and 
sensitive detection of photons in vivo, which is limited by absorption and light 
scattering in conventional imaging. NIR-QDs have tremendous potential for in vivo 
imaging, and have already been used in various in vivo studies, including lymphatic 
mapping in animal models [37]. 
1.3.3 Dendrons and dendrimers 
Dendrons and dendrimers are highly branched macromolecules that can incorporate 
either synthetic polymeric building blocks or natural components [38]. Their 
hierarchical factorial structure presents numerous conjugation sites for cargoes or 
targeting moieties. Although spherical in shape, dendrons and dendrimers possess a 
large cavity that can be utilized for passive entrapment and eventual release of drugs 
or other cargoes. The physico-chemical nature of the cavity determines the 
entrapment efficiency and release profile of the cargo. The ability to selectively tune 
the cavity’s properties is considered a significant advantage of dendrons and 
dendrimers. They have the benefit of a highly controlled synthesis as well as yielding 
a single monodisperse compound, giving perfect control over the size, weight, and 
terminal functionalities of the resulting structure.  
1.3.4 Nanoparticles 
Nanoparticle drug delivery systems are nanometeric carriers used to deliver drugs or 
biomolecules. Generally, nanometeric carriers also comprise sub-micron particles 
with size below 1000 nm and with various morphologies [39]. Nanoparticles have 
outstanding advantages: 1) they can pass through the smallest capillary vessels 
because of their ultra-tiny volume and avoid rapid clearance by phagocytes so that 
their duration in blood stream is greatly prolonged; 2) they could show controlled 
release properties due to the biodegradability, pH, ion and/or temperature sensibility 
of materials; 4) they can improve the utility of drugs and reduce toxic side effects. As 
drug delivery system, nanoparticles can entrap drugs or biomolecules into their 
interior structures and/or absorbe drugs or biomolecules onto their exterior surfaces. 
Presently, nanoparticles have been widely used to deliver drugs, polypeptides, 
proteins, vaccines, nucleic acids, genes and so on. Over the years, nanoparticles 
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have shown huge potential in biological, medical and pharmaceutical applications 
[18,40]. 
1.4 Biomolecules passage across the cell membrane 
When a drug delivery tool is administered by any route, it must be absorbed into the 
bloodstream from the site of administration. Many of these macromolecular drugs 
exploit specific cellular processes, which require internalization of the molecules and 
their delivery to appropriate cellular compartments. The barely permeable cell 
membrane remains a formidable barrier to exert their efficacy. Indeed, an important 
function of a biological membrane is to serve as a barrier against the outside world. 
However, membranes are not impenetrable walls; obviously, nutrients must enter the 
cell and waste products have to leave in order for the cell to survive; for example, the 
movement of ions across membranes is important in regulating vital cell features 
such as cellular pH and osmotic pressure.  
The phospholipids, that compose the biological membrane, are amphipathic 
molecules, consisting of two hydrophobic fatty acid chains linked to a phosphate-
containing hydrophilic head group, arranged with the hydrophilic heads on both 
sides, in contact with water and the lipophilic chains facing the interior of the 
membrane. This gives a sandwich effect, with two hydrophilic layers surrounding the 
central hydrophobic one. Spanning this bilayer or attached to the outer or inner 
leaflets are proteins, which may act as ion channels, receptors, intermediate 
messengers (G-proteins) or enzymes. The efficacy of a biomolecule, which should 
be used as a therapeutic and/or diagnostic agent in biomedical research and in the 
pharmaceutical industry, is subject to its pharmacodistribution properties. Thus, cell 
compartmentalization and impermeability of membranes represent the major 
obstacle for delivery of therapeutic molecules; in fact, many bioactive molecules are 
incapable of overcoming the membrane permeability barrier and this represents the 
major impediment for gene and drug targeting in theranostics. Although a wide 
variety of biomolecules, including peptides and proteins, are now produced on a 
commercial scale, one challenging task for pharmaceutical researchers is to devise 
ways to deliver these drugs effectively and safely via non-invasive, patient-friendly 
routes.  
In particular, many pharmaceutical agents should be delivered intracellularly to exert 
their therapeutic action inside the cytoplasm or onto individual organelles, such as 
nuclei (target for gene and antisense therapy), lysosomes (target for the delivery of 
deficient lysosomal enzymes), and mitochondria (target for pro-apoptotic anticancer 
drugs). Thus, intracellular delivery of therapeutic molecules is one of the key 
problems in drug delivery [41]. 
The intracellular bioavailability depends on several parameters relative to 
biomolecules and membrane physicochemical properties in particular: molecular 
size, concentration gradient, ionization, lipid solubility. 
Molecular size. 
The rate of passive diffusion is inversely proportional to the square root of molecular 
size (Graham’s law). In general, small molecules will diffuse much more readily than 
large ones.  
Concentration gradient. 
Fick’s law states that the rate of transfer across a membrane is proportional to the 
concentration gradient across the membrane. Thus, increasing the plasma 
concentration of the unbound fraction of drug will increase its rate of transfer across 
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the membrane and will accelerate the onset of its pharmacological effect. 
Ionization. 
The lipophilic nature of the cell membrane only permits the passage of the 
uncharged fraction of any drug. The degree to which a drug is ionized in a solution 
depends on the molecular structure of the drug and the pH of the solution in which it 
is dissolved and is given by the Henderson–Hasselbalch equation. 
Lipid solubility. 
The lipid solubility of a drug reflects its ability to pass through the cell membrane; 
this property is independent of the pKa of the drug. However, high lipid solubility 
alone does not necessarily result in a rapid onset of action. 
Several basic cellular mechanisms can be exploited for the intracellular delivery of 
biomolecules across the plasma membrane (Figure 2). There are active 
mechanisms, such as endocytosis, and passive mechanisms, such as translocation 
across the lipid bilayer; alternatively, there are highly invasive procedures, such as 
microinjection and/or electroporation, which could cause transient damage to 
membranes. The internalization processes are mainly classified in two types and a 
brief description is reported below.  
 
 
 
Figure 2. Mechanism of intracellular delivery. 
 
1.4.1 Passive diffusion 
Passive transport is a movement of biochemicals and other atomic or molecular 
substances across cell membranes. Unlike active transport, it does not require an 
input of chemical energy, being driven by the growth of entropy of the system. The 
rate of passive transport depends on the permeability of the cell membrane, which, 
in turn, depends on the organization and characteristics of the membrane lipids and 
proteins. The four main kinds of passive transport are facilitated diffusion, filtration 
and osmosis. 
Facilitated diffusion 
Facilitated diffusion, also called carrier-mediated diffusion, is the movement of 
molecules across the cell membrane via special transport proteins that are 
embedded within the cellular membrane. Facilitated diffusion is a passive process: 
the solutes move down the concentration gradient and do not use extra cellular 
energy to move. The rate of diffusion of the molecule protein complex is still down a 
concentration gradient but is faster than would be expected by diffusion alone. 
Examples of this process include the absorption of steroids and amino acids from 
the gut lumen. The absorption of glucose, a very polar molecule, would be relatively 
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slow if it occurred by diffusion alone and requires facilitated diffusion to cross 
membranes (including the blood brain barrier) rapidly. 
Filtration 
Filtration is movement of water and solute molecules across the cell membrane due 
to hydrostatic pressure generated by the cardiovascular system. Depending on the 
size of the membrane pores, only solutes of a certain size may pass through it. For 
example, the membrane pores of the Bowman's capsule in the kidneys are very 
small, and only albumins, the smallest of the proteins, have chances of being filtered 
through. On the other hand, the membrane pores of liver cells are extremely large, 
to allow a variety of solutes to pass through and be metabolized. 
Osmosis 
Osmosis is the diffusion of water molecules across a selectively permeable 
membrane. The net movement of water molecules through a partially permeable 
membrane from a solution of high water potential to an area of low water potential. A 
cell with a less negative water potential will draw in water but this depends on other 
factors such as solute potential (pressure in the cell e.g. solute molecules) and 
pressure potential (external pressure e.g. cell wall). 
1.4.2 Active transport 
Active transport is the movement of molecules across a cell membrane in the 
direction against their concentration gradient, i.e. moving from an area of lower 
concentration to an area of higher concentration. Active transport is usually 
associated with accumulating high concentrations of molecules that the cell needs, 
such as ions, glucose and amino acids. Energy can be supplied either directly to the 
ion pump, or indirectly by coupling pump-action to an ionic gradient that is actively 
maintained. 
Among the means of active transport the endocytosis is an energy-using process by 
which cells absorb molecules (such as proteins) by overfilling them. It is the process 
by which cells take in materials. The cellular membrane folds around the desired 
materials outside the cell. The ingested particle becomes trapped within a pouch, 
vacuole or inside the cytoplasm. Often enzymes from lysosomes are then used to 
digest the molecules absorbed by this process. 
There are essentially two main types of endocyctosis: pinocytosis and phagocytosis. 
In pinocytosis, cells overfill liquid particles (in humans this process occurs in the 
small intestine, cells there overfill fat droplets). In phagocytosis, cells overfill solid 
particles.  
1.5 Nanoparticles to facilitate cellular membrane penetration 
One of the most important features of nanosystems is the possibility to functionalize 
them with delivery ligands, in order to overcome barriers that reduce access of 
agents used for treatment of tumors and for imaging of tumors. Delivery ligands are 
sequences able to cross the membrane bilayer, such as cell penetrating peptides 
(CPPs) and membranotropic peptides. 
1.5.1 Cell penetrating peptides (CPPs)  
CPPs are a group of peptides, usually containing a cluster of basic residues that 
have been recognized as promising drug delivery vectors over the last decade. It was 
found that the coupling of CPPs to different cargoes (e.g., small molecules, peptides 
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or proteins, genes, or nanoparticles) enabled efficient internalization of these cargoes 
into cells [42,43]. The exact mechanism of CPP entry into cells still remains unknown 
and probably each peptide uses more than one mechanism (Figure 3). Their 
properties determine which mechanism is predominant, in particular concentration, 
length, charge, hydrophobicity and other chemical and physical features.  
 
 
 
 
Figure 3. Proposed mechanisms of cellular internalization pathways of different CPPs. For simplicity; 
the pathways described have been indicated for specific peptides; but none of the pathways 
proposed is mutually exclusive. 
 
Historically, two hypotheses were put forward to explain how these peptides could 
cross the plasmatic membrane and possibly deliver various kinds of molecules into 
the cell. [44] It was first proposed that CPPs, especially Tat and Antennapedia, but 
also others such as poly-Arg [45], Transportan [46], MPG [47] or Pep-1 [48] , could 
pass through the plasma membrane via an energy-independent pathway. This 
hypothesis of a direct translocation through the plasma membrane became less 
popular when the entry mechanism for the Tat and the poly-arginine CPPs had to be 
re-evaluated following evidences of fixation artifacts during the preparation of 
samples for microscopic observation [49]. Indeed, fixation has been described to 
interfere with the sub-cellular localization of constructs with a high content of cationic 
residues, such as histones and the VP22 protein [50]. 
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As a consequence, the majority of the new microscopic studies on CPPs localization 
have been conducted on living cells and the conclusions drawn from these very 
elegant works indicated that CPPs mainly follow a cellular endocytosis-mediated 
uptake [51 ,52 ,53].  
According to this mechanism, CPPs, particularly those with a high content in cationic 
residues, are first simply adsorbed at the cell surface bearing numerous anionic 
moieties, such as heparan sulfate, sialic or phospholipidic acid [54,55,56]; then CPP-
mediated transport proceeds through different endocytosis routes [49]: caveolae 
[57], macropinocytosis [58,59], clathrin-dependent pathway [60], cholesterol-
dependent clathrin-mediated pathways [61] or the trans-Golgi network [62]. 
Since the endosomal pathway is mainly involved in the cellular delivery of CPPs and 
CPPs-conjugated molecules independent from initial route, a strong enzymatic 
degradation within this compartment and consequently a poor cytoplasmic release of 
intact molecules are expected, leading to a global weak drug transfer into the 
cytoplasm. In conclusion, the endosomal entrapment may limit the utility of CPPs. 
1.5.2 Membranotropic peptides  
Although the uptake mechanism of CPPs is largely debated it seems to involve 
mainly the endocytic pathway, trapping the coniugated cargo (eventually 
transported) in endosomes and lastly ending in lysosomes where common 
enzymatic degradation processes take place decreasing its intracellular 
bioavailabilty. 
Therefore, it is particularly challenging the possibility of exploiting alternative 
mechanisms of internalization which may avoid completely or partially the endocytic 
pathways in order to optimize the uptake kinetic/rate and the intracytoplasmatic 
distribution improving thus their target-specific bioactivity. A novel intriguing 
hypothesis is that hydrophobic peptides that partition into membranes may also be 
able to cross cell membranes and enter cells. Therefore, these peptides may also 
cross endothelial layers in vivo, including the blood–brain barrier [63,64]. The 
hydrophobic peptides characterized by a propensity for membrane binding and a 
high interfacial hydrophobicity or amphipathicity, such as those derived from 
enveloped virus glycoproteins, represent a novel alternative to CPPs. These 
peptides can interfere with enveloped virus entry by direct physical interaction with 
the hydrophobic surfaces present on membranes and/or fusion proteins and are, 
thus, critical for both fusion and entry. 
Fusion peptides are typically 20-30 residues long and potentially fold into 
amphipathic helices and are rich in glycines and alanines, providing them a high 
degree of conformational flexibility. There are numerous studies demonstrating that 
a delicate balance between α and β structures, is essential for membrane fusion and 
is influenced by environmental conditions such as pH, ionic strength, peptide 
sequence, presence or absence of divalent cations, cholesterol content and also by 
the lipid/peptide ratio. 
Aromatic residues are generally present in fusion peptides and may help in 
overcoming the energy cost of peptide bond partitioning into membranes. The 
interactions with phospholipid moieties located at the membrane interfaces may also 
help in stabilizing the insertion into just one leaflet of the bilayer. The initial 
interaction with the external leaflet is thought to generate elastic stresses which drive 
to bilayer fusion, helping to overcome the hydration repulsion forces between 
approaching bilayers by orienting the poorly solvated face toward the external 
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medium [65]. The asymmetric insertion into one membrane monolayer may promote 
expansion of the polar head region and determine a curvature stress onto the overall 
lipid bilayer; the created bulges that protrude from the membrane can facilitate the 
formation of lipid contacts between fusing bilayers [66]. Hydrophobic peptides 
traverse efficiently biological membranes, promote lipid-membrane reorganizing 
processes, such as fusion or pore formation [67,68] may be able to circumvent the 
endosomal entrapment either favouring the escape from the endosome or by 
translocating a cargo through the plasma membrane directly into the cytosol.  
The twenty residue peptide gH625 (from aa 625 to aa 644) is a membrane-perturbing 
domain, derived from glycoprotein H of Herpes simplex virus type I, that  interacts 
with biological membranes and is implicated in the merging of the viral envelope and 
the cellular membrane [69,70]. 
It contains particular residues that are crucial for the capacity of the peptide to 
interact and destabilize target lipid membranes. It is rich in hydrophobic residues 
including glycines, leucines, alanines, and aromatic residues such as tryptophan and 
tyrosines, which are known to be located preferentially at the membrane interface 
(Figure 4). An amphipathic α-helix is believed to be an important feature of fusion 
peptides playing a crucial role in mediating lipid-protein interactions during the 
binding of proteins to membranes and once bound, the hydrophobic face of the 
amphipathic peptide would then allow the peptide to enter. 
The membrane interior, thereby triggering local fusion of the membrane leaflets, pore 
formation, cracks and membrane fusion. gH625 has been shown to strongly interact 
and to spontaneously penetrate the lipid-phase and insert into membranes [71]. The 
peptide–lipid interactions are initiated by the arginine residue located at the C-
terminus, in fact, when the arginine is mutated the fusogenic activity of the peptide is 
strongly impaired. The hydrophobic domain is also crucial for insertion of the peptide 
into the membrane and corroborates the notion that hydrophobic interactions 
between fusion proteins and cell-membrane phospholipids initiate membrane 
perturbation in the early stages of viral fusion. gH625 cellular uptake is thus 
associated with its ability to interact with membrane lipids and to form a transient 
helical structure that temporarily affects membrane organization, thereby facilitating 
insertion into the membrane and translocation [41]. 
 
 
 
 
Figure 4. Crystal structure of gH-gL complex. White: H1 Domain; Blue: H2 Domain and Red: H3 
Domain of gH.  Yellow: gL interacting with H1 of gH. 
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1.6 Nanoparticles to facilitate targeting of tumors 
Advancement in nanomaterials and nanotechnology have provided a promising 
strategy for cancer targeted drug delivery. The accumulation of nanocarriers in 
tumor tissue might be realized by either passive or active targeting mechanisms 
(Figure 5). Passive targeting exploits accumulation phenomena that are based on 
the pathophysiological peculiarities of the target tissue. Active targeting, on the other 
hand, recruits targeting vectors that specifically recognize biomarkers which are 
mutated or overexpressed solely in the target tissue [72,73]. 
1.6.1 Passive targeting 
Passive targeting relies on the preferential accumulation of the nanoparticles at the 
target site based on their inherent bio-physico-chemical properties (such as size, 
shape, charge, modulus (flexibility), etc.) [72,74]. It can be applied if the target tissue 
manifests a distinct pathophysiology as compared to the neighbouring healthy tissue. 
The nanoparticles after opsonisation could be rapidly cleared from the bloodstream 
through phagocytosis by mononuclear phagocyte system (MPS) in the liver and by 
spleen filtration [75]. An approach that was first used with liposome nanovectors that 
has found utility with other types of nanovectors is “PEGylation,” a modification of 
surface characteristics using poly(ethylene glycol) (PEG), resulting in what has been 
defined as sterically stabilized nanoparticle platforms. This PEG modification 
provides protection against uptake by resident macrophages within the RES, thus 
increasing the circulation time of tool delivery of antitumor agent, resulting in 
significantly increased tumor accumulation and therapeutic efficacy [76]. 
In tumor tissue, there is an uncontrolled angiogenesis and abnormal vasculature, [77] 
so the tumor blood vessels are heavily branched and present large gaps between the 
endothelial cells. These vascular fenestrations facilitate the leakage of nanomaterials 
from the blood vessels into the tumor interstitium. In addition, the absence in tumor 
tissue of lymphatic vessels, allows nanomaterials to enter and not be efficiently 
removed and thus accumulate in the tumor over time. This phenomenon of leaky 
vasculature and lack of sufficient lymphatic drainage is collectively known as the 
enhanced permeability and retention (EPR) effect and is considered the gold 
standard for cancer targeting [78,79,80]. Passive targeting of nanoprobes via the 
EPR effect is largely dependent on their molecular size and circulation time. These 
two factors are closely related as the kidneys have a filtration threshold of 7 nm (or 
40 kDa) and particles that exceed this threshold can evade renal clearance [78,81]. 
1.6.2 Active targeting 
While passive targeting relies solely on the physico-chemical properties of the 
nanoparticles, active targeting recruits one or several targeting vectors that are 
conjugated to the functionalized nanoprobe surface. These targeting vectors are 
moieties that have a high affinity and specificity to biomarkers that are excessively or 
exclusively expressed on the membrane surface of target tissue cells. The targeting 
vectors thereby direct the nanoprobe to its target tissue and retain it there. A big 
benefit of actively targeted nanoprobes is that they generally improve internalization 
in target cells [72]; it is particularly useful in theranostic for the delivery of therapeutic 
and diagnostic agents to intracellular targets [48,82]. 
Commonly used targeting vectors can be divided into several categories: 
1) monoclonal antibodies (mAbs, e.g., trastuzumab, anti-mesothelin mAbMB), 
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2) antibody-fragments, Fab (fragment, antigen binding), 3) proteins (e.g., transferrin), 
4) peptides (e.g., bombesin, Arg-Gly-Asp (RGD) sequence), 5) carbohydrates (e.g., 
glucose, mannose, galactose), (6) aptamers (e.g., ssDNA), and 7) small molecules 
(e.g., folate, biotin) [82]. The most common targeted biomarkers are transmembrane 
proteins expressed on the outer membrane of the tumor cells. Most targeting vectors 
are covalently attached to the nanoprobe surface via conjugation chemistries; some 
are attached via electrostatic, coordinative, or hydrophobic interactions, avoiding to 
lose their targeting activity because chemical modification does not interfere with the 
binding region [83]. 
Peptides represent a viable targeting moiety with several advantageous 
characteristics, including low molecular weight (ca. 1 kDa), tissue penetration 
capability, lack of immunogenicity, ease of production, and relative flexibility in 
chemical conjugation processes [48]. Various peptides that can recognize cancer-
specific epitopes overexpressed on tumor cells and vasculature have been used as 
targeting moieties for drugs and drug carriers. For examples, the epidermal growth 
factor receptor binding peptide (EGBP) showed a high binding affinity to the 
epidermal growth factor receptor (EGFR). EGFR is a transmembrane protein in the 
tyrosine kinase receptor family and is overexpressed in several solid tumors. 
 
 
 
 
Figure 5. A Passive drug targeting. Circulating nanoparticles passively extravasate in solid tumor 
tissue via the enhanced permeability of blood vessels (EPR effect). B Active drug delivery. Once 
nanoparticles passively extravasate and concentrate in the target tissue via the EPR effect, the 
presence of ligands grafted onto the nanoparticle surface enable active targeting of the nanoparticles 
to receptors that are overexpressed on tumor cells. 
1.7 Aim of the work 
The aim of this project is to develop and design new nanotechnological systems for 
theranostic. A fundamental limitation of current diagnostics and therapeutics is the 
poor water solubility of most anticancer drugs, lack of targeting capability, non 
specific distribution, systemic toxicity, and low therapeutic index. Actual treatments 
of cancer disease remain an elusive alternative, offering limited efficacy with 
extensive secondary effects as a result of severe cytotoxic effects in healthy tissues. 
Peptide Based Platforms for Cancer Drug Delivery 
 
 
23 
 
Over the past years, my research team has worked extensively on peptides derived 
from Herpes simplex virus type 1 (HSV-1) glycoprotein H. They have identified the 
membranotropic sequence, gH625 (Figure 6), as a potential intracellular transporter, 
that interacts and spontaneously penetrates the lipid-phase and inserts into 
membranes [71]. The peptide-lipid interactions are initiated by the arginine residue 
located at the C-terminus; the hydrophobic domain is crucial for insertion of the 
peptide into the membrane. gH625 cellular uptake is associated with its ability to 
interact with membrane lipids and to form a transient helical structure that 
temporarily affects membrane organization, thereby facilitating insertion into the 
membrane and translocation.  
 
 
 
Figure 6. Three dimensional NMR structure of gH625-644 
 
 
Compared to the commonly used CPPs, such as Tat (RKKRRQRRR, derived from 
HIV-1), which mainly exploits the endocytic pathway, the viral membranotropic 
peptide gH625 crosses membrane bilayers mainly through a translocation 
mechanism and is non-toxic to cells up to a concentration of 400 μM. 
The specific goal of this project was to combine the benefits of the drug delivery tool 
with a peptide that can overcome the cell membrane mainly via a non-active 
translocation mechanism and a peptide that can selectively target cancer cells. In 
particular, several nanosystems with different composition, shape and size, were 
decorated on their surface with gH625 and with the targeting sequence EGBP. 
EGBP is a targeting sequence with a high binding affinity to the epidermal growth 
factor receptor, overexpressed in several solid tumors. The nanosystem 
fuctionalizzation can significantly increase the amount of drug to target cells. 
Two different drugs were selected for the development of our drug delivery tool: 
doxorubicin (Doxo) and mitoxantrone (MTX). Doxo is an anthracycline closely 
related to the natural product daunomycin. MTX is a synthetic anthracenedione 
antineoplastic agent derived from the anthraquinone dye ametantrone [84]. It is 
structurally similar to the anthracycline agent Doxo. Both drugs having a planar 
aromatic ring structure which enables them to interact with DNA by intercalation 
between base pairs and can inhibit the activity of nuclear enzyme DNA 
topoisomerase (II). Their main side effect is cardiotoxicity; although also 
neutropenia, bone marrow suppression and secondary acute myelogenous leukemia 
have been reported in patients treated with MTX [85]. 
Liposomes and nanoparticles were selected as nanosystems. 
Liposomes provide substantial advantages over many other nanoparticular drug 
delivery systems because they meet clinical manufacturing requirements, such as 
low batch-to-batch variability, ease of synthesis, scalability, and biocompatibility. 
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Benefits associated with liposomal drugs are: i) protection of encapsulated drugs 
from chemical and biological degradation into the blood stream; ii) controlled release 
and reduced toxicity through decreased exposure of healthy tissues to anti-cancer 
drugs; iii) increased anti-tumor activity resulting from a relatively long systemic 
circulation time (especially in the case of PEGylated liposomes) [24,86,87]; iv) 
subsequent extended exposure and accumulation in growing tumor sites. Moreover, 
liposomes, can be easily surface functionalized with targeting ligands to enhance the 
selective targeting of tumors [79,88]. The grafting of targeting ligands to the 
liposome surface can further enhance tumor targeting and facilitate intracellular 
uptake.  
Nanoparticles (NPs) are colloidal systems that range in size from 1 to 100 nm. They 
can be fabricated by a variety of substances such as polymers, lipids, dendrimers, 
ceramics, and carbon nanotubes; and can be structurally adapted to deliver a wide 
variety of drugs, enhance delivery efficiency, and reduce side effects by targeted 
delivery [89,90]. Polystyrene (PS) NPs are widely used as a model to study 
interactions between NPs and cells due to various practical reasons including their 
commercial availability, high quality and wide variety of size and surface chemistry.  
Superparamagnetic iron oxide nanoparticles (SPIONs) are extensively studied as 
platforms for numerous clinical applications, such as cancer diagnostics by magnetic 
resonance imaging (MRI) [91] and cancer treatment by hyperthermia [91,92] and/or 
magnetically targeted drug delivery [93]. Multifunctional SPIONs simultaneously 
modified with biocompatible polymers, anticancer agents, and fluorescence labels 
are especially interesting, because they combine the possibility of targeted drug 
delivery and in vivo imaging of treated tumors. Proper modification of the SPIONs 
surfaces should provide stability against aggregation at physiological pH and ionic 
strength, reduce capture by the body’s immune system, and provide reactive sites 
suitable for further binding of drugs and biological ligands.  
The nanosystems obtained were characterized in terms of physico-chemical 
properties (size, zeta potential, loading and release of the drug) and biological 
activity (cytotoxicity, antitumoral activity, cellular uptake and subcellular fate). 
 
 
 
 
Figure 7. Schematic rappresentation of nanosystem obtained. 
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2. Materials and methods 
2.1 Materials and equipments 
Peptides were synthesized by standard solid-phase techniques on a Syro I 
MultiSynThec GmbH automatic synthesizer. Protected Fmoc-amino acid derivatives, 
coupling reagents and Rink amide p-methylbenzhydrylamine (MBHA) resin were 
purchased from Calbiochem-Novabiochem (Laufelfingen, Switzerland), Wang resin 
was purchased from Fluka. The Fmoc-8-amino-3,6-dioxaoctanoic acid (Fmoc-
AdOO-OH) and Fmoc-L-propargylglycine (Fmoc-Pra-OH) were purchased from 
Polypeptide (Strasbourg, France). All phospholipids were purchased from Avanti 
Polar Lipids (Alabaster, AL). Doxorubicin hydrochloride, and the other chemicals 
were purchased from Sigma–Aldrich, Fluka (Buchs, Switzerland), or LabScan 
(Stillorgan, Ireland) and were used as received, unless otherwise stated. Dialysis 
membranes (SpectraPor 6) were purchased from Spectrum Labs and used after 
rinsing the membrane in water for 30 min. 
Peptide purification was performed on LC8 Shimadzu HPLC with a Phenomenex C18 
column (300 Å, 250x21.20 mm, 5 μ) and a UV lambda-Max model 481 detector. 
Peptide purity was analyzed by a Finnigan Surveyor MSQ single quadrupole ESI 
LC-MS with a Phenomenex C18 column eluted with an H2O/0.1% TFA (A) and 
CH3CN/0.1% TFA (B). Size-exclusion chromatography was performed using a 1x18 
cm Sephadex G-50 column. Cell media (Phosphate buffered saline [PBS, pH 7.4], 
Fetal bovine serum [FBS], 0.25% trypsin in EDTA, Eagle’s minimum essential 
medium [EMEM], and penicillin/streptomycin solution) were purchased from 
Invitrogen. Cell microscopy was done by a Nikon Eclipse Ti inverted microscope 
equipped with a FITC filter set for fluorescence imaging. Dynamic light scattering 
(DLS) was performed at 25°C on a Zetasizer Nano ZS, Malven, UK in aqueous 
solution. 
2.2 Solid-phase peptide synthesis 
Peptides (Table 3) were synthesized using standard solid-phase-9-
fluorenylmethoxycarbonyl (Fmoc) procedures using a Syro I MultiSynThec GmbH 
(Wullener, Germany) automatic synthesizer. The Rink-amide MBHA resin 
(substitution 0.51 mmol/g) was used as the solid-phase support, and syntheses were 
performed on a scale of 50 µmol. Fmoc-amino acids, 4 equivalents relative to resin 
loading, were coupled according to the PyBop/HOBt/DIPEA (benzotriazol-1-yl-
oxytris(pyrrolidino)phosphonium/N-hydroxybenzotriazole/Di-iso-ropylethylamine) 
method: 1 equivalent of Fmoc-amino acid, 1 equivalent of PyBOP, 1 equivalent of 
HOBt (0.5 M HOBt in DMF) and 2 equivalents of DIPEA (2 M DIPEA in DMF). The 
Fmoc protecting group was removed with 30% piperidine in DMF (v/v). All couplings 
were performed twice for 35 minutes. 
When necessary Fmoc-Pra-OH and Fmoc-8-amino-3,6-dioxaoctanoic acid (PEG2) 
were coupled once for 45 min with 2 equivalents of PyBop/HOBt and 4 equivalents 
of DIPEA. Fully-synthesized peptides were deprotected from the resin with 
trifluoroacetic acid (TFA) with 2.5% (v/v) water, 2.0% (v/v) anisole, 2.0% (v/v) 
thioanisole as scavengers, at room temperature, and then precipitated in ice-cold 
ethyl ether, filtered, dissolved in water and lyophilized. The crude peptides were 
purified by RP-HPLC on a LC8 Shimadzu HPLC system (Shimadzu Corporation, 
Kyoto, Japan) equipped with a UV lambda-Max Model 481 detector using a 
Phenomenex (Torrance, CA) C18 (300 Ǻ, 250x21.20 mm, 5 μ) column eluted with an 
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H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B) from 20% to 80% over 20 minutes at 
20 mL/min flow rate. Purity and identity were assessed by analytical LC–MS analysis 
by using Finnigan Surveyor MSQ single quadrupole electrospray ionization 
(Finnigan/Thermo Electron Corporation San Jose, CA), column: C18-Phenomenex 
eluted with H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B) from 20% to 80% over 10 
minutes at 0.8 mL/min flow rate. The final yields of purified peptides ranged between 
20 and 40%. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3 Conjugation of EGB targeting peptide to Cholesterol 
Chol-GGG-EGBP (Chol-TP1) and Chol-PEG2-EGBP (Chol-TP2) were prepared 
conjugating NH2-GGGEGBP-CONH2 (TP1) or NH2-PEG2EGBP-CONH2 (TP2) with 
the cholesteryl chloroformate. In particular, 20 mg of purified TP1 and TP2 were 
dissolved in 2.5 mL of DMSO, and 6 mg of cholesteryl chloroformate (1.2 eq), 
dissolved in 420 µL of THF were added. 15 µL (1% v/v) of DIPEA was added to the 
mixture, which was moderately stirred at room temperature overnight. The 
conjugation efficiency was determined by LC-MS ((Finnigan/Thermo Electron 
Corporation San Jose, CA) with a column Kinetex PFP Phenomenex (100 Å 150 x 
4.6 mm 5 u) using as eluents (A) 0.1% trifluoroacetic acid in water and (B) 0.1% 
trifluoroacetic acid in acetonitrile, and the following linear gradient: 20–95% (B) in 15 
min, flow rate 0.8 mL min-1. The resulting cholesteroylated peptides were 
precipitated in water to remove the organic solvent. The purified peptides were 
characterized by LC/MS on a Finnigan Surveyor MSQ single quadrupole 
electrospray ionization. 
2.4 Preparation of triflyl azide 
Sodium azide (650 mg, 10 mmol) was dissolved in distilled water (1.5 mL) and then 
dichloromethane (DCM, 2.4 mL) was added. The mixture was cooled on ice bath for 
20 min. Triflyl anhydride (336 µL, 2 mmol) was added slowly over 5 min and the 
mixture was stirred for 2 h. The mixture was extracted with DCM two times. The 
organic portions, containing the triflyl azide, were pooled, washed once with 
saturated Na2CO3, and evaporated to dryness. 
2.5 Synthesis of Azide-AdOO-Lys(C(O)CH2CH2C(O)N-(C18H37)2)-amide ((C18)2L-
N3)  
(C18)2L-N3 monomer was synthesized in solid phase under standard conditions using 
Fmoc/tBu strategy. Rink-amide MBHA resin (0.51 mmol/g, 0.1 mmol scale, 0.196 g) 
was used as polymeric support. The Fmoc protecting group on the resin was 
removed by a DMF/Piperidine (70/30) mixture. Fmoc-Lys(Mtt)-OH residue (0.125 g, 
Table 3. Peptide sequences and their molecular weight 
PEPTIDES SEQUENCES M.W 
Ac-gH625 Ac-NH2-HGLASTLTRWAHYNALIRAF-COOH 2339.6 
gH625-Pra NH2-HGLASTLTRWAHYNALIRAF-Pra-CONH2 2391.3 
Ac- gH625-GGG Ac-NH2-HGLASTLTRWAHYNALIRAFGGG-COOH 2510.8 
GGG-EGBP (TP1) NH2-GGGFPMFNHWEQWPPG-CONH2 1844.1 
PEG2-EGBP (TP2) NH2-PEG2-FPMFNHWEQWPPG-CONH2 1817.1 
Chol-GGG-EGBP (Chol-TP1) Chol- GGGFPMFNHWEQWPPG-CONH2 2257.2 
Chol-PEG2-EGBP (Chol-TP2) Chol-PEG2-FPMFNHWEQWPPG-CONH2 2231.2 
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0.2 mmol) was activated by 1 equiv of PyBop and HOBt and 2 equiv of DIPEA in 
DMF and coupled on the resin stirring the suspension for 1 h. The Nα amine function 
of the lysine residue was deprotected from Fmoc group, and two equivalents of 
Fmoc-AdOO-OH were coupled under standard condition in DMF for 1 h. After Fmoc 
removal from linker, peptidyl-resin was washed three times with DMF and three times 
with MeOH, and treated by 1 mL of solution containing K2CO3 (0.04 mmol) 
CuSO4·5H2O (0.01 mol) and TFN3 (2 mmol). The resin was stirred at room 
temperature overnight. The solution was filtered and the resin was washed 4 times 
with DCM; the Mtt-protecting group on the Nɛ amino function of lysine was removed 
by treatment with the DCM/TIS/TFA (94:5:1) mixture. The peptide resin was stirred 
with 5.0 mL of this solution for 2 min. This procedure was repeated several times until 
the solution became colorless. The resin was washed 3 times by DCM and 3 times 
by DMF. Then, N,N-dioctadecylsuccinamic acid (0.249 g, 0.4 mmol) was coupled 
twice for 1 h in the NMP (N-methylpyrrolidone)/DCM (1/1) mixture. N,N-
dioctadecylsuccinamic acid was synthesized according to published procedure. The 
lipophilic moiety was activated in situ by the standard HOBt/PyBop/DIPEA procedure. 
The coupling was monitored by the qualitative Kaiser test [94]. The resin was washed 
3 times by DMF, 3 times by DCM, and 3 times by ethyl ether. (C18)2L-N3 was 
removed from the resin by treatment with TFA containing TIS (2.5%) dithiothreitol 
(DTT, 2.5%) and water (2.5%) under vortexing for 2 hours. The crude product was 
slowly precipitated at 0 °C by adding water drop-wise, washed several time with 
small portions of water, and lyophilized in order to remove the solvent. The white 
solid was recrystallized from MeOH/H2O and recovered with high yields (>85%). The 
product was identified by MS (ESI+) and NMR spectra. 1H NMR and 13C-NMR 
spectra were recorded on a Varian 400 MHz spectrometer (Palo Alto, CA). 
2.6 Liposomes preparation 
Liposomes were prepared by the thin lipid film hydration procedure. Two different 
liposomes compositions were prepared: DOPG/DSPE-PEG/(C18)2 (85:5:10 molar 
ratio) and soy-lipids/Chol/DSPE-PEG/(C18)2 (57:28:5:10 molar ratio). They were 
prepared by dissolving the lipids in a small amount of chloroform, and subsequently 
evaporating the solvent by slowly rotating the tube containing the solution under a 
stream of nitrogen and lyophilized overnight. In this way a thin film of amphiphiles 
was obtained. The dry lipid film was suspended in HEPES-NaCl buffer (5 mM-
100mM) at pH 7.4 by vortexing for 1 h; then the lipid suspension was freeze–thawed 
ten times and extruded ten times thought a polycarbonate membrane with 100 nm 
pore size using a thermobarrel extruder (Northern Lipids).  
2.7 Synthesis of SPIONs-PEG-Doxo 
Unfunctionalized SPIONs were prepared by the coprecipitation method as previously 
described [95]. Magnetite nanoparticles were precipitated by adding ammonia 
solution (30 mL, 35%) to an aqueous mixture of Fe3+ (0.032 mol, 350 mL) and Fe2+ 
(0.016 mol, 20 mL, HCl 1.5 M) salts. The black precipitate was isolated from the 
solution by magnetic decantation and washed three times with water. Nanoparticles 
were treated with nitric acid (30 mL, 2 M) prior to the oxidation of the outer shell by 
iron(III) nitrate (60 mL, 0.33 M) at 100°C and peptized again with nitric acid (30 mL, 2 
M). Finally, nanoparticles were washed three times with acetone and redispersed in 
water at pH 3. The prepared nanoparticles were characterized by TEM, dynamic light 
scattering (DLS), zeta potential measurements, and FTIR spectroscopy.  
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Functionalized SPIONs were prepared according to a one-pot synthesis protocol 
similar to that previously published [96]. 100 μL aqueous suspension of SPIONs at 
an iron concentration of 20 g/L was suspended in 5 mL of DMSO, and water was 
removed by evaporation. The suspension of SPIONs in DMSO was sonicated for 30 
min prior to functionalization. NH2-PEG-OCH3, NH2-PEG-NH2, and Doxo were 
freeze-dried. An approximately 4:1 molar mixture of NH2-PEG-OCH3 (250 mg, 0.05 
mmol) and NH2-PEG-NH2 (35 mg, 0.058 mmol) dissolved in 10 mL of anhydrous 
DMSO was allowed to react with GOPTS (12 μL, 0.054 mmol), dissolved in 1 mL of 
anhydrous DMSO, for 4 h at 65°C (Figure 8, step I). Doxo (1.2 mg, 2 μmol), dissolved 
in 1 mL of anhydrous DMSO, was added to the reaction mixture and left to react with 
GOPTS for 1 h (Figure 8, step II).  
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Figure 8. Schematic representation of surface functionalization of superparamagnetic iron oxide 
nanoparticles (SPIONs) with Doxo and PEG. 
Step I 
Step II 
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Then, SPIONs in DMSO were added, and the reaction was kept under stirring for 48 
h at 65°C in the dark under nitrogen (Figure 8, step II). The suspension was 
dispersed in 10 mL of ultrapure water and purified by dialysis against deionized water 
on MWCO 25000 Da. Dialysis was carried out for 48 h, while water in the acceptor 
volume was changed every 2 h for the first 12 h and then every 12 h. The 
donor/acceptor volume ratio was 10 mL/5 L. This purification eliminates molecules 
not bonded to the SPION surface (NH2-PEG-OCH3, NH2-PEG-NH2, and Doxo). A 
small amount of non functionalized nanoparticles was removed by magnetic 
decantation at pH 7. The resulting nanoparticles were characterized by TEM, DLS, 
zeta potential measurements, FTIR. 
2.8 Peptides conjugation to liposomes 
The click reaction was carried out on liposomes adding CuSO4•5H2O (4.4 equiv), 
ascorbic acid (6.7 equiv), and the peptide derivative (1 equiv) with respect to the 
azido moiety. In particular, solutions containing CuSO4•5H2O (60.5 mM, solution A), 
ascorbic acid (81.4 mM, solution B), and the alkyn-modified peptide (1 mM, solution 
C) were freshly prepared in water.  
Solution A, solution B, and solution C were added to a suspension of azido-
functionalized preformed liposomes in HEPES-NaCl buffer. The concentration of 
solution C was determined measuring the tryptophan absorbance at 280 nm on a 
UV/Vis Jasco V-5505 spectrophotometer. 
The reaction mixture was stirred at 40°C for 30 min and then left overnight at room 
temperature. After the conjugation step the liposomes were purified by exclusion 
chromatography on a 1×18 cm Sephadex G-50 (Amersham Biosciences) column 
pre-equilibrated with HEPES buffer. 
The peptide EGBP, conjugated to cholesterol, was included directly during the 
preparation of lipids film. 
2.9 Peptides conjugation to SPIONs 
A solution of the peptide, EDC (1-ethyl-3(3-dimethylamino-propyl)-carbodiimide, 
hydrochloride) and NHS (N-Hydroxysuccinimide) in molar ratio of 4:4:1 was 
prepared in PBS buffer at pH 7.4, at room temperature under stirring for 30 min. 
SPIONs were conjugated with preactivated-peptide in DMSO at room temperature 
for 36 h in presence of Tween 20. The peptide-SPIONs were purified from 
unconjugated SPIONs by dialysis against deionized water on MWCO 25000 Da. 
Dialysis was carried out for 48 h, while water in the acceptor volume was changed 
every 2 h for the first 12 h and then every 12 h. The donor/acceptor volume ratio was 
10 mL/5 L. This purification eliminates peptides not bonded to the SPION surface. 
Peptide-NPs were prepared with a ratio molar of 1:0.3 respect to NH2-PEG-NH2. 
2.10 Peptides conjugation to NPs 
A solution of the peptide, EDC (1-ethyl-3(3-dimethylamino-propyl)-carbodiimide, 
hydrochloride) and NHS (N-Hydroxysuccinimide) in molar ratio of 4:4:1 was 
prepared in PBS buffer at pH 7.4, at room temperature under stirring for 30 min. NPs 
were conjugated with the preactivated-peptide, in MES 0.1 M buffer at pH 5.5 over 
night at room temperature in presence of Tween 20 (0.2%v\v) and the yield of the 
reaction was higher than 90%. The peptide-NPs were purified from the 
unconjugated-NPs by exclusion chromatography on a 1×18 cm Sephadex G-50 
(Amersham Biosciences) column pre-equilibrated in PBS buffer at pH7.4. The 
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fluorescence spectra of peptide-NPs and un-conjugated NPs were measured in a 
Cary Eclipse Varian fluorescence spectrophotometer in the same condition. Peptide-
NPs were prepared with 35% degrees of functionalization 
2.11 Drugs loading into liposomes 
Doxorubicin (Doxo) and Mitoxantrone (MTX) were remote-loaded in liposomes via an 
ammonium sulfate gradient method and the free drugs were removed by gel filtration. 
Briefly, a liposomal solution was prepared as reported above in an ammonium 
sulphate solution (250 mM) at pH 5.5. Next, the external buffer was removed by 
ultracentrifugation at 151332 g, at 4°C for 3 h, and the liposomes were resuspended 
in HEPES-NaCl buffer (5-100 mM) at pH 7.4. A drug solution in water was added to 
the liposomal solution, to achieve a final lipid to drug weight ratio of 10:1. This 
suspension was stirred for 30 min at 60°C. Unloaded drug was removed with a 
Sephadex G50 column for determination of entrapment efficiency. The drug 
concentration was determined by UV spectroscopy measuring the drug absorbance. 
The Drug Loading Content (DLC, defined as the weight ratio of encapsulated drug 
vs. the amphiphilic moieties) was quantified by substracting the amount of drug 
removed from the total amount loaded. Finally, the drug pre-loaded liposomes were 
modified with gH625 by using the click-chemistry reaction procedure, as reported 
above. 
2.12 Structural studies of conjugated peptides 
2.12.1 Circular dichroism measurement 
CD spectra were recorded from 260 to 195 nm on a Jasco J-810 spectropolarimeter 
using a 1.0, 0.1 cm quartz cell at 25°C. For the measurements, the DOPG/DSPE-
PEG liposomes decorated with gH625 were diluted 10 times in a H2O and placed in 
a 0.1 cm quartz cell stabilized at 25°C. The SPIONs conjugated with gH625 were 
diluted 10 times in H2O and in presence of trifluoroethanol (TFE) and placed in a 1.0 
cm quartz cell at 25°C. Other experimental settings were: scan speed of 10 nm min-
1, sensitivity of 50 mdeg, time constant of 16 s, bandwidth of 1 nm. Each spectrum 
was obtained through averaging three scans, subtracting the contributions from 
other species present in solution, and converting the signal to mean molar ellipticity. 
CD spectra were recorded using a Jasco J-715 spectropolarimeter in a 1.0 or 0.1 cm 
quartz cell at room temperature. The spectra are an average of 3 consecutive scans 
from 260 to 195 nm, recorded with a band width of 3 nm, a time constant of 16 s, 
and a scan rate of 10 nm/min. Spectra were recorded and corrected for the blank 
sample.  
2.12.2 Zeta potential and size measurements 
For Dynamic light scattering characterizations of self-assembled liposomes in 
HEPES-NaCl solution were prepared at the final concentration of 1x10-3 M. The 
SPIONs and polystyrene nanoparticles measurements were conducted at 25°C at 
and with a pH varying from 3 to 10. The measurements were performed with a 
Malvern Nanosizer Nano ZS (Malvern Instruments, Worcestershire, UK), a He–Ne 
laser 4mW source operating at 633 nm with the scattering angle fixed at 173°. All the 
measurements were performed at (25.00± 0.05)°C. For zeta potential analysis of 
liposome preparations and SPIONs was used a Zetasizer Nano-ZS (Malvern 
Instruments, Worcestershire, UK). The measurements were conducted at 25°C at 
pH from 3 to 10. All measurements were performed in triplicate for each sample. 
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2.12.3 Transmission Electron Microscopy  
The morphology and size of SPIONs were examined by transmission electron 
microscopy using a JEOL JEM-1230 microscope with 0.2 nm resolution, operating at 
120 kV. Samples were diluted with ultrapure H2O to an iron concentration of 20 mg/L 
before being deposited on a carbon-coated copper grid and left to air-dry. 
2.12.4 Fourier Transform Infrared Spectroscopy 
The chemical composition of nanoparticles was studied by FTIR on a Bruker Vector 
22 FTIR spectrometer. All dried samples were prepared as KBr pellets. FTIR spectra 
were recorded from 400 to 4000 cm−1 with a resolution of 4 cm−1, using a pure KBr 
pellet as zero absorbance reference. 
2.12.5 Atomic Absorption Spectroscopy 
The total iron concentration of SPIONs was determined by atomic absorption 
spectrophotometry at 248 nm. The measurements were performed on an atomic 
absorption spectrometer (AAS) iCE 3000 Series Thermo Scientific. Prior to AAS 
measurements, samples were digested by concentrated hydrochloric acid (37%) and 
then diluted with hydrochloric acid (1%). The calibration procedure for the iron 
absorbance at 248 nm was performed with a series of Fe solutions at concentrations 
of 0.5, 1, 1.5, 2, 2.5, and 3 mg/L (prepared from a 1 g/L Fe standard solution). 
2.12.6 Analysis of the fluorescence emission of tryptophan 
The fluorescence emission spectra were recorded using a Jasco Model FP-750 
spectrofluorimeter (Easton, MD) equipped with a Peltier temperature controller in 1.0 
cm path length quartz cell at 25°C. Emission spectra of liposomes dual decorated 
with gH625 and EGBP were obtained in the range 310 to 400 nm exciting at 295 nm 
at a peptide concentration of 1×10-5 M. Equal excitation and emission bandwidths 
were used throughout the experiments, with a recording speed of 125 nm min-1 and 
automatic selection of the time constant. 
2.13 In vitro drug release from liposomes  
The in vitro release of Doxo from biomimetic liposomes functionalized with gH625 
and biomimetic liposomes functionalized with gH625 and EGBP was determined 
using a dialysis method. Briefly, free Doxo and Doxo-loaded liposomes (with free 
Doxo removed) were placed in a dialysis bag (MW cut off of 1000 Da) and dialyzed 
against HEPES-NaCl and HEPES-NaCl with 50% fetal bovine serum under 
continuous stirring at 37°C. At predetermined time intervals, aliquots were withdrawn 
and replaced with an equal volume of fresh medium. The Doxo concentrations were 
calculated based on the fluorescence absorbance intensity of Doxo excited at 485 
nm using a previously established calibration curve. The cumulative amount of Doxo 
released over the 72 h was quantified, and results were plotted against time.  
The in vitro release kinetics of MTX from liposomes was determined using UV-visible 
spectrophotometry. LMTX and LMTX-gH625 at equivalent MTX concentration were 
placed into 2 mL of HEPES-NaCl buffer and into under continuous stirring at 37°C. 
The release studies were carried out in triplicate. At predetermined time intervals, 
200 µL aliquots were withdrawn and replaced with equal volume of fresh medium. 
The free drug was collected by a Sephadex G50 column and MTX was quantitated 
based on the UV-Vis absorbance at 655 nm using a previously established 
calibration curve. The cumulative amount of MTX released over 24 h was quantified, 
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and results were plotted against incubation time.  
2.14 In vitro studies 
2.14.1 Trypan Blue assay 
The estimation of cell viability for MTX loaded liposomes, composed of 
DOPG/DSPE-PEG was performed by staining with Trypan Blue (TB) (Invitrogen). 
This marker, added to a cell suspension, is able to cross cell membranes that have 
been changed significantly. The TB penetrates only into damaged cells giving them 
a blue colour observable under anoptical microscope. The viable cells, which are not 
permeable to the marker, remain colourless. This assay was performed on HeLa, 
cervical cancer cell of an African-American woman (ATCC, Rockille, MD, USA, CCL-
2) grown as monolayers in Dulbecco’s Minimal Essential Medium (Gibco BRL, 
Invitrogen Corporation, Carlsbad, CA, USA), supplemented with 10% fetal bovine 
serum.(FBS-Euroclone, Milan, Italy), 100mg/ml sodium pyruvate, 100g/ml of 
nonessential aminoacids, 100g/ml penicillin/streptomycin and 100U/ml glutamine 
(Invitrogen - Life technologies, Italy). These cells were cultured at 37°C, in a 
humidified incubator in presence of 5% CO2, using sterile flasks. After reaching the 
confluence of the flask, the medium was removed and the cells were washed with 
phosphate buffer saline (PBS). Subsequently, the cells were incubated with a 
solution of trypsin (0.05% trypsin, 0.0022% EDTA) and PBS at 37°C in the presence 
of 5% CO2 for 3 minutes. Finally, cells detached from the flask were transferred into 
a sterile tube (Falcon) and centrifuged at 325 g for 10 minutes. The cell pellet 
obtained was resuspended in fresh culture medium and the cells were seeded in 12 
well plates (Falcon) in complete medium at a concentration of 350.000-400.000 
cells/well. The following day, the cells were treated with different concentrations of 
LMTX and LMTX-gH625; controls were used as untreated cells (negative control) 
and cells treated with H2O2 (positive control). At the end of the treatments of 1, 4, 6, 
12, 24, 48 and 72 hours, cells were washed three times with PBS to remove the 
liposomes in excess, and then trypsinized. The cells completely detached were 
transferred in falcon tubes and 25 μl of the cell suspension were mixed with 475 μl of 
TB. The cells were counted using the appliance Countess® Cell Counter (Invitrogen). 
The results were expressed as percentage of control. 
2.14.2 MTT viability assay 
The evaluation of cell proliferation for Doxo loaded liposomes composed of 
soy/CHOL/DSPE-PEG was performed on human lung adenocarcinoma cell line wild 
type and doxorubicin resistant in the presence of increasing concentrations of 
samples in a range of 5-0.04 µM or free Doxo in a range of 3-0.02 µM. A549 and 
A549 Dx cells were seeded in 96-well plates in a number of 25x102 per well. The 
growth inhibition was assessed by MTT viability assay after 72 h of treatment as 
previously described [97]. Then the concentrations inhibiting 50% of cell growth 
(IC50) were obtained and these values were used for subsequent experiments. MTT 
assay was carried out by triplicate determination on at least three separate 
experiments. All data are expressed as mean ± SD. 
2.14.3 Alamar Blue assay 
The cytotoxicity of polystyrene NPs was quantified on bEnd.3 by Alamar Blue assay 
and compared to non-treated cells, which were used as a control. Briefly, 3×104 cells 
were seeded on a 35 mm cell culture dish and incubated 24 h with NP suspensions 
to allow endocytosis. Conversely, for NP shooting, cells were shot with NPs by gene 
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gun, washed roughly with PBS and, then, allowed to recover for 24 h at 37°C. After 
recovery, cells were trypsinized, counted and seeded on fresh 35 mm cell culture 
dishes. Alamar Blue Assay was performed according to the manufacturer’s 
procedure at 1 day after NP exposure. Absorbance of Alamar Blue reagent solution 
was read at 570 nm and 600 nm by a plate reader (Perkinelmer). Data were 
reported as percentage of viable cells normalized to non-treated cells.  
2.14.4 Cholesterol depletion 
To extract cholesterol from cell membrane, cells were incubated with 10 mM MβCD 
for 30 minutes at 37°C as previously described [98,99]. After MβCD treatment, NPs 
were added to cell culture medium and incubated with cells for 15 minutes at 37°C. 
Then, cells were rinsed twice with PBS to remove non-internalized NPs and fixed 
with 4% paraformaldehyde for 20 min. Finally, cell nuclei and membranes were 
stained with DAPI and red fluorescent wheat germ agglutinin (WGA), respectively. 
All samples were then observed at confocal microscope (SP5 Leica) with a 63× oil 
immersion objective. Confocal images were analyzed with ImageJ analysis software 
to quantify NP uptake. At least 20 cells of each three independent experiments were 
analyzed. Data were shown as mean ± standard deviation. 
2.15 Flow cytometric analysis 
2.15.1 Flow cytometric analysis of drug accumulation 
The cellular uptake of MTX-loaded liposomes was analyzed by flow cytometry. HeLa 
cells, cultured in Dulbecco’s Minimal Essential Medium supplemented with 10% fetal 
bovine serum, were seeded into six-well at a density of 3 × 105 cells per mL at 37 °C 
for 48 h. Then, cells were treated with a final concentration of 5 μM of LMTX and 
LMTX-gH625 in PBS medium for 1 and 4 hours in a volume of 1 mL. Thereafter, 
cells were washed three time, trypsinized, harvested and then resuspended in 0.5 
mL of PBS. The MTX fluorescence associated to the cells was measured by FACs 
analysis (BD Accuri), using FL4 channel 675/25 nm. The events collected were ten 
thousand and BD Accuri C6 software was used to calculate mean fluorescence 
intensity (MFIs) for each sample. MFIs values were reported as histogram. The 
accumulation of Doxo was analyzed by FACSAria™ (BD Bioscences) after treating 
A549 and A549 Dx cells with a fixed concentration (10 µM) of Lipo, LipoDoxo, 
LipoDoxo-gH625 and Doxo. Briefly, A549 and A549 Dx cells were seeded in 6-well 
plates in a number of 2x105 cells per well and were treated 24 h later with each 
formulation and free Doxo. After 3, 6, 12 and 24 h of treatment cells were 
trypsinezed, washed twice with PBS 1X and pellets were resuspended in 500 μL of 
PBS 1X. Doxo fluorescence associated to the cells was measured using FL2 
channel and calculated as mean fluorescence intensity (MFIs) for each sample. For 
each sample, 2x104 events were acquired. Analysis was carried out by triplicate 
determination on at least three separate experiments.  
2.15.2 Flow cytometric analysis of oxidative stress 
The evaluation of ROS accumulation was detected using dihydroethidium (DHE), a 
specific marker for the determination of reactive oxygen species, in detail superoxide 
anion. Once oxidized within the cell, DHE is converted into ethidium (HE) and emits 
at the wavelength of 605 nm. Briefly, A549 and A549 Dx cells were seeded in 6-well 
plates in a number of 2 x 105 cells per well and were treated 24 h later with 
concentration inhibiting 50% of cell growth of each formulation and Doxo. A549 and 
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A549 DX cells were also treated with 500 µM of H2O2, which is able to induce 
superoxide anion formation, 200 µM of N-acetylcysteine (NAC) as antioxidant agent, 
and H2O2 in combination with NAC. At the end of treatments, A549 and A549 Dx 
cells were incubated for 1 h with 20 ng/mL DHE stock solution (2.5 mg/mL). At the 
time of processing, cells were trypsinized, washed twice with PBS 1X and the pellet 
was resuspended in 500 µl of PBS 1X. The dye accumulation was analyzed by BD 
FACSAria™ (BD Bioscences). For each sample, 2 x 104 events were acquired. 
Analysis was carried out by triplicate determination on at least three separate 
experiments.  
2.15.3 Flow cytometric analysis of apoptosis 
Apoptotic cell death was analyzed by Annexin-V–FITC staining and by propidium 
iodide (PI) detection systems (eBioscences, Vienna, Austria). Briefly, A549 and 
A549 Dx cells were seeded in 6-well plates in a number of 2 x 105 cells per well and 
were treated 24 h later with concentration inhibiting 50% of cell growth of LipoDoxo, 
LipoDoxo-gH625, Doxo and 5 µM of Lipo (concentration proved to be not toxic). 
After 3-6-12-24 h of treatment cells were trypsinezed, washed twice with PBS 1X 
and pellets were resuspended in 200 μL Binding Buffer 1X. Then, 5 μL Annexin V-
FITC were added to 195 μL cell suspension, mixed and incubated for 10 min at 
room temperature. Cells were washed with 200 μL Binding Buffer 1X, resuspended 
in 190 μL Binding buffer 1X and 10 μL Propidium Iodide (20 μg/mL) was added. The 
detection of viable cells, early apoptosis cells, late apoptosis cells and necrotic cells 
were performed by FACSAria™ (BD Bioscences). For each sample, 2 x 104 events 
were acquired. Analysis was carried out by triplicate determination on at least three 
separate experiments.  
2.16 Confocal microscopy studies 
2.16.1 Evaluation of intracellular distribution of Doxo by confocal microscopy 
After 6 and 24 h of incubation of A549 and A549 Dx cells with fluorescent Lipo, cells 
were fixed for 20 minutes with a 3% (w/v) paraformaldehyde (PFA) solution and 
permeabilized for 10 minutes with 0.1% (w/v) Triton X-100 in phosphate-buffered 
saline (PBS) at room temperature. To prevent nonspecific interactions of antibodies, 
cells were treated for 2 h in 5% bovine albumin serum (BSA) in PBS, then cells were 
incubated with a specific mouse monoclonal Ab raised against vimentin (1:1,000 in 
blocking solution, 3% (w/w) BSA in TBS-Tween 0.1%, Sigma) for 2 h at 37 ° C. After 
several washes, cells were incubated with a secondary IgG goat anti-mouse 
antibody (Alexa Fluor 488, Life Technologies, Carlsbad, CA) diluted 1:1,000 in 
blocking solution for 1 h at room temperature. The slides were mounted on 
microscope by Mowiol. The analyzes were performed with a Zeiss LSM 510 
microscope equipped with a plan-apochromat objective X 63 (NA 1.4) in oil 
immersion. The fluorescences of the Doxo and Alexa Fluor 488 were collected in 
multi-track mode using BP550-625 and LP650 as emission filters, respectively. 
2.16.2 In vitro cellular uptake and distribution by Confocal Spectral Imaging 
HeLa cells were plated at a density of 4 × 104 cells/well in 24-well plates onto cover 
glasses for 48 h in DMEM media supplemented with 10% serum. HeLa cells were 
then incubated with either LMTX orLMTX-gH625 at drug concentration of 1 µM for 1 
and 4 h at 37 °C in DMEM media without serum. After the incubation with the 
liposomes, the medium was removed and the cells were washed three times with 
fresh HBSS (Hank’s Balanced Salt Solution, Fisher Bioblock Scientific, Illkirch, 
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France).Washed cells were placed between slide and slip cover. Fluorescence 
measurements were carried out using a LabRam confocal microspectrometer 
(Horiba, Villeneuve d’Ascq, France). The MTX fluorescence was excited with a 
632.8 nm line of an internal, air-cooled, helium-neon laser. The power on the 
samples was ~30 µW, the acquisition time was 0.02 or 0.05 s/spectrum. After the 
acquisition, all the spectra were normalized to an intensity corresponding to the 
same acquisition duration. Treatment of spectral maps was made using LabSpec 
4.18 software (Horiba Villeneuve d’Ascq, France). 
2.16.3 Atomic force microscopy  
For atomic force microscopy (AFM), cells were incubated 10 minutes with blank and 
gH625-NPs, washed twice to remove non internalized NPs and fixed with 4% 
paraformaldehyde for 20 min. Cells not incubated with NPs were used as a control. 
AFM (NanoWizard II, JPK, GMBH) analysis was performed in contact mode by using 
triangular tip with a nominal spring constant of 0.03 N/m (MLCT, Brukerprobes). 30 × 
10 µm2 images were taken at different size applying a force of 1.5 nN with a scan 
rate of 1 Hz and a resolution of 512 × 171. At least 10 images were used to calculate 
the mean roughness (RMS) and processed by JPK analysis software mapping the 
different regions of the whole cell surface.  
2.16.4 Colocalization with endosomes and lysosomes 
For co-localization experiments, after 100 nm PS NPs incubation, cells were firstly 
rinsed twice with PBS to remove non-internalized nanoparticles and fixed. For 
endosome staining, cells were fixed with 4% paraformaldehyde for 10 min at room 
temperature (RT). Then, cells were permeabilized with 0.01% saponin-PBS for 8 min 
and blocked with FBS-PBS 10% for 20 min at RT. Endosomes were localized with 
rabbit anti-Rab 5 polyclonal (Abcam) primary antibodies and with AlexaFluor 633 
goat anti-rabbit secondary antibodies (Molecular Probes, Invitrogen). For lysosomes 
staining, cells were fixed with 4% paraformaldehyde for 20 min at RT. Then, cells 
were permeabilized with 0.05% saponin-PBS for 20 min and blocked with FBS-PBS 
10% for 20 min at RT. Lysosomes were localized with rabbit anti-LAMP 2 polyclonal 
(Abcam) primary antibodies and with AlexaFluor 633 goat anti-rabbit secondary 
antibodies (Molecular Probes, Invitrogen). All samples were then observed at 
confocal microscope (SP5 Leica) with a 63× oil immersion objective and dual-
channel images were acquired. The co-localization analyzes were performed by LAS 
AF (Leica) and ImageJ analysis softwares. Data were expressed as co-localization 
percentage. Moreover, Pearson’s coefficient was also calculated by JACoP plugin 
[100] to have an estimation of the correlation among the pixels in the dual-channels 
images. 
2.16.5 Intracellular shooting of NPs by gene gun method 
To have free NPs in the cytoplasm, a ballistic system (gene gun, BioRad) was used 
as described elsewhere.[101] Briefly, 100 nm amine-modified polystyrene NPs were 
suspended in 30 µl of distilled water at the final concentration of 4.5 × 1012 NPs/ml, 
respectively, deposited and left to dry on a rupture disk under a sterile hood. After 
solvent drying, a 900 psi pressure was used to shoot NPs within cells. After 
shooting, cells were roughly rinsed with PBS to remove non-internalized NPs and, 
the day after, the cells were recovered and 3×104 cells were seeded in each fresh 35 
mm culture dish. 
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2.16.6 Multiple particle tracking 
Images of shot and endo 100 nm NPs in bEnd3 cells were collected in time-lapse for 
100 s with a sampling time of 1 second by using a wide field fluorescence 
microscope (Olympus Cell-R, 60x oil immersion objective, NA = 1.35). Tracking 
algorithm has been described in details elsewhere.[102] NP trajectories were built 
and then the mean square displacement (MSD) was calculated and correlated with 
the NP diffusion by the equation: MSD = 4Dtα, where D is the diffusion coefficient 
and α represents the time dependence. The MSD curve of each tracked NP was 
fitted by using equation (1), in order to gain information about the nature of particle 
motion into the cells. Briefly, we indicate as Brownian or sub-diffusive, NPs 
exhibiting MSD curve that undergoes a power law with exponent α =1 and α<1, 
respectively, and super-diffusive, particles presenting MSD, whose dependence on 
time was described by the power law with α>1. NPs presenting a MSD curves with a 
time exponent α ≤1 at low Δt and α≈0 were classified as entrapped (random caged) 
in confined endo-lysosomal regions and not computed. The percentages of 
randomly moving NPs (α≤1) and transported NPs (1<α<2) were evaluated and 
compared for shooting and endocytosis as a function of NP surface functionalization 
with gH625 peptides. For each experiment, at least, 5 cells were analyzed. 
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3 Results 
3.1 Abstract 
The work was aimed at exploring the possible applications of a drug delivery 
nanoplatform for cancer diagnostic and therapy. Cancer is the second leading cause 
of death in the world. Nanomedicine has opened up a new world of opportunities for 
the development of efficient medical diagnostic methods and of selective cancer 
therapy. In this project three different nanosystems were investigated, in order to 
exploit the benefits of each one. Moreover, peptides were used to overcome the 
cellular barriers. 
1. The first nanoplatform is liposome based. We focused on: 
o The analysis of quantitive and qualitative effects of gH625-liposomes 
on the delivery of the anticancer drug mitoxantrone in HeLa cells. 
o The analysis of the eventual ability of gH625–liposomes to deliver the 
anticancer drug doxorubicin and to overcome resistance in lung 
adenocarcinoma cells. 
o The analysis of the eventual ability of gH625-liposomes also decorated 
with the EGB peptide to actively target the epidermal growth factor receptor 
(EGFR) and thus determine the selectivity of the nanoplatforms. 
 
2. The second nanoplatform is based on multifunctional magnetic nanoparticles 
(SPIONs). We focused on the preparation of SPIONs carrying the doxorubicin and 
functionalized with gH625 in order to obtain a novel theranostic system with 
enhanced uptake. 
 
3. The third nanoplatform is based on polystyrene nanoparticles. We focused on 
the possibility to functionalize the NPs with gH625 and ehance the crossing of the 
blood brain barrier. 
 
 
3.2 Peptide synthesis and characterization  
3.2.1 Synthesis and characterization of gH625  
The peptide gH625 (Table 4) was synthetized using standard solid-phase-Fmoc 
method. We synthetized it with different functionalizations which allowed use to 
couple it on the selected nonosystems with different strategies. The peptide was 
synthetized with an acetyl protecting group at the N terminus and a carboxyl group 
at the C-terminus in order to couple it to SPIONs and polystyrene NPs and with a 
propargylglycine moiety (Pra) at C-terminus to couple it to liposomes. After the 
synthesis, the final products were cleaved from the resin and purified by RP-HPLC. 
The purified peptides were characterized using LC-MS. Figure 9 reports the TIC 
profile, HPLC spectrum (panel A) and mass spectrum (panel B) of gH625 Pra, as an 
example.  
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Figure 9. gH625-Pra: TIC profile and HPLC spectrum (A); mass spectrum (B) 
 
 
Table 4. Peptide sequences and their molecular weight 
PEPTIDES SEQUENCES M.W 
Ac-gH625 Ac-NH2-HGLASTLTRWAHYNALIRAF-COOH 2339.6 
gH625-Pra NH2-HGLASTLTRWAHYNALIRAF-Pra-CONH2 2391.3 
Ac-gH625-GGG Ac-NH2-HGLASTLTRWAHYNALIRAFGGG-COOH 2510.8 
GGG-EGBP (TP1) NH2-GGGFPMFNHWEQWPPG-CONH2 1844.1 
PEG2-EGBP (TP2) NH2-PEG2-FPMFNHWEQWPPG-CONH2 1817.1 
Chol-GGG-EGBP (Chol-TP1) Chol- GGGFPMFNHWEQWPPG-CONH2 2257.2 
Chol-PEG2-EGBP (Chol-TP2) Chol-PEG2-FPMFNHWEQWPPG-CONH2 2231.2 
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3.2.2 Synthesis and characterization of EGBP 
The EGBP peptide (Table 4) was synthetized using standard solid-phase-Fmoc 
method. We synthetized it with a spacer of three glycines and with a hydrophilic 
PEG based linker at N-terminus. The linker is necessary to expose the targeting 
peptide and enhance its interaction with the receptor. The glycine linker increases 
the space between the peptide and the nanosystem and increases the flexibility of 
the peptides. The PEG linker, not only increases the flexibility but thanks to its 
hydrophilic nature, exposes more the targeting peptide on the liposome surface. The 
synthesis of the GGG-EGBP (TP1) and PEG2-EGBP (TP2) were carried out entirely 
on a solid phase using standard Fmoc/tBu (tBu=tert-butyl) chemistries. The final 
products were cleaved from the resin and purified by RP-HPLC and analyzed by 
mass spectrometry. 
The N-terminus of both EBGP peptides were conjugated to cholesterol in solution as 
reported in “Materials and Methods” in order to use them directly in the liposome 
preparation. The conjugates obtained were analyzed by LC-MS. Figure 10 reports 
the TIC profile, HPLC spectrum (panel A) and mass spectrum (panel B) of Chol-TP2, 
as an example.  
 
 
 
 
Figure 10. Chol-TP2: TIC profile and HPLC spectrum (A); mass spectrum (B) 
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3.3 Synthesis of the lipid moiety (C18)2L-N3 
The lipid moiety (C18)2L-N3 was synthetized on solid phase following a modified 
protocol of the classical Fmoc/tBu strategy (Figure 11). The Fmoc-Lys(Mtt)-OH was 
anchored on the Rink amide resin. The Fmoc protecting group was removed and an 
ethoxylic linker was introduced. Its NH2 function was converted into azide by diazo 
transfer using a sulfonyl azide, as previously reported in literature [94]. After removal 
of the Mtt group from the Nɛ of the lysine, the lipid chain was added. As expected, no 
reductive side reaction of azide functionalized derivative was observed during the 
cleavage step of the lysine derivative from the resin (data not shown) [103]. The 
obtained compound was analyzed by 1H and 13C-NMR  to confirm compound identity. 
 
 
 
Figure 11. (A) Schematic representation of (C18)2L-N3 synthetic monomer; (B) Scheme for the solid-
phase synthesis of the (C18)2L-N3 monomer. Rink-amide Resin is schematically represented as an 
empty circle 
 
 
 
3.4 Liposomes preparation with and without peptides 
Liposomes were generated by the thin-film hydration method [104]. Briefly, the lipid 
mixture was prepared by dissolving the lipids and when necessary Chol-GGG-EGBP 
(Chol-TP1) or Chol-PEG2-EGBP (Chol-TP2) in a small amount of organic solvent, 
and subsequently evaporating the solvent. The lipid film was then dissolved in 
aqueous media and extruded to ensure the desired size, thought a polycarbonate 
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membrane with 100 nm pore size using a thermobarrel extruder (Northern Lipids). 
The composition of the liposomes is reported in each paragraph. 
3.5 Quantitative and qualitative effect of gH625 on the liposome-mediated 
delivery of mitoxantrone  
The in vitro delivery of the anticancer drug mitoxantrone (MTX) to HeLa cancer cells 
by liposomes, composed of DOPG and DSPE-PEG functionalized with the cell 
penetrating peptide gH625 was investigated. In order to get a better insight into the 
role of gH625 on the mechanism of liposome-mediated drug delivery, we treated 
HeLa cells with liposomes functionalized and not with gH625 and loaded with MTX. 
The subcellular drug distribution was analyzed by fluorescence-based techniques, 
such as fluorescence-activated cell sorting (FACS) and confocal spectral imaging 
(CSI). 
3.5.1 MTX loading 
MTX was loaded into DOPG/DSPE-PEG/(C18)2L-N3 (85/5/10 molar ratio) liposomes 
using the well-assessed procedure based on the ammonium sulphate gradient [105]; 
in particular, a solution containing MTX was incubated under stirring for 30 min at 
60°C. Subsequently, unloaded MTX was removed using a Sephadex G50 column 
pre-equilibrated with HEPES-NaCl buffer (5mM-100mM) at pH 7.4. The drug/lipid 
weight ratio chosen for the loading experiments was 0.1. The drug loading efficiency 
calculated from the unloaded MTX absorbance at λ=655 nm was higher than 97% of 
the total amount incubated. 
3.5.2 Functionalization of liposomes with gH625 
The resulting liposomes loaded with MTX (LMTX) further modified with the gH625-
Pra (to become LMTX-gH625) via click-chemistry reaction performed in aqueous 
medium. The coupling of the Pra moiety of the gH625 to the liposome surface was 
obtained due to a copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition reaction of 
azides and alkynes [106]. CuI catalyser was generated in situ by reduction of CuSO4 
with ascorbic acid [107]. The LMTX-gH625 was obtained with a yield higher than 
90% after 12 h at room temperature. The unreactive nature of both azides and 
alkynes towards any other functional group present in the biomolecules, as well as 
the thermal and hydrolytical stability of their cycloaddition product make this reaction 
particularly appealing for liposome functionalization with peptides. After the 
conjugation step, liposomes were purified by exclusion chromatography on a 1x18 
cm Sephadex G-50 (Amersham Biosciences) column pre-equilibrated with HEPES 
buffer. 
3.5.3 MTX fluorescence intensity and release kinetics 
In spite of the same concentration inside the liposomes, the MTX fluorescence 
intensity from LMTX in aqueous suspension was about 5.7 times higher than in 
LMTX-gH625. The MTX fluorescence in gH625 is partially quenched by Cu ions 
used to catalyze the peptide coupling to the liposomes. This result was obtained by 
the experiment described below. Both LMTX and LMTX-gH625 were dissolved with 
0.2% of Triton X-100 and incubated for 1 h with EDTA (10 mM) at 37°C. This 
treatment brought to a full restoration of the absorbance intensity of the MTX 
realesed from LMTX-gH625, while for LMTX, which did not contain copper, the 
absorbance intensity of the released drug was not affected (Figure 12). Therefore, 
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copper ions are able to penetrate LMTX-gH625 and to quench the loaded MTX 
fluorescence and absorbance. 
 
 
Figure 12. Effect of combination of Triton and EDTA on LMTX and LMTX-gH625. Both liposomes 
were treated by Triton X-100 (TX-100) and 10 mM of EDTA at 37°C. The presence of EDTA brought 
full restoration of MTX absorbance intensity in LMTX-gH625, while on LMTX had not effect. 
 
 
There were no pronounced differences between LMTX and LMTX-gH625 from the 
point of view of the drug release kinetics in vitro, in HEPES-NaCl buffer (Figure 13). 
Less than 30% of loaded MTX was released within 24 h, indicating the good stability 
of liposomes. 
 
 
 
 
Figure 13. Kinetics of in vitro release of MTX from LMTX and LMTX-gH625. 
 
3.5.4 Liposomes Characterization  
Physico-chemical characterization of liposomes alone and functionalized with gH625 
was performed by Circular Dichroism (CD) and Dynamic light scattering (DLS). CD 
Peptide Based Platforms for Cancer Drug Delivery 
 
 
43 
 
spectra showed that gH625 when conjugated to liposomes at a concentration of 
1.25x10-6 M adopts an α helical conformation (Figure 14), while the peptide alone in 
buffer adopts a random coil structure; suggesting that the coupling on the surface of 
the liposomes was sufficient to induce the secondary structure which is probably 
playing a key role in translocation across the membrane bilayer. 
 
Figure 14. Circular dichroism spectrum of gH625 conjugated to liposomes and of gH625 
alone 
 
 
DLS data on LMTX and on LMTX-gH625 dispersed in aqueous medium at pH 7 
(Table 5) showed that the liposome functionalization with gH625 only slightly 
increased their average hydrodynamic diameter, from ca. 111.80 to 122.05 nm. The 
polydispersity index changed from ca. 0.09 to ca. 0.19, indicating that the distribution 
of the liposome size remained rather narrow and there are no signs of aggregation. 
These parameters should favour both the effective extravasation of liposomes and 
their longer retention in tumor tissues. The surface charge of the liposomes, as 
determined by measurement of their zeta potential, was also slightly reduced on 
going from LMTX to LMTX-gH625, from ca. -26.30 to -21.30 mV (Table 5). It is 
widely accepted that at high values of zeta potential (over 20 mV, positive or 
negative) the electrostatic repulsions between particles are strong enough to ensure 
their colloidal stability. The aqueous suspensions of both LMTX to LMTX-gH625 
were stable colloids.  
 
Table 5. Colloidal characteristics of LMTX and LMTX-gH625 
Liposome type Average size (nm) PDI Zeta potential (mV) 
LMTX 111.80±1.42 0.09±0.02 -26.30±1.00 
LMTX-gH625 122.05±1.05 0.19±0.07 -21.30±1.10 
Data obtained for three independently prepared batches of each liposome type, with at least 13 runs per 
batch. 
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3.5.5 Liposomes cytotoxicity on HeLa cells 
The cytotoxicity of liposomes was evaluated staining Triptan Blue on HeLa cells. 
Within 4 and 6 h treatment duration, a higher cytotoxicity was observed for LMTX-
gH625 than LMTX (Figure 15 a). At 48 and 72 h, no significant differences were 
noticed between the two types of liposomes; indicating that at high incubation times 
both are significantly toxic to the cells.  
3.5.6 Liposomes uptake by flow cytometry 
The uptake of LMTX and LMTX-gH625 in HeLa cells was determined using flow 
cytometry analysis.  
Flow cytometry allowed to compare quantitatively the MTX uptake by HeLa cells 
treated with LMTX-gH625 or with LMTX (Figure 15 b). An increased uptake of MTX 
from liposomes was clearly observed in presence gH625. 
 
 
 
Figure 15. Cytotoxicity of liposomes on HeLa cells at several times of incubation (panel a). Flow 
cytometry data on the MTX uptake by HeLa cells (panel b).  
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3.5.7 Liposomes uptake by CSI technique 
For better understanding of the observed cytotoxicity and uptake, the subcellular 
distribution and interaction of the delivered MTX in live HeLa cancer cells was 
determined by confocal spectral imaging (CSI) technique. As described above, the 
CSI approach consists in recording the complete fluorescence at each scanned 
point of the cell and therefore exploiting both the spectral shape and intensity. Full 
fluorescence spectra (in the 640-920 nm range) were then recorded via point-by-
point scanning of the equatorial optical section of the treated cells (see the 
Experimental section). From these spectra, the parametric maps were generated 
using either total fluorescence intensity (area of the whole spectrum) or  coefficients 
determined from fitting each experimental spectrum with spectra characteristic of 3 
intracellular molecular interactions of the drug: I) MTX at lipophilic environment, 
where the spectrum is very close in shape to that of the drug in LMTX suspension 
(blue zones and spectra in Figure 16); II) MTX in nucleus, where a significant 
bathochromic shift of the spectrum is observed due to the drug intercalation between 
DNA base pairs (green zones and spectra in Figure 16); and III) an oxidative 
metabolite of the drug stained in the low polarity environment, with the blue-shifted 
spectrum (red zones and spectra in Figure 16). These characteristic spectra are 
consistent with those previously reported by Prof. Chourpa group for the MTX 
incubated as aqueous solution with MDA-MB-231 and MCF-7 cancer cell lines [108]. 
In the present study, the fact that not only the blue spectra but also the shifted ones 
were observed indicates that the drug was released, at least in part, from the 
liposomes and was able to reach the nucleus. Interestingly, the blue and red spectra 
were highly co-localized in some perinuclear regions, indicating that the lipophilic 
locations favour the drug oxidative metabolism. In previous studies, [108] it was 
found that the metabolite co-localized with the fluorescent label of endoplasmic 
reticulum and its presence was correlated with higher sensitivity of cancer cells to 
chemotherapeutic drug MTX. From the point of view of the fluorescence intensity, it 
is difficult to establish the exact quantum yields in these three subcellular situations. 
Nevertheless, it is commonly believed that the lower polarity environment of 
fluorophore favours higher quantum yields while the DNA intercalation leads to a 
partial quenching of the drug fluorescence. For this reason, the intensities used in 
Figure 16 allow only a comparative discussion, but could be calibrated to 
concentrations once the quantum yields are established (it was not a subject of the 
present study). 
The results shown in Figure 16 allow to analyze two effects, incubation duration (1 h 
versus 4 h) and liposomes functionalization with gH625. The spectral maps show 
that the increase of the incubation duration from 1 h to 4 h, determines a significant 
increase in the total intracellular drug fluorescence (2 to 5 fold, see the statistical 
summary in Figure 16). Similar total fluorescence intensity was reached with both 
types of nanosystems. In contrast, for the LMTX and not for the LMTX-gH625, 4 h 
versus 1 h incubation resulted in a different subcellular redistribution of the MTX 
fluorescence: the relative fractions of lipophilic vs nuclear locations were inversed. 
The analysis of this inversion together with the nearly 2-fold increase of total 
intensity in LMTX between 1 h and 4 h, lead to the supposition that the total drug in 
the nucleus is probably not decreased while the drug presence in the perinuclear 
locations is more pronounced. For the LMTX-gH625, the drug fluorescence from the 
hydrophobic perinuclear regions was dominant even after only 1h of incubation and 
the subcellular distribution remained nearly constant between 1 h and 4 h of 
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incubation. The latter means that the 5-fold increase of the intracellular fluorescence 
intensity for the gH625-modified liposomes is related to the increased uptake of the 
liposomes and not to the quantum yields changes.  
The subcellular distribution of MTX delivered with liposomes was different from that 
of MTX in solution: while the drug solution was mainly and rapidly stained in nucleus 
of cancers cells [108], liposomes mainly directed the drug to the perinuclear zones 
where the metabolite production/staining by the cells was also more significant than 
with solutions. This could be the effect of the liposomal delivery of MTX. The above 
described results lead to the following conclusions about the effect of the liposomes 
functionalization with gH625: I) it makes the MTX uptake to the hydrophobic 
perinuclear staining zones even more efficient; II) it favours even more the presence 
of an oxidative metabolite of the drug in the same perinuclear regions. 
 
 
 
 
 
 
 
Figure 16. In vitro study of subcellular interaction and distribution of MTX delivered from LMTX and 
LMTX-gH625to live HeLa cancer cells. Left panel: representative images of individual cells, i.e. merge 
of the white light images with the fluorescence spectral maps showing either total spectral intensity 
(yellow zones) or merged spectral maps characteristic of 3 intracellular molecular interactions of the 
drug: MTX at lipophilic environment (blue zones and spectra), MTX-DNA complex in nucleus (green 
zones and spectra) and presence of an oxidative metabolite of the drug (red zones and spectra). 
Average spectra of the respective cells are shown in the middle column. Right panel: statistical 
summary of the data over a population of at least 6 cells. 
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3.6 Liposome armed with gH625 peptide to overcome resistance in lung 
adenocarcinoma cell lines 
Liposomes with enhanced biomimetics characteristics (phospholipids derived by soy) 
and functionalized on their external surface with PEG were used for this study. The 
success of pharmacological treatments is often hampered by the onset of the drug 
resistance. MDR is due to the selection of cancer cell clones expressing molecules 
that protect tumor cells from anti-cancer agents [109,110]. New delivery systems 
including liposomes have been developed to circumvent drug resistance; they have 
attracted great attention since they are ideal for loading and delivery of different 
molecules, therefore, offering novel opportunities for cancer treatment [64,82,111]. 
Here, the anti-cancer activity of Doxo-encapsulating liposomes was investigared in 
vitro. The liposomes were constituted by soy phospholipids, cholesterol and 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] 
(DSPE-PEG), in order to improve biocompatibility and lead to a prolonged presence 
in the systemic circulation. 
3.6.1 Conjugation of gH625 
The coupling of gH625 on the surface of preformed liposomes, composed of soy 
phospholipid mixture/cholesterol/DSPE-PEG/(C18)2L-N3 (57:28:5:10 molar ratio) was 
performed by click chemistry (Figure 17). This procedure involves a copper(I)-
catalyzed Huisgen 1,3-dipolar cycloaddition reaction of azides and alkynes yielding 
1,4-disubstituted 1,2,3-triazole-linked conjugates [106]. The click reaction was 
performed in an aqueous solution and was catalyzed by CuI generated, in situ, by 
reduction of CuSO4 with ascorbic acid [107]. An equimolar mixture of NH2-gH625-
Pra and azido functions on the liposome surface were used and the expected 
gH625-functionalized liposomes were obtained with a yield higher than 90% after 12 
h at room temperature. In the absence of the copper catalyst no reaction was 
observed.  
 
 
 
Figure 17. Scheme of the functionalization reaction of gH625 to LipoDoxo 
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3.6.2 Doxo loading  
Doxo was loaded into soy phospholipid mixture/cholesterol/DSPE-PEG/(C18)2L-N3 
liposomes using the well-assessed procedure based on the ammonium sulphate 
gradient [105]; in particular, a solution containing Doxo was incubated under stirring 
for 30 min at 60°C. Subsequently, unloaded Doxo was removed using a Sephadex 
G50 column pre-equilibrated with HEPES-NaCl buffer (5mM-100mM) at pH 7.4. The 
drug/lipid weight ratio chosen for the loading experiments was 0.1. The drug loading 
content (DLC) was above 90% of the total. The drug loaded liposomes (LipoDoxo) 
were then efficiently modified with the gH625-Pra peptide (LipoDoxo-gH625) 
according to the click-chemistry procedure used in the case of empty liposomes. 
 
3.6.3 Liposomes physico-chimical characterization 
Dynamic light scattering (DLS) measurements were performed on liposomes alone 
and on gH625 functionalized liposomes. All liposome solutions (Table 6) present a 
monomodal distribution with a polydispersity index (PDI)< 0.2, indicating a narrow 
and homogenous size distribution, optimal not only for the more effective 
extravasation of liposomes, but also for their longer retention in tumor tissues. The 
analysis of the zeta potential shows a change between Lipo and LipoDoxo 
compared to LipoDoxo-gH625, which indicates a change in the surface of the 
liposomes upon functionalization with the peptide. 
 
 
Table 6. Zeta potential, size, expressed as z-average, as measured by DSL and 
polydispersivity index (PDI). Data are expressed as means±standard deviation (SD) of three 
separate experiments for each of two batch formulations, with at least 13 measurements for 
each. 
Liposomes Average Size (nm) PDI Zeta potential (mV) 
Lipo 104.95±1.63 0.17±0.01 -7.40±1.50 
LipoDoxo 129.85±1.82 0.15±0.03 -7.43±1.84 
LipoDoxo-gH625 143.90±0.64 0.14±0.02 9.43±1.61 
 
 
 
3.6.4 Release kinetics of Doxo 
The release of Doxo was carried out in HEPES-NaCl buffer or HEPES-NaCl buffer 
with 50% FBS and the results are presented in Figure 18. Free Doxo was used as 
control and its release rate was nearly 100% in 2 h, which means that the release of 
Doxo from dialysis membrane to buffer solution is not a restricting factor and the 
release of Doxo from the liposomes is the only rate limiting step. There were no 
pronounced differences in Doxo release (Figure 18) from LipoDoxo and LipoDoxo-
gH625 at each time point, indicating that the decoration of the surface of the 
liposomes with gH625 did not substantially change the release kinetics of liposomes. 
The Doxo release from liposomes decorated and not with gH625 is less than 30% 
within 72 h, indicating their good stability. 
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Figure 18. Release profile of doxorubicin from liposomes at 37 °C in HEPES-NaCl buffer (A) and in 
HEPES-NaCl buffer with 50% FBS (B). 
 
3.6.5 Antitumoral activity of liposomes 
The effects of Doxo, empty liposomes and liposomes encapsulating Doxo 
conjugated or not with gH625 were evaluated on the proliferation of either parental 
A549 or Doxo-resistant cells (A549 Dx) by MTT assay. Doxo, LipoDoxo and 
LipoDoxo-gH625 induced a dose-dependent growth inhibition in both cell lines after 
72 h, while treatment with Lipo produced no significant cytotoxic effects in both cell 
lines (Figure 19 A e B). In Table 6, the results are reported as concentrations 
inhibiting 50% of cell growth (IC50) after 72 h of treatment. The IC50 was reached 
with 0.06 µM and 0.2 µM of Doxo (Figure 19 C, Table 7), with 2.5 µM and 5 µM of 
LipoDoxo (Figure 19 A e B, Table 7), with 0.5 µM and 2.7 µM of LipoDoxo-gH625 
(Figure 19 A e B, Table 7) in A549 and A549 Dx cells, respectively. These data 
suggested that A549 cells were more sensitive to the treatment with Doxo compared 
to A549 DX, confirming the drug-resistant phenotype of this cell line. Both cell lines 
were more responsive to LipoDoxo-gH625 compared to LipoDoxo. These data 
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suggested that the conjugation of liposomes with gH625 probably facilitated the 
entry and retention of doxorubicin in both sensitive and drug-resistant tumor cell 
lines allowing an increase of cell growth inhibition. 
 
 
 
 
 
Figure 19. Evaluation of cell growth in lung adenocarcinoma cell line sensistive (A549) and resistant 
(A549 Dx) to doxorubicin after 72 h of treatment with Lipo, LipoDoxo, LipoDoxo-gH625 (A- B) and 
doxorubicin (Doxo) (C). 
 
 
 
Table 7. IC50 values of the different formulations Concentration inhibiting 50% of cell growth 
(IC50) reached after 72 h of treatment with Lipo, LipoDoxo, LipoDoxo-gH625, Doxo in A549 and 
A549 Dx cells. Data are shown as mean ± SD. 
Compounds IC50 ± SD A549 IC50± SD A549 DX 
Lipo >5.00 µM ± 0.02 >5.00 µM ± 0.02 
LipoDoxo 2.50 µM ± 0.02 5.00 µM ± 0.02 
LipoDoxo-gH625 0.50 µM ± 0.02 2.70 µM ± 0.04 
Doxo 0.06 µM ± 0.03 0.20 µM ± 0.02 
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3.6.6 FACS analysis in A549 and A549 Dx cell lines: accumulation, evaluation 
of oxidative stress, evaluation of cell death 
The accumulation of doxorubicin, free or encapsulated in liposomes conjugated or 
not with gH625, was investigated by flow cytometry analysis. A time-dependent 
accumulation of free and encapsulated Doxo was observed in A549 and A549 Dx 
cells and the maximal levels were reached after 24 h (Figure 20 and 21). Moreover, 
LipoDoxo-gH625 induced in both cell lines a greater doxorubicin accumulation than 
LipoDoxo (Figure 20 and 21). In particular, A549 Dx cells showed an early 
accumulation of doxorubicin after 3 h of treatment with both liposomal formulations 
and the accumulation was higher if compared to the one observed in parental A549 
cells (Figure 20 and 21). This effect was more evident in resistant cells treated with 
LipoDoxo-gH625 that induced an increase of about 86.9% of MFI against an 
increase of about 64.3% of MFI induced in parental cells (Figure 20 and 21, 
respectively). Moreover, after 24 h we observed a two-fold increase of percentage of 
MFI in A549 Dx cells treated with LipoDoxo-gH625 if compared to those exposed to 
LipoDoxo (Figure 20). Similar data were also obtained in parental cells but to a 
lesser extent (Figure 21). Therefore, these data suggested that the conjugation of 
liposomes with the viral peptide increased the retention of doxorubicin into the cells 
supporting the data obtained on the growth inhibition. 
 
 
 
 
 
 
 
 
Figure 20. Doxorubicin accumulation in A549 cells after 3, 6, 12 and 24 h of treatment with LipoDoxo, 
LipoDoxo-gH625 and Doxo. (A) Flow cytometry overlay of Doxo fluorescence intensity. (B) Histogram 
of Doxo mean fluorescence intensity (% of control). The bars represent means ± SD of three 
independent experiments. Asterisks indicate significant difference between LipoDoxo vs LipoDoxo-
gH625 (**P<0.01) (*P<0.05) 
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Figure 21. Doxorubicin accumulation in A549 Dx cells after 3, 6, 12 and 24 h of treatment with 
LipoDoxo, LipoDoxo-gH625 and Doxo. (A) Flow cytometry overlay of Doxo fluorescence intensity. (B) 
Histogram of Doxo mean fluorescence intensity (% of control). The bars represent means ± SD of 
three independent experiments. Asterisks indicate significant difference between LipoDoxo vs 
LipoDoxo-gH625 (**P<0.01) (*P<0.05). 
 
 
 
 
The accumulation of superoxide anions (O2−) in A549 e A549 Dx was also studied. 
In both cell lines free doxorubicin induced a time-dependent accumulation of 
superoxide anions (Figure 22 and 23) significantly lower compared to that induced 
by both liposomal formulations. In details, the maximal O2− level increase in A549 
cell line was detectable after 48 h of treatment with LipoDoxo. LipoDoxo-gH625 
induced an accumulation of O2− lower than LipoDoxo but this effect was maintained 
up to the end of treatment (72 h) differently from LipoDoxo (Figures 22). On the 
other hand, both formulations induced similar effects on A549 Dx cells after 24 h of 
treatment, but a significant increase of oxidative stress was observed after 72 h of 
treatment with LipoDoxo-gH625 if compared to the one induced by LipoDoxo (Figure 
23). In both cell lines NAC had no effect on the increase of O2− levels in contrast to 
H2O2 and acted as a scavenger in combination with H2O2 (Figures 22 and 23) 
decreasing the accumulation of superoxide anions.  
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Figure 22. Evaluation of oxidative stress in A549 cells after 24, 48 and 72 h of treatment with 
LipoDoxo, LipoDoxo-gH625 and Doxo. A) Flow cytometry overlay of dihydroethidium (DHE) 
fluorescence intensity. (B) Histogram of DHE mean fluorescence intensity (% of control). The bars 
represent means ± SD of three independent experiments. Asterisks indicate significant difference 
between LipoDoxo vs Doxo and LipoDoxo-gH625 vs Doxo (**P<0.01) (*P<0.05). 
 
 
 
 
Figure 23. Evaluation of oxidative stress in A549dx cells after 24, 48 and 72 h of treatment with 
LipoDoxo, LipoDoxo-gH625 and Doxo. (A) Flow cytometry overlay of dihydroethidium (DHE) 
fluorescence intensity. (B) Histogram of DHE mean fluorescence intensity (% of control). The bars 
represent means ± SD of three independent experiments. Asterisks indicate significant difference 
between LipoDoxo vs Doxo and LipoDoxo-gH625 vs Doxo (**P<0.01). 
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A further experiment was performed to evaluate the effects of Doxo and liposomial 
preparation on inducing apoptosis or necrosis. In agreement with the data obtained 
from the MTT assay, empty liposomes did not induce any significant toxic effects on 
both cell lines at any time-point tested (Figure 24 and 25).  
 
 
 
 
Figure 24. Evaluation of apoptosis in A549 cells by Annexin V/PI assay (flow cytometry) after 48 h of 
treatment with LipoDoxo, LipoDoxo-gH625 and Doxo. (A) Flow cytometry dot plots. (B) Histogram of 
data expressed as percentage of viable cells, early/late apoptotic cells and necrotic cells after 3, 6,12 
and 24 h. The bars represent means ± SD of three independent experiments. Asterisks indicate 
significant difference between LipoDoxo-gH625 vs Doxo (**P<0.01). 
 
 
In contrast, LipoDoxo caused an accumulation of about 27.7% necrotic cells in 
parental A549 and about 21.1% of late apoptotic cells were recorded after 24 h. This 
effect was more marked when using LipoDoxo-gH625 with about 41.8% of necrotic 
cells and about 23.3% of apoptotic cells (Figure 24).  
On the other hand, LipoDoxo induced late apoptosis in about 5.5% of A549 Dx cells 
while necrosis was recorded in about 36.5% of A549 Dx  cells after 24h of treatment 
(Figure 25). This effect was potentiated also in doxorubicin-resistant cells by 
LipoDoxo-gH625 that caused about 3.8% of late apoptosis and about 50.5 % of 
necrosis (Figure 25). Free doxorubicin induced more significant effects on A549 cells 
than on A549 Dx cells but to a lesser extent. In fact, it caused an accumulation of 
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about 25.7% and 16.4% of necrotic cells in A549 and A549 Dx cells, respectively 
(Figure 24 and 25, respectively).  
On the basis of these results, it can be suggested that LipoDoxo-gH625 induced 
more significant effects on cell death in both cell lines, but with different 
mechanisms. In fact, we have found that the main mechanism by which LipoDoxo 
caused cell death in parental A549 was necrosis while it caused apoptosis in 
doxorubicin-resistant counterpart. These effects were potentiated by LipoDoxo-
gH625 in both experimental cell models (Figure 24 and 25). 
 
 
 
 
 
Figure 25. Evaluation of apoptosis in A549dx cells by Annexin V/PI assay (flow cytometry) after 48 h 
of treatment with LipoDoxo, LipoDoxo-gH625 and Doxo. (A) Flow cytometry dot plots. (B) Histogram 
of data expressed as percentage of viable cells, early/late apoptotic cells and necrotic cells 3, 6, 12 
and 24 h. The bars represent means ± SD of three independent experiments. Asterisks indicate 
significant difference between LipoDoxo-gH625 vs Doxo (**P<0.01). 
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3.6.7 Intracellular distribution of Doxo in A549 and A549 Dx cells 
In order to investigate the intracellular distribution of the different formulations, the 
Doxo fluorescence associated to the cells was evaluated by confocal laser scanning 
microscopy (CLSM). A549 and A549 Dx were incubated with IC50 of free Doxo, 
LipoDoxo and LipoDoxo-gH625 for 6 and 24 h. After 6 h, free Doxo and LipoDoxo-
gH625 entered A549 cells and translocated into the nucleus as indicated by the red 
fluorescence in the center of the cell body (Figure 26) while LipoDoxo accumulate in 
the cytoplasm, without entering into the nucleus (Figure 26). In fact, cell nuclei are 
dark and only few red fluorescent spots, distributed in the cytoplasm, are visible. No 
fluorescence was observed in A549 treated with empty liposome as expected. On 
the other hand, in A549 Dx free Doxo was not able to enter into the nucleus 
accumulating in perinuclear region while CLSM results showed a widespread and 
intense fluorescence, with intranuclear red spots for cells incubated with LipoDoxo-
gH625 (Figure 26). Cells treated with LipoDoxo evidenced a significant lower 
fluorescence intensity, with visible red spots into the cytoplasm. We observed a 
time-dependent accumulation of free and encapsulated Doxo and the maximal levels 
were reached after 24 h in both cell lines (Figure 27). Therefore, the intracellular 
uptake of liposomes armed with gH625 could contribute to overcome resistance in 
lung adenocarcinoma cell lines 
 
 
 
 
 
 
 
Figure 26. Confocal microscopy images of A549 and A549 Dx cells after 6 h incubation with free 
Doxo, LipoDoxo, or LipoDoxo-gH625. On the left, merged image (green vimentin; red doxo; blue 
dapi). On the right, Doxo distribution. 
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Figure 27. Confocal microscopy images of A549 (A) and A549 Dx (B) cells after 24 h incubation with 
free Doxo, LipoDoxo, or LipoDoxo-gH625. On the left, merged image (green vimentin; red doxo; blue 
dapi). On the right, Doxo distribution. 
 
3.7 Design of dual-ligand nanoliposomes using a specific ligand and gH625 
Liposomes conjugated to gH625 are promising because the internalization is highly 
efficient; however, the major obstacle for their use in therapy is the lack of specificity. 
Thus, in order to develop a novel dual-ligand modified liposomal nanocarrier to 
overcome the nonselectivity of gH625 liposomes, multifunctional liposomes 
decorated on their surface with gH625 and the EGBP peptide specifically targeting 
EGFR, which is overexpressed in several type of cancer cells, were designed. The 
addition on the liposome surface of targeting ligands to selectively target tumor cells 
that overexpress a particular cell surface receptor can significantly increase the 
amount of drug delivery to the target cell relative to free drug or passively targeted 
liposomes. 
3.7.1 Design of peptide conjugated to cholesterol  
The design of peptide-targeted liposomes is crucial. The strategy, followed in this 
study, was to synthetize the targeting peptide conjugated to cholesterol which could 
be used directly in the preparation of liposomes and then to further decorate the 
surface of preformed liposomes with gH625. In particular, in our design, the targeting 
conjugates consist of: 1) a receptor specific peptide (EBGP), 2) a spacer, 3) a lipid 
molecule to enable insertion into the lipid bilayer of the liposomes. The linker used to 
conjugate the targeting ligand to cholesterol is fundamental for effective activity. 
EBGP was conjugated to cholesterol both with a glycine spacer or with a hydrophilic 
PEG linker. The linker aids in presenting the targeting peptide on the liposomes 
surface and in facilitating binding to the target receptor. 
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3.7.2 Preparation and characterization of peptide-targeted liposomes 
Liposomes were prepared using: soy-lipids, cholesterol, DSPE-PEG and (C18)2L-N3 
(57:28:5:10 molar ratio), when necessary Chol-TP1 or Chol-TP2. The components 
were mixed at specific stoichiometries to achieve precise control over the number of 
functional ligands on each particle and thus allowing reproducibility in liposome 
preparation. The liposomes were sized through the extrusion method.  
Cytotoxic Doxo was loaded into liposomes using the well-assessed procedures 
based on an ammonium sulphate gradient [105]. Unloaded Doxo was removed on a 
Sephadex G50 column. The drug/lipid weight ratio chosen for the loading 
experiments was 0.1. The drug loading content (DLC) was calculated by UV/Vis 
measurements at λ=480 nm and was above 90% of the total.  
The resulting drug loaded liposomes were then efficiently modified with the gH625-
Pra peptide. In particular, the coupling of gH625 on the surface of liposomes was 
performed by click chemistry and the expected gH625-functionalized liposomes 
were obtained with a yield higher than 90% after 12 h at room temperature.  
Dynamic light scattering (DLS) data on liposomes preparations (Table 8) showed 
that the liposome functionalization with gH625 had an average hydrodynamic 
diameter of 143.90 nm and the presence of EGBP does not influence the size of the 
liposomes: 148.62 nm for LipoDoxo-gH625-TP1 and 144.52 nm for LipoDoxo-
gH625-TP2. The polydispersity index remains stable in all the preparations (Table 
8). The values are below 0.2, indicating that the distribution of the liposome size 
remained rather narrow and there are no signs of aggregation. These parameters 
should favour both the effective extravasation of liposomes and their longer retention 
in tumour tissues.  
The analysis of the zeta potential shows a change between LipoDoxo-gH625 
compared to LipoDoxo-gH625-TP1/TP2, which indicates a change in the surface of 
the liposomes upon functionalization with the peptide. 
 
Table 8. Zeta potential, size, expressed as z-average, as measured by DSL and 
polydispersivity index (PDI). Data are expressed as means±standard deviation (SD) of three 
separate experiments for each of two batch formulations, with at least 13 measurements for 
each. 
Liposomes Average Size (nm) PDI Zeta potential (mV) 
LipoDoxo-gH625 143.90±0.64 0.14±0.02 9.43±1.60 
LipoDoxo-gH625-TP1 148.62±2.12 0.15±0.03 4.41±0.63 
LipoDoxo-gH625-TP2 144.52±1.60 0.11±0.05 3.82±0.54 
 
 
 
Moreover, the analysis of the tryptophan fluorescence spectra recorded on the 
liposomal suspension on Lipo-gH625, Lipo-gH625-TP1 and Lipo-gH625-TP2 
showed an increase in fluorescence emission in the last two preparation, due to the 
presence of tryptophan also in the sequence of EGBP. In particular the emission is 
greater for LipoDoxo-gH625-TP1, indicating that the peptide is more exposed on the 
surface (Figure 28). 
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Figure 28. Fluorescence spectra of tryptophan residue at 25°C and 1x10
-5
 M peptide concentrations. 
The spectrum was excited at 280 nm and recorded between 310 and 400 nm. 
 
 
 
3.7.3 Realese kinetics of Doxo  
The release of Doxo was carried out in HEPES-NaCl buffer or HEPES-NaCl buffer 
with 50% FBS and the results are presented in Figure 29. Free Doxo was used as 
control and its release rate was nearly 100% in 2 h, which means that the release of 
Doxo from dialysis membrane to buffer solution is not a restricting factor and the 
release of Doxo from the liposomes is the only rate limiting step. There were no 
pronounced differences in Doxo release (Figure 29) from LipoDoxo-gH625, 
LipoDoxo-gH625-TP1 and LipoDoxo-gH625-TP2 at each time point, indicating that 
the decoration of the surface of the liposomes with both peptides did not 
substantially change the release kinetics of liposomes. The Doxo release from 
liposomes is less than 30% within 72 h, indicating their good stability. 
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Figure 29. Release profile of doxorubicin from liposomes at 37 °C in HEPES-NaCl buffer (A) and in 
HEPES-NaCl buffer with 50% FBS (B). 
 
 
3.7.4 Facs analysis: accumulation 
The accumulation of doxorubicin, free or encapsulated in liposomes conjugated with 
gH625 or in liposomes conjugated with gH625 and EGBP, was investigated by flow 
cytometry analysis. A time-dependent accumulation of free and encapsulated Doxo 
was observed in KB cells. We used two types of KB cells, which overexpress the 
EGFR: one type with 35000 EGFR/cell and another with 300000 EGFR/cell. In 
particular, we observed a greater accumulation of doxorubicin when using LipoDoxo-
gH625-TP2 compared to the other two preparations (Figure 30). Therefore, these 
data suggested that the conjugation of liposomes with the homing peptide increased 
the retention of doxorubicin into the cells, that overexpress EGF receptor. Further in 
vitro studies are now being carried out to better unravel mechanism of the activity of 
these liposomal preparation. 
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Figure 30. Doxorubicin accumulation in KB cells with 35000 EGFR/cell (A) and with 300000 
EGFR/cell (B), after 3, 6, 12 and 24 h of treatment with LipoDoxo-gH625 LipoDoxo-gH625-TP1 and 
LipoDoxo-gH625-TP2. 
 
3.8 Supermagnetic iron oxide nanoparticles coated with gH625 
Superparamagnetic iron oxide nanoparticles (SPIONs) are extensively studied as 
platforms for numerous biomedical applications including cancer therapy and 
diagnosis. They can be coated with a biocompatible polymer to enhance stability 
and stealthiness properties; but in order to achieve high intracellular drug 
concentrations, nanoparticles have to release their drug load inside tumor cells. In 
this study SPIONs were functionalized with gH625 to improve drug delivery into 
cancer cells. 
3.8.1 Synthesis of initial SPIONs 
The initial suspension of SPIONs was prepared as described previously [95]. The 
nanoparticles were precipitated from a basic medium containing iron(II) and iron(III) 
salts. The material obtained is known to consist of two iron oxide phases, namely, 
magnetite (Fe3O4) (particle core) and maghemite (γ-Fe2O3) (superficial layers) [112]. 
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The treatment of nanoparticles with iron nitrate and nitric acid ensures the 
enrichment of the superficial maghemite layer and prevents further uncontrollable 
oxidation. To confirm the chemical composition of the initial material, we performed 
FTIR analysis. The FTIR spectrum of the freeze-dried initial SPIONs (Figure 31 A) 
confirms the presence of the two iron oxide phases maghemite and magnetite [113]. 
In agreement with literature, the band at 630 cm-1 is assigned to maghemite, while 
the band at 590 cm-1 corresponds to both magnetite and maghemite vibrations [114]. 
The strong narrow band at 1380 cm-1 is due to traces of NO3
- anions on the surface 
of SPIONs. There is also a wide band at 3400 cm-1 attributed to surface OH groups 
of SPIONs. These data were in agreement with Raman microspectroscopy analysis 
described previously [112] that also indicated that magnetite and maghemite were 
the two major oxide species, at a relative fraction of ca. 60 and 40%, respectively. 
The morphology and size of initial SPIONs were analyzed by means of transmission 
electron microscopy (Figure 31 C) and DLS. The nanoparticles appear to have a 
uniform roughly spherical morphology, with an average size of ca. 10.02 nm. This 
value and the DLS data for the aqueous suspension of SPIONs (average diameter 
70.02 ± 1.05 nm) are similar to those reported in the literature [115]. 
 
 
 
 
Figure 31. Typical FTIR spectra of freeze-dried samples of initial SPIONs (A) and SPIONs-DOX-PEG 
(B) (the dashed line is a spectrum of initial methoxy poly(ethylene glycol) amine). TEM images of 
initial SPIONs (C) and SPIONs-DOX-PEG (D). 
 
3.8.2 SPIONs modified with PEG and/or Doxo 
The surface modification of nanoparticles was performed according to a protocol 
developed in the Prof. Chourpa’s laboratory involving the reaction between amine 
and epoxide functional groups. The use of this type of chemistry offers sufficient 
reactivity at room temperature. In addition, compared to adsorption, the covalent 
linkage of the drug to the carrier is more stable and will require a specific release 
mechanism for drug delivery, for instance, enzymatic cleavage. The synthesis 
procedure we used to generate SPIONs modified with both Doxo and PEG (SPIONs-
Doxo-PEG) comprises three stages (Figure 32): Doxo, NH2-PEG-OCH3, and NH2-
PEG-NH2 were coupled to epoxysilane to form silylated conjugates (step I e II). The 
reaction consists in the opening of the epoxide ring by the amino group to form an 
amine linkage. These silylated conjugates were bonded to the SPIONs surface by 
reaction of the silanol groups with the hydroxyl groups of iron oxide reaction between 
epoxy silane and doxorubicin, and condensation of the silanized polymer and drug on 
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the surface of SPIONs. To avoid a lengthy separation process and purification of the 
intermediates, all synthetic stages were combined into a one pot synthesis 
procedure. This method allows easy and efficient preparation of PEG- and Doxo-
modified SPIONs. Several experiments were performed to set up the best ratio 
between NH2-PEG-OCH3 and NH2-PEG-NH2; eventually a ratio of 1:4 was chosen. 
Freeze-dried samples of SPIONs-Doxo-PEG contained ca. 60 mg/L (w/w) of iron as 
determined by atomic adsorption spectroscopy. Since the concentration of iron in the 
sample is lower than the typical sensitivity threshold in IR spectroscopy (∼5% (w/w)), 
the iron oxide bands were no more detectable in the FTIR spectra of modified 
nanoparticles (Figure 31 B). These IR spectra showed the major bands characteristic 
of PEG at 1113 (C-O), 1242 (C-N), and 2888 (CH) cm-1, as well as a band of OH at 
3400 cm-1.  
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Step I e II 
Figure 32. Schematic representation of surface functionalization of superparamagnetic iron oxide 
nanoparticles (SPIONs) with Doxo and PEG. 
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To further investigate the effect of the organic coating on the nanoparticles, we 
performed DLS measurements. After functionalization, the hydrodynamic size of 
SPION-Doxo-PEG dispersed in aqueous medium at pH 7 was 65.05 nm (Figure 33). 
These values are close to those reported in literature for PEG-modified SPIONs 
[95,116]. The colloidal stability of functionalized SPIONs was studied by means of 
zeta potential and hydrodynamic diameter (DH) measurements versus pH. For the 
initial SPIONs, the colloidal stability is strongly pH dependent because it is mainly 
due to electrostatic repulsion between particles. It is widely admitted that at high 
values of zeta potential (over 30 mV, positive or negative) the electrostatic 
interactions between particles are strong enough for electrostatic stability, while at 
lower values of zeta potential, particles can flocculate, resulting in increased DH. 
Initial iron oxide nanoparticles typically tend to flocculate near their isoelectric point, 
[95] i.e., between 5<pH< 9. Figure 33 shows plots of both zeta potential (left axis) 
and mean hydrodynamic diameter (right axis) of SPION-Doxo-PEG in aqueous 
dispersion at different pH between 3 and 11. Unlike for unfunctionalized SPIONs, the 
DH of the functionalized particles remained nearly constant over the entire pH range, 
with no sign of aggregation in spite of the low values of the zeta potential. Such a 
behavior is typical of particles coated with the neutral polymer PEG, and it highlights 
that their stabilization is via steric hindrance rather than electrostatic repulsion. 
 
 
 
 
 
 
Figure 33. Variation of zeta potential and hydrodynamic diameter versus pH of SPIONs and 
functionalized SPIONs. 
 
 
 
3.8.3 Functionalization of SPIONs with gH625 
The carboxy terminal end of the peptide gH625 was activated by EDC and NHS, as 
described in Materials and Methods. Functionalization of SPIONs was performed in 
DMSO (Figure 34) in presence of Tween and the obtained peptide-SPIONs were 
purified from the un-conjugated NPs by dialysis.  
 
 
Peptide Based Platforms for Cancer Drug Delivery 
 
 
65 
 
 
 
 
Figure 34. Schematic rapresentation of functionalization of SPIONs with gH625 
 
 
3.8.4 Characterization of SPIONs functionalized with gH625 
As previously reported [117], gH625 adopts a random coil conformation in aqueous 
media, but forms a helix in membrane-mimetic environments. To verify the 
secondary structure of the peptide bound to the SPIONs circular dichroism (CD) 
S P I O N s 
O 
S i 
O 
S i 
O 
O 
O 
S i 
O 
O 
O N 
H 
O 
O N H 
O O 
O 
O H 
O H 
O 
O 
O 
O 
N H 2 
O 
O O C H 3 
n 
n 
O H 
N 
O 
O 
O H 
O H O 
C H 3 
H O 
O H H O 
O O 
H 3 C O 
O H 
S P I O N s 
O 
S i 
O 
S i 
O 
O 
O 
S i 
O 
O 
O N 
H 
O 
O N H 
O O 
O 
O H 
O H 
O 
O 
O 
O 
N 
H 
O 
O O C H 3 
n 
n 
O H 
N 
O 
O 
O H 
O H O 
C H 3 
H O 
O H H O 
O O 
H 3 C O 
O H 
p u r i f i c a t i o n   b y   d i a l i s y s   d u r i n g   4 8 h 
g H 6 2 5 
O 
N H S - g H 6 2 5   i n   D M S O 
2 4 h ,   r o o m   t e m p e r t a u r e 
S P I O N s - P E G - N H 2 
s u s p e n s i o n   i n   DMSO    
S P I O N s - P E G - g H 6 2 5 
s u s p e n s i o n   i n   DMSO    
Step III 
Resuls 
66 
experiments were performed. CD spectra in several percentages of trifluoroethanol 
(TFE, allowing the solution to mimic the environment of the membrane) show that 
gH625 at a concentration of 8 µM adopts an α helix (Figure 35). This result 
confirmed that gH625 retains its helical structure when bound to the nanoparticle 
surface, suggesting that the secondary structure of the peptide was not disturbed by 
coupling to SPIONs. 
 
 
 
Figure 35. Circular dichroism of SPIONs functionalized with gH625 
 
 
3.9 Surface decoration of Polystirene NPs with gH625: method to escape 
endo-lysosomal compartment and reduce nanoparticles toxicity 
Many therapeutic drugs are excluded from entering the brain, due to their lack of 
transport through the blood-brain-barrier (BBB) [118]. The BBB is formed by the 
endothelial cells of brain capillaries, and restricts the exchange of most endogenous 
molecules between the blood and the brain; the very tight regulation of brain 
homeostasis imposed by the BBB prohibits many therapeutic compounds from 
entering brain tissues [119]. The development of new strategies for enhancing drug 
delivery to the brain is of great importance in diagnostics and therapeutics of central 
nervous diseases. To overcome this problem, it was hypothesized that brain delivery 
of polystyrene nanoparticles conjugated with gH625 should be efficiently enhanced. 
gH625 was coupled to the surface of fluorescent aminated polystyrene nanoparticles 
(NPs) via a covalent binding procedure and NP uptake mechanism and permeation 
across an in vitro BBB model were studied.  
Clear understanding of the detailed uptake mechanism of gH625-functionalized 
polystyrene nanoparticles in mouse brain endothelial cells, from their interaction with 
the cell membrane to their intracellular final destination was the principal aim of this 
part of the thesis in order to elucidate how gH625 affects the behavior of the 
nanoparticles and their cytotoxic effect on an in vitro model of the BBB. This novel 
theranostic platform may be broadly applicable for the development of new 
therapeutics with increased brain penetration.  
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3.9.1 Interaction of gH625-NPs with the cell membrane 
gH625 was synthesized with an acetyl protecting group at the N terminus and with 3 
glycines at the C-terminus for this study. 35% of the functional group present on the 
nanoparticles were functionalized with gH625; this percentage of functionalization 
was previously shown to be sufficient for enhanced internalization.  
gH625 enhances nanoparticle cellular uptake at early incubation times. In fact, we 
observed a 2-fold increment of NP internalization within endothelial cells in presence 
of gH625 compared to blank NPs already after 10 minute incubation [120]. Moreover, 
accordingly to cellular uptake kinetics, scanning electron microscopy (SEM) analyzes 
indicated a better and more rapid adsorption of gH625-NPs on cell membrane, 
compared to blank-NPs after 10 min incubation, probably due to the membrane 
tropism of the peptide and, thus, an enhancement of gH625-NPs internalization 
[120]. To better elucidate the interaction of gH625-NPs with the cell membrane, 
coupling of confocal laser scanning microscopy (CLSM) images with atomic force 
microscopy (AFM) was carried out. This analysis is very instructive on assessing the 
status of the NPs at the cell membrane [121]. Indeed, by matching topographical 
features of cell membrane with fluorescence signal, we observed that, after 10 
minute incubation, there was a partial co-localization between NP fluorescence and 
cell membrane humps, suggesting that gH625-NPs are both on cell membrane and 
inside the cytoplasm (Figure 36 B). Moreover, NP deposition on the cell membrane 
was examined at different time points upon incubation with NPs. As shown by the 
chart in Figure 36 E, an overall increment of cell membrane roughness is observed 
upon 10 minute incubation with gH625-NPs compared to control cells (non-treated 
with NPs) and cells incubated with blank NPs. Conversely, no differences in cell 
membrane roughness are present among all samples after 24 h incubation, likely due 
to NP cellular uptake. These observations further confirm the higher interaction of 
gH625-NPs with the cell membrane compared to blank NPs, in agreement with 
previously reported results [120]. gH625 assumes in membrane mimetic 
environments a helical conformation that makes it particularly affine for lipids [122]. 
Indeed, we previously demonstrated its capability to hemi-fuse liposomes and its 
tropism for cholesterol enriched membranes in vitro [122]. Therefore, we 
hypothesized that a similar mechanism could be used by gH625-NPs to bind the cell 
membrane and, thus, for their translocation within the cell. To address this issue, 
cells were treated with methyl beta cyclodextrin (MβCD) in order to deplete 
cholesterol from the cell membrane and investigate the effect of this treatment on 
nanoparticle cellular uptake. Results, reported in Figure 37 A-B, show no effects on 
intracellular distribution of blank NPs after 30 minute treatment with 10 mM MβCD. 
On the other hand, gH625-NP uptake is inhibited by cholesterol depletion (Figure 37 
C and D). In particular, we observed a reduction of about 40% in cellular uptake for 
gH625-NPs after 30 minute of MβCD treatment compared to non-treated cells 
(Figure 37 E). Taken altogether these data suggest that the interaction with the cell 
membrane lipids plays a pivotal role in controlling the mechanism of gH625-NPs 
uptake. 
 
Resuls 
68 
 
 
Figure 36. AFM/CLSM coupling analysis. CLSM z-sectioning maximum projection of bEnd.3 cells 
incubated for 10 min at 37°C with gH625-NPs (a) and blank NPs (c). Red fluorescence: cell 
membrane staining with WGA; green fluorescence: NPs; the dashed squares indicate the zoomed 
areas in b (scan area is about 3 × 8 µm) and d (scan area is about 14 × 25 µm). Transparence image 
merge of CLSM image and AFM scanning of cell membrane (b and d).  
 
 
 
 
 
Figure 37. Blank and gH625-NP cellular uptake upon cholesterol depletion treatment. Confocal 
microscope images of bEnd.3 cells incubated with blank (a and b) and gH625- (c and d) NPs; b and d 
represent cells treated with 10 mM MβCD. Cell membranes are stained with red fluorescent WGA, 
cell nuclei are stained with DAPI and green spots are fluorescent NPs. Scale bar 20 µm. 
Quantification of NP uptake inhibition (e). Data are reported as mean ± standard deviation. p < 0.05 is 
considered statistically significant (*). 
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3.9.2 gH625-NP intracellular behavior 
In order to confirm that the presence of gH625 affects the intracellular behavior of 
NPs by-passing the endo-lysosomal pathway, cell membrane was forced crossing by 
shooting NPs with gene gun method [101]. 
As previously reported, [101,120] once internalized by cells, blank NPs show 
prevalently a pearl-on-a-string behavior, with a little percentage of random walk 
trajectories (Figure 38 A). On the contrary, if forced to enter cell by using gene gun 
method, shot blank NPs show almost exclusively random walk trajectories, 
suggesting very low NP confinement inside endo-lysosomal compartments (Figure 
38 B) [101]. In the case of gH625-NPs, no significant changes in intracellular 
trajectories were observed upon delivery of NPs using gene gun method (Figure 38 
B). These data strongly suggest that gH625 allows NPs to by-pass/escape the endo-
lysosomal pathway.  
 
 
 
 
Figure 38. Intracellular trajectories of endocytosed (endo) (a) and shot (b) NPs analyzed by MPT 
technique. The number of analyzed trajectories was 226 for endo blank NPs, 216 for shot blank NPs, 
38 for endo gH625-NPs and 101 for shot gH625-NPs. 
 
 
 
3.9.3 gH625-NP intracellular distribution 
To further investigate the fate of gH625-NPs, nanoparticles intracellular distribution 
was followed by co-localization experiments within endocytic compartments, namely 
endosomes and lysosomes. After 10 minute incubation, both NPs were able to enter 
cells and partially co-localize with Rab5 protein, a marker of early endosomes, thus 
indicating that both NPs use vesicular structures to enter cells (Figure 39). 
In particular, at earlier incubation time, no significant differences of co-localization 
percentages were observed between blank and gH625-NPs. By increasing the 
incubation time, the percentage of co-localization for blank NPs increased up to 30 
min and then decreased becoming about 4% at 2 h. Conversely, for gH625-NPs the 
percentage of co-localization with Rab5 protein remained almost constant with time. 
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Already after 2 h incubation, both blank and gH625-NPs partially co-localize with 
lysosomes (Figure 40). However, the percentage of co-localization of blank NPs 
increased over time, reaching almost 80%. On the other hand, for gH625-NPs, the 
percentage of co-localization was lower than blank NPs and increased up to 6 h 
remaining almost constant after 24 h incubation. These observations suggested a 
partial lysosomal escape of gH625-NPs.  
 
 
 
 
 
 
 
Figure 39. Co-localization of blank and gH625-NPs with endosomes over time. Confocal images of 
blank (a and c) and gH625-NPs (b and d) upon 10 min (a and c) and 1 h (b and d) of incubation. 
Scale bar 20 µm. Quantification of colocalization by ImageJ analysis software (e). 
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Figure 40. Co-localization of blank and gH625-NPs with lysosomes over time. Confocal images of 
blank (a and c) and gH625-NPs (b and d) upon 2 h (a and c) and 24 h (b and d) of incubation. Scale 
bar 20 µm. Quantification of colocalization by ImageJ analysis software (e).  
 
 
 
3.9.4 gH625-NP cytotoxicity 
The capability to by-pass the lysosomal compartment can offer great advantages in 
terms of efficacy of nanocarriers to overcome biological barriers [120] and of reduced 
nanotoxicity [101]. Recent works reported on the cytotoxic effects of positively 
charged polystyrene NPs as a consequence of their localization in lysosomes and 
interaction with lysosomal components [123,124]. Therefore, we tested the effect of 
gH625 on cytotoxicity of positively charged polystyrene nanoparticles and compared 
results to cells treated with blank NPs delivered by “classical” endocytosis and gene 
gun method, as positive and negative controls, respectively. The used particle 
concentration of 50 µg/ml, reported in literature as cytotoxic [123] and corresponding 
to 6×104 NPs/cell for 100 nm NPs. 
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Data indicated a reduction of viability of cells treated with positively charged NPs, as 
expected (Figure 41). On the other hand, after NP shooting, no cytotoxic effect was 
observed, clearly indicating that the cytotoxicity was strongly dependent on NP 
intracellular localization. More interestingly, after incubation with gH625-NPs, a 
recovery of cell viability was observed, compared to endocytosed blank NPs. 
However, the reduction in cytotoxicity of gH625-NPs was less evident than shot 
blank NPs likely due to their partial co-localization with lysosomes as shown above. 
 
 
 
 
 
 
Figure 40. Cytotoxicity of gH625-NPs compared to non-treated control cells (ctrl) and cells incubated 
for 24 h with blank NPs delivered by “classical” endocytosis (endo-NPs) and by gene gun method 
(shot-NPs). 
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4. Discussion and conclusion 
The goal of this PhD project was to design a toolbox to easily functionalize with 
different delivery, targeting and drug moieties which could be adapted to several 
cancer pathologies. The delivery tool should transport the drug to the target cells not 
only with high efficacy, but also with minimal toxicity against normal cells and 
immune response avoiding its degradation and entrapment in endosomes. In fact, 
one of the major challenges in cancer therapy, is the selective delivery of the 
chemotherapeutic agents to specific tumor cells and tissues. 
The first part of this thesis was focused on the design of the strategies for the 
achievement of a toolbox easily to functionalize and on its obtainment. The second 
phase was the physico-chemical characterization of each selected nanosystem with 
particular attention to the size, zeta potential and drug loading and release. The third 
phase was to analyze in vitro the subcellular fate of the vectorized drug and the 
effect on the cells.  
Several nanosystems (liposomes, magnetic nanoparticles, polystyrene 
nanoparticles) were selected and functionalized with peptides both to enhance tumor 
targeting and facilitate intracellular uptake. Peptides or peptidomimetics are 
emerging as favoured targeting and uptake enhancers owing to their ease of 
preparation, lower cost, lower antigenicity, decreased opsonization, increased 
resistance to enzymatic degradation, high affinity and selectivity [125]. In particular, 
development of a delivery carrier which successfully combines specific targeting and 
enhancement of uptake using high affinity and selectivity of peptides, may potentially 
lead to decreased administered doses and therefore to lower toxicity of the 
chemotherapeutics. Notwithstanding the use of peptides, following intravenous 
injection, many drug delivery tools are easily recognized by the reticulo-endothelial 
system (RES) resulting in rapid clearance and nonlinear pharmacokinetics. To 
reduce this effect we used polyethylene glycol (PEG) coupled on the surface of our 
nanosystem, which is a milestone breakthrough in the field of drug delivery, known 
as stealth technology [76]. 
In order to facilitate the interaction between the nanosystem and cells, we have 
decorated their surface with cell penetrating peptides (CPPs), which were shown to 
be able to enhance drug delivery into target cells. In particular, we used a novel CPP 
(namely, gH625) which is able to overcome the known limits of classic CPPs. In fact, 
classic CPPs uptake mechanism seems to involve mainly the endocytic pathway, 
trapping the conjugated drug in endosomes eventually ending in lysosomes where 
common enzymatic degradation mechanisms take place, therefore leading to a 
limited delivery of therapeutic agents to the intracellular target. On the contrary, 
gH625 is able to efficiently traverse biological membranes, promoting lipid-
membrane reorganizing processes, such as fusion or pore formation and involving 
temporary membrane destabilization and subsequent reorganization; gH625 was 
thus shown to be able to circumvent the endosomal entrapment either favouring the 
escape from the endosome or by directly translocating the drug across the 
membrane. 
In order to make the nanosystem cell and tissue specific, we have further 
functionalized the surface of the nanosystem with a targeting peptide. Active 
targeting allows to target the nanosystem to tumor cells that overexpress a particular 
cell surface receptor. We exploited the EGB peptide, which recognizes the 
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epidermal growth factor receptor (EGFR), a tyrosine kinase receptor overexpressed 
in several solid tumors. 
Liposomes platform 
The first nanosystem was based on liposomes. The coupling of a bioactive ligand on 
the surface of liposomes can be obtained according to several synthetic approaches. 
The choice of the strategy depends on whether it is necessary to perform the 
coupling before or after the liposome assembly. gH625 is a hydrophobic peptide with 
high tendency to locate in the hydrophobic portion of liposomes; thus, for the 
preparation of liposomes carrying on their surface gH625 we used a post-
aggregation pathway based on the click chemistry technology. In order to obtain the 
dual functionalized liposomes with a precise control on the molar ratio between the 
two peptides, we decided to prepare a lipid derivative of the EGB peptide to use 
directly in the assembly of liposomes, a strategy usually preferred for amphiphilic 
peptides; then, gH625 was attached on pre-formed liposomes with the previously 
described strategy. 
In collaboration with Prof Igor Chourpa of Tours University, we prepared liposomes 
(made of DOPG/DSPE-PEG = 85/5 molar ratio) functionalized with gH625 and 
carrying the drug MTX to analyze the internalization mechanism. The purpose of this 
study was to explore the possibility of using nanoliposomes decorated on their 
external surface with gH625 to change the uptake mechanism and enhance the 
internalization of mitoxantrone (MTX). The clarification of the mechanism of 
internalization is useful to improve the design of anticancer delivery tools that may 
determine an increase of internalization and may also help in overcoming resistance 
problems. Liposomes decorated with gH625 and carrying the drug (LMTX-gH625) 
were prepared and characterized. The drug loading was very high and resulted to be 
around 97%; moreover, less than 30% of loaded MTX was released after 24 h, 
which further supports the stability data obtained by the analysis of the zeta 
potential. To analyze the uptake mechanism, we used Confocal Spectral Imaging 
(CSI) which allows to distinguish very fine modifications of MTX intrinsic 
fluorescence within different intracellular microenvironments. The obtained results 
clearly show that the presence of gH625 on the surface of liposomes is favouring 
their uptake in HeLa cells. This correlates well with toxicity data; within 4 h, the 
LMTX-gH625 was more active than LMTX. The gH625 peptide probably induced a 
greater and more rapid internalization, which could contribute to the earlier 
cytotoxicity of LMTX-gH625 compared to LMTX. It has also been reported in 
literature that a fast cytoplasmic delivery of the drug can be related to a better 
chance to overcome drug resistance [2]. Nevertheless, at high incubation times 
there were no significant differences. From the CSI spectra, we detected three 
intracellular molecular situations for the drug: MTX at lipophilic environment, MTX in 
nucleus and an oxidative metabolite of the drug stained in the low polarity 
environment. The spectra observed indicate that the drug was partially released 
from the liposomes and was able to reach the nucleus; moreover, the effect of 
gH625 consists also in an increased presence of an oxidative metabolite of the drug 
which Prof. Chourpa previously demonstrated to be correlated with sensitivity of 
cancer cells to chemotherapy by MTX [108]. Our results support the view that, in 
addition to the nuclear one, several mechanisms may be involved in the cytotoxicity 
of LMTX-gH625 internalization. To summarize, gH625 modifies the internalization of 
liposomes and therefore the drug transport to the cells. Although the liposome-
mediated drug delivery to the nucleus is delayed compared to the drug solution, it 
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could be compensated by complementary mechanisms of cytotoxicity taking place 
into the cytosol, namely those involving the oxidative metabolism of the drug. These 
mechanisms are of particular interest for the anticancer activity evaluation of the 
nanosystem for drug delivery. 
The success of pharmacological treatments is often hampered by the onset of the 
drug resistance. The multidrug resistance (MDR) represents the principal 
mechanism by which many cancers develop resistance to chemotherapy, and poses 
the major obstacle to the successful clinical treatments of cancers. Due to these 
problems, it is highly important to explore alternative strategies for utilizing currently 
available drugs against MDR cancer cells. In collaboration with Dr. Bonelli of 
Microtech and Prof. Caraglia of SUN we used liposomes with enhanced biomimetics 
characteristics (phospholipids derived by soy), carrying on their external surface 
PEG. These liposomes were armed with gH625 to enhance the antitumor efficacy of 
liposomes encapsulating anti-cancer agents and to circumvent drug resistance. 
Physico-chemical characterization of the liposome system revealed a diameter of 
140 nm with uniform distribution and high doxorubicin encapsulation efficiency. We 
have evaluated the growth inhibition on either wild type (A549) or doxorubicin-
resistant (A549 Dx) human lung adenocarcinoma cell lines treated with increasing 
concentrations of liposomes encapsulating Doxo (LipoDoxo), liposomes 
encapsulating Doxo conjugated to gH625 (LipoDoxo-gH625), empty liposomes 
(Lipo) or free Doxo for 72 h. The presence of gH625 on the surface of liposomes is 
favouring their uptake in both sensitive and drug-resistant tumor cell lines allowing 
an increase of cell growth inhibition: in fact, a greater quantity of Doxo from 
functionalized liposomes is accumulated into cells. A higher oxidative stress is 
obtained after treatment with functionalized liposomes for 72 h indicating that 
probably also other mechanisms contribute to the activity in presence of gH625. 
Doxo encapsulated in functionalized liposomes was able to enter in the nuclei of 
Doxo-resistant cancer cells indicating that the peptide gH625 was probably inducing 
a greater and more rapid internalization also in resistant cells, which could contribute 
to overcome drug resistance [2]. In conclusion, further details have been shed on the 
mechanism of internalization promoted by gH625 which clearly indicates that this 
translocating peptide hold promise for the development of a platform for cancer 
therapy, which could be useful also for cancers developing resistance to 
chemotherapy. 
Moreover, we worked to develop a nanoplatform based on dual decorated 
liposomes, both for the uptake and the targeting. gH625 is widely used for its highly 
efficient but nonspecific translocation into many cell types. Although these features 
enable gH625 to deliver therapeutic agents into cells efficiently, they also make very 
difficult to achieve target-specific delivery. In this study, we converted the non 
specific gH625 liposomes into an EGFR targeting delivery carrier by conjugating the 
EGBP moiety on the surface of the gH625-liposomes. In order to find the best way to 
enhance the interaction of the EGBP peptide with its receptor, we used two different 
linkers for conjugating the peptide to the liposome. Thus, the EGBP was synthesized 
with a small spacer of three glycines and with a small hydrophilc PEG based linker. 
In order to evaluate the position of the peptide on the liposome surface, we recorded 
tryptophan fluorescence spectra on Lipo-gH625 and Lipo-gH625-EGBP with both 
types of linkers. The comparison between the fluorescence intensity of Lipo-gH625 
and the dual-functionalized liposomes showed an increase which could be attributed 
to the exposure of both tryptophans that of gH625 and EGBP. The comparison 
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between the two dual-functionalized liposomes showed a higher intensity for the one 
with the PEG linker indicating that in this case thanks to the longer linker the 
tryptophan is more exposed as expected. We have also evaluated the Doxo 
accumulation of the dual decorated liposomes in KB cells by FACS analysis. The 
conjugation of liposomes with the homing peptide increased the retention of 
doxorubicin into cells, overexpressing EGF receptor. Further works is under way to 
characterize the uptake mechanism of dual fuctionalized liposomes in vitro. 
Magnetic nanoparticles platform 
The second nanosystem which was selected to be developed for the obtainment of 
the nanoplatform was magnetic nanoparticles. Our goal was to verify if we could 
enhance the cellular uptake also of this kind of cargo. We focused on optimization of 
the peptide conjugation strategy, in order to find the best compromise between the 
colloidal stability of nanosystems, their half-life in blood and their efficient 
translocation into cells. Indeed, a little is known about the optimal density/quantity of 
CPPs on a nanosystem which is required for its efficient transport through 
membranes of a given cancer cell line. In addition, depending on the peptide 
sequence, we add a certain hydrophobicity; thus an excess of peptide on the 
nanosystem surface reduces its colloidal stability in aqueous media and may reduce 
its half-life in blood circulation. We optimized several important parameters such as 
the concentration of gH625 on the polymeric surface of SPIONs. Moreover, we 
found that Circular Dichroism (CD) data confirmed that gH625 retains its helical 
structure when bound to the nanoparticle surface, suggesting that the secondary 
structure of the peptide was not disturbed by attachment to SPIONs. We are now 
working on the physico-chemical, characterization of the nanosystem and the 
eventual ability of gH625 to increase the nanoparticle uptake by cancer cells. 
Polystyrene nanoparticles platform 
The last system selected in this thesis was polystyrene nanoparticles (NPs). We 
explored the possibility of using NPs functionalized with gH625 to deliver a drug 
across the Blood Brain Barrier (BBB). The BBB is formed by the endothelial cells of 
brain capillaries, and restricts the exchange of most endogenous molecules between 
the blood and the brain; the very tight regulation of brain homeostasis imposed by the 
BBB prohibits many therapeutic compounds from entering brain tissues [119]. The 
development of new strategies for enhancing drug delivery to the brain is of great 
importance in diagnostics and therapeutics of central nervous diseases.The uptake 
and subcellular localization of the NPs were investigated by exposing an in vitro BBB 
model to 100 nm polystyrene NPs functionalized and not with gH625. The 
functionalized nanoparticles were thoroughly characterized using a variety of 
complementary techniques to gain a better understanding of their properties. In 
particular, gH625 only slightly modified the particle sizes with a zeta potential 
indicative of colloidal stability at pH 7. gH625-NPs translocated efficiently across the 
in vitro model of the BBB and their mechanism of uptake does not seem to 
exclusively involve classical endocytosis mechanisms. In fact, conjugation with 
gH625 facilitated the delivery of nanoparticles across the BBB, leading to significant 
higher cell uptake and crossing. It is clear from our results that the majority of blank 
NPs end up in intracellular organelles, mostly in lysosomes, similarly to several other 
NP systems [92,93]. A significant number of blank NPs are observed associated with 
lysosomes and after 24 h the degree of lysosomal accumulation was around 80%. 
Interestingly, gH625-NPs only slightly co-localize with lysosomes and their degree of 
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lysosomal accumulation did not increase with time. The endothelial brain cells are 
rich in cholesterol. To verify if gH625-NPs were still able to cross the membrane 
depleted of cholesterol, we have studied the interaction with an in vitro model of the 
BBB depleted of cholesterol. Our results showed that the depletion of cholesterol did 
not have any effect on the intracellular distribution of blank NPs but significantly 
reduced the uptake of gH625-NPs. We also demonstrated by the gene gun 
experiments, that gH625-NP interaction with the cell membrane plays a key role in 
controlling the uptake mechanism. In fact, most trajectories of blank NP resulted in 
pearls-on-a-string walk, indicative of motor protein facilitated transport, mediated by 
endocytic vesicles. Conversely, in presence of peptide functionalization, we observed 
that most trajectories showed a random walk behaviour with just a lower percentage 
of pearls-on-a-string trajectories, suggesting a translocation across the bilayer. 
Furthermore, we also observed a significant reduction of cytotoxicity compared to 
blank NPs. These studies clearly indicate that gH625 is able to change the 
mechanism of uptake of the cargo and it is able to cross the BBB in a fashion that 
can be distinguished from other cell-penetrating peptides such as TAT and penetratin 
[91]. 
Conclusion 
In conclusion we have developed a nanoplatform based on different nanosystems 
(liposomes, magnetic nanoparticles, polystyrene nanoparticles) which could be 
decorated on their surface with gH625 and a targeting peptide; these nanoplatforms 
could be exploited for obtaining target-specific therapeutics. In fact, replacing the 
EGBP moiety with a different molecule targeting another tumor surface marker, 
along with the relevant therapeutic agent, we might be able to obtain a theranostic 
system specific for each patology. 
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Abstract
The molecular mechanism of entry of herpesviruses requires a multicomponent fusion system. Cell invasion by Herpes
simplex virus (HSV) requires four virally encoded glycoproteins: namely gD, gB and gH/gL. The role of gB has remained
elusive until recently when the crystal structure of HSV-1 gB became available and the fusion potential of gB was clearly
demonstrated. Although much information on gB structure/function relationship has been gathered in recent years, the
elucidation of the nature of the fine interactions between gB fusion loops and the membrane bilayer may help to
understand the precise molecular mechanism behind herpesvirus-host cell membrane fusion. Here, we report the first
biophysical study on the two fusion peptides of gB, with a particular focus on the effects determined by both peptides on
lipid bilayers of various compositions. The two fusion loops constitute a structural subdomain wherein key hydrophobic
amino acids form a ridge that is supported on both sides by charged residues. When used together the two fusion loops
have the ability to significantly destabilize the target membrane bilayer, notwithstanding their low bilayer penetration when
used separately. These data support the model of gB fusion loops insertion into cholesterol enriched membranes.
Citation: Falanga A, Tarallo R, Vitiello G, Vitiello M, Perillo E, et al. (2012) Biophysical Characterization and Membrane Interaction of the Two Fusion Loops of
Glycoprotein B from Herpes Simplex Type I Virus. PLoS ONE 7(2): e32186. doi:10.1371/journal.pone.0032186
Editor: Robert J. Geraghty, University of Minnesota, United States of America
Received October 24, 2011; Accepted January 23, 2012; Published February 23, 2012
Copyright:  2012 Falanga et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by MIUR (Ministero dell’Istruzione, dell’Universita` e della Ricerca) (FIRB Prot. RBRN07BMCT). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: massimiliano.galdiero@unina2.it (MG); sgaldier@unina.it (SG)
Introduction
Enveloped viruses infect host cells by fusion of viral and target
membranes. The initial apposition step is followed by fusion of the
outer leaflets of membranes (the hemifusion step), leading to the
formation of a transient fusion intermediate, which evolves into
the fusion of inner leaflets and the formation of a pore, with the
mixing of the internal compartments of both fusion partners.
Thus, the viral genome is transferred to the cytoplasm of the host
cell and viral replication ensues [1–3]. This fusion event is
triggered by specific glycoproteins in the viral envelope. Fusion
glycoproteins belong to either class I, class II or the newly
described class III, depending upon their arrangement at the
surface of the virion, their structure and the location within the
protein of a short stretch of hydrophobic amino acids called the
fusion peptide, which is able to induce the initial lipid
destabilization that ends in fusion [4].
Although, viral fusion proteins are divided in three classes and
the cellular membrane undergoing fusion might vary (plasma
membrane vs. endosomal membrane), these proteins have to act
on lipid assemblies. Thus, lipids contribute to fusion through their
physical, mechanical and/or chemical properties and play a role
in determining the preferential partitioning of some amino acid
sequences into membrane microdomains called ‘‘rafts’’, and/or in
modulating the curvature of the membranes involved in the fusion
process [3].
Considering lipids and fusion proteins the necessary partners
involved in the fusion process, it becomes clear that the overall gist
of viral-induced membrane fusion is dictated by several features
common to different families of viruses [1]. All fusion machineries
need to interact with lipids, so they possess hydrophobic segments
(fusion peptides) or are able after rearrangements to make
hydrophobic interactions with membranes; moreover, need to
adopt specific conformations related to the pre and post-fusion
states, since fusion is limited in space and time. Therefore,
different viruses infect their host cells by very similar mechanisms
at the molecular level and fusion peptides represent a key element
of the fusion machinery, being the trigger for controlled
membrane destabilization.
Recently, the novel concept of ‘‘lipid packing sensor’’ emerged,
indicating protein motifs or domains that recognize the curvature
of lipid membranes. The most studied sensor is the amphipathic
helical motif present both in cellular membrane proteins and in
viral proteins [5,6]; but also other structural motifs, such as loops
or unfolded peptides, may be involved in the sensing of the
membrane curvature and in the initial steps of membrane fusion.
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32186
The discovery of sensor motifs opens new perspectives with respect
to viral fusion proteins, which may contain such sensors; and may
help our understanding of the subtle and complex interplay
between protein-induced fusion and lipid modulation and may
represent targets for future antiviral therapies.
Herpes simplex virus type 1 (HSV-1) is a member of the a-
herpesvirus subfamily and enters cells through fusion of the viral
envelope with a cellular membrane in a cascade of molecular
interactions involving multiple viral glycoproteins and cellular
receptors. The envelope glycoproteins gH/gL, gB and gD are all
essential for the entry process [7] and expression of this quartet of
glycoproteins induces the fusion of cellular membranes in the
absence of virus infection [8]. gH/gL and gB, also play important
roles in primary fusion events that occur during egress of the
capsid from the nucleus of infected cells [9]. Recently, it was
shown that gB and gH/gL interact with each other concomitantly
with fusion and that this interaction is triggered by binding of gD
to its cellular receptor [10,11]. Thus, gB may function coopera-
tively with gH/gL, and each may have some fusogenic potential
on its own. Although gB and gH/gL constitute the core fusion
machinery of all members of the Herpesviridae, their mechanisms
of action are still under investigation.
Peptides derived from the ectodomain of gH block virus entry
[12], while others have the ability to bind and disrupt model
membranes [13–18]. The recently solved crystal structure of the
gH-gL complex [19] showed that gH has no structural homology
with any known fusion protein supporting the hypothesis that gH
may act as a regulator of fusion through interactions with gB,
while the crystal structure of the gH-gL complex of EBV presents
considerable differences in the structural arrangements of domains
supporting the view that the complex can undergo dynamic
rearrangements [7,20].
gB is highly conserved within all the members of the
Herpesviridae and is involved in virus attachment, penetration
and cell-to-cell spread. gB may undergo large conformational
changes to bring about fusion and even though evidence for its
refolding has yet to be obtained a model for pre-fusion gB has been
proposed and it seems that gB undergoes a refolding transition
during fusion. The structures of gB from HSV-1 [21] and EBV
[22] demonstrated that gB has structural homology with viral
fusion proteins belonging to other virus families: the vesicular
stomatitis virus (VSV) G protein [23] and the baculovirus protein
gp64 [24] and is probably the key fusion protein; moreover,
several synthetic gB peptides induced the fusion of large
unilamellar vesicles and inhibited herpes virus infection [25,26].
gB belongs to a newly formed group of fusion proteins, class III,
which share similar individual domain structures and contain a
central three-stranded coiled-coil reminiscent of the class I
proteins. Whereas class I proteins have an N-terminal fusion
peptide, class III proteins have internal bipartite fusion loops
within domain I which are similar to the single fusion loop of class
II fusion proteins. The class II fusion loop is composed entirely of
hydrophobic amino acids whereas those of gB have both
hydrophobic and charged residues [21–24]. In particular, the
fusogenic loops correspond to the domains 173–179 and 258–265
of the protein gB.
Hydrophobic amino acids within the gB loops (W174, F175,
G176, Y179, A261) are essential for gB function [27]. Similar
studies of VSV G, gp64 and EBV gB support the notion that
hydrophobic amino acids of both fusion loops are critical for fusion
[28,29] and together constitute a fusion domain. Moreover, also
charged amino acids play a fundamental role, in fact, mutations of
H263 or R264 also negatively affected gB function [27]. These
data support the view that the two fusion loops constitute a
subdomain where key hydrophobic amino acids form a ridge that
is flanked on both sides by charged amino acids that enhance the
ability to interact with target membranes, in fact, one of the two
gB fusion loops (namely HB168–186) was identified by highly
interfacial hydrophobicity analysis without the aid of structural
data [25].
Although much information has been gathered in recent years,
we do not yet know the precise molecular mechanism behind
herpesvirus host cell membrane fusion; thus, elucidating the nature
of the fine interactions between gB fusion loops and the membrane
may help to districate this interesting matter. In the present study,
we report the synthesis and characterization of membrane
interactions of the two fusion peptides present in gB. The goals
of the experiments reported here were to verify the fusion ability of
the two peptides, to assess the dependence of the fusion activity on
the composition of the membrane and in particular on the content
of cholesterol and to verify the eventual presence of a synergic or
cooperative effect when the two isolated peptides are used
together.
As far as we know, this is the first biophysical study on the two
putative fusion peptides of gB, with a particular focus on the effects
determined by both peptides on lipid bilayers of various
compositions.
Results
Design of peptides
The proposed post-fusion structure of gB ectodomain is
comprised of three protomers, and each protomer coils around
the others with a left-handed twist [21]. There are multiple
contacts between protomers throughout the molecule contributing
to trimer stability. Each protomer of gB can be divided into five
distinct domains: I, base; II, middle, III, core; IV crown; and V,
arm (Figure 1). Domain I (Ile154 to Val363) is a b sandwich
composed of two nearly orthogonal b sheets of four and three
strands, with a long loop and short helix covering one opening of
the b sandwich. An insertion (Tyr165 to Ile272) between strands
b4 and b11 creates a subdomain at the base of the trimer,
consisting of a four-stranded b sheet (with three long and one short
strand), the convex side of which is covered with an a helix, a b
hairpin, and a short two-stranded b sheet; the four-stranded b-
sheet presents hydrophobic tips that have been proposed to
represent the fusion peptides of gB (Figure 1). Fusion peptides are
generally considered as being domains with a high interfacial
hydrophobicity calculated with the Wimley-White hydrophobicity
scale which was systematically used for searching fusion peptides in
other viral glycoproteins. HB168–186, comprising the precise
fusion loop HB173–179 [21], is located in the insertion between
strands b4 and b11 and we were able to identify this region on the
basis of its hydrophobicity, and analyse its role in peptide/lipid
fusion assays [25]. The second loop (HB258–265), identified on
the basis of structural data [21] contributes to the formation of the
bipartite fusion peptide, but does not correspond to a hydropho-
bicity peak calculated with the interfacial scale and thus was not
considered in our previous study [25].
Both fusion loops have been characterized by point-mutations
in the protein sequence and showed to be critical for gB function
in cell fusion [30]. In the present study, we report on the structural
characterization of the two fusion loops by using peptides
corresponding to their sequences. We synthesised a short version,
corresponding exactly to the sequences of the loops, and a longer
version, embracing the flanking b-sheets, in order to understand
the contributions of each region that constitutes the gB fusogenic
domain (Table 1). Moreover, we tried to understand the
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contribution of lipids that take part to the interplay between the
membrane and fusogenic peptides.
Ability of peptides to induce lipid mixing
To investigate the fusogenicity of gB peptides, NBD and Rho
labelled PE were used as the donor and acceptor of fluorescence
energy transfer. A population of LUVs labelled with both was
mixed with a population of unlabelled LUVs and increasing
amounts of peptides were added. Dilution of the fluorescent-
labelled vesicles via membrane fusion induced by the peptide
results in a reduction of the fluorescence energy transfer efficiency,
hence dequenching of the donor fluorescence. The dependence of
the extent of lipid mixing on the peptide to lipid molar ratio was
analysed. The fusogenic capacity was monitored by measuring
their ability to induce lipid mixing of model membranes composed
of DOPG, DOPG/Chol (3/2), DOPC, DOPC/Chol (3/2),
POPC/Chol (3/2), and POPC/Chol/SM at various ratios (4/1/1,
2/1/1, 1/1/1).
Interestingly, there was a different behaviour of the peptides
depending on the lipid composition of LUVs. Figure 2A and B
show the results of lipid mixing assays in LUVs of different
compositions for peptides HB168–186 and HB254–270. The
graphs show that in all tested conditions HB168–186 has higher
fusogenic ability. DOPC/Chol, POPC/Chol and DOPG/Chol all
proved to be good fusogenic conditions. Furthermore, it is evident
from the results obtained that DOPG in presence or absence of
cholesterol represents a less fusogenic condition, indicating that the
negatively charged phospholipids are not preferred. This is a
rather interesting result as both peptides contain arginine residues
and thus we could expect a greater interaction with anionic lipids.
Several viruses such as HIV, influenza virus and Semliki Forest
virus have been shown to involve lipid microdomains, which are
enriched in cholesterol during virus budding as well as virus entry.
Also herpesvirus has been shown to require cholesterol [31,32],
and such a need for cholesterol has also been highlighted in our
experiments using model membranes where a significant increase
in fusion is always observed in presence of cholesterol. The lipids
allowing the highest level of fusion are DOPC and POPC which
are both zwitterionic but present a difference in their unsaturation,
with POPC having only one unsaturated acyl chain and DOPC
having two. DOPC results in a more flexible bilayer, which
appears to be an important feature for the fusion activity of the
analyzed peptides. We also tested the peptide fusion ability of
liposomes containing sphingomyelin, a component commonly
found in lipid rafts. The ternary lipid system POPC/Chol/SM is a
good model for lipid rafts and from the ternary phase diagram [33]
it is possible to determine the boundaries for lipid rafts which are
strongly dependent on the percentage of each lipid in the system.
We used three different conditions to probe the activity of our
peptides in LUVs mimicking rafts: POPC/Chol/SM 4/1/1, 2/1/1
and 1/1/1, characterized by different percentages of the liquid
Figure 1. Three dimensional structure of a single gB protomer. The different domains are shown. In the insert are shown molecular details of
the two fusion loops: HB168–186 (green) and HB254–270 (red).
doi:10.1371/journal.pone.0032186.g001
Table 1. Peptides.
Sequence
HB168–186 NH2-VTVSQVWFGHRYSQFMGIF-COOH
HB173–179 NH2-VWFGHRY-COOH
HB254–270 NH2-YNPSRVEAFHRYGTTVN-COOH
HB258–265 NH2-RVEAFHRY-COOH
scrambled NH2-MRWFSVVSYQVIGTQFGFH-COOH
doi:10.1371/journal.pone.0032186.t001
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ordered and liquid disordered phases. The results obtained
(Figure 2 C–D) show that both peptides present a significant
percentage of fusion
Figure 2E shows the results obtained in DOPC/Chol for the
peptides HB168–186 and HB254–270 as well as their shorter
versions corresponding exactly to the loop sequences derived from
Figure 2. Ability of peptides to induce lipid mixing. Peptide-promoted membrane fusion as determined by lipid mixing; peptide aliquots were
added to 0.1 mM LUVs, containing 0.6% NBD and 0.6% Rho. The increase in fluorescence was measured after the addition of peptide aliquots;
reduced Triton-X-100 (0.05% v/v) was referred to as 100% of fusion. In figure is reported the dose dependence of lipid mixing at 37uC: panels A and B
HB168–186 and HB254–270 in LUVs of different composition; panels C and D HB168–186 and HB254–270 in LUVs mimicking lipid rafts; panel E
HB168–186, HB254–270 and shorter versions in DOPC/Chol LUVs; panel F equimolecular mixtures of peptides HB168–186 and HB254–270 in DOPC/
Chol (3/2) and POPC/Chol/SM (2/1/1).
doi:10.1371/journal.pone.0032186.g002
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the crystallographic structure. The two shorter peptides (HB173–
179 and HB258–265) induced lower levels of fusion compared to
longer sequences, suggesting that shorter peptides were unable to
cross or stably position inside the bilayer. This result further
supports the view that fusion loops are structured by the overall
organization of the fusion domain of the protein and longer
peptides are, therefore, necessary to evidence an appreciable
fusion activity.
In the case of the peptide equimolar mixtures (Figure 2F), we
can observe that in DOPC/Chol as well as in POPC/Chol/SM
(2/1/1) we have a significant fusion activity supporting a
cooperative mechanism.
Ability of peptides to induce lipid mixing of inner-
monolayer
In the inner monolayer assay, the fluorescence from the vesicle
membranes’ outer monolayer is eliminated by the addition of an
aqueous reducing agent, and this experiment reveals the extent of
lipid mixing between the inner monolayers of vesicles in solution.
Figure 3A shows a significant fusion of the inner monolayer in
DOPC/Chol. This is slightly lower than the fusion level obtained
in the lipid mixing experiment, since the latter measures both
hemi-fusion and complete fusion. Therefore, this assay clearly
indicates that the two peptides are able to induce fusion of both the
inner and the outer monolayers.
We also verified the ability of peptide equimolar mixtures to
induce lipid mixing of the inner-monolayer. The results obtained
indicate that the peptides cooperate in the fusion process.
Ability of peptides to induce membrane leakage
In order to explore the effects of the peptides in the
destabilization of membrane vesicles, we studied their effect on
the release of encapsulated fluorophores in model membranes
made of DOPC/Chol. A content-mixing assay (Figure 3B) was
employed to monitor any mixing of internal vesicle components as
a result of vesicle exposure to HB168–186 and HB254–270.
Release of ANTS and DPX from vesicle is commonly used as a
measure of bilayer perturbation and interpreted as ‘‘transient pore
formation’’ [34,35]. Content-mixing is manifested by a decrease in
fluorescence intensity if vesicles encapsulating fluorescent cargo
(e.g., ANTS) merge contents with those containing quenchers (e.g.,
DPX). The leakage experiment shows that the probe did not leak
out significantly to the medium after the interaction with any of
the peptides used in this study. Figure 3B shows that no content-
mixing occurs over the same P/L range where substantial outer
and inner monolayer lipid-mixing occurs, confirming that vesicle
fusion may happen within our system without concomitant pore
formation. The low leakage value observed for both peptides
might be due to the fact that they are located at the membrane
interface and do not completely traverse the bilayer. We also
verified the eventual ability of equimolar mixtures of HB168–186
and HB254–270 to induce membrane leakage, but no significant
difference from results obtained for individual peptides was
detected.
Peptide aggregation
The peptide’s aggregation state in buffer and DOPC/Chol
LUVs was assayed using ThT [36], in order to know the possible
effects of the peptide aggregation on the membranes. As observed
in Figure 4 A–B, the two peptides present a completely different
behaviour. The peptide HB168–186 at a concentration of 4 mM
(Figure 4A) is already aggregated in an aqueous medium, in fact,
the fluorescence change increased dramatically after the addition
of the peptide from a stock solution, while in the presence of
DOPC/Chol a lower aggregation is reported. The peptide
HB254–270 is not aggregated in the aqueous medium nor in the
presence of DOPC/Chol at the same concentration. Furthermore,
we studied the intrinsic relationship between the concentration of
the peptides and the aggregation in buffer and in LUVs and we
can interpret the data for HB168–186 reported in Figure 4C as
aggregated both in the aqueous medium and in LUVs at high
concentrations. Our results are consistent with two hypothesis; the
first is an initial aggregation in the aqueous medium, followed by a
disaggregation when initially interacting with the membrane and
again an aggregation inside the membrane bilayer, indicating that
the insertion of the peptide into the membrane could occur in a
monomeric form and only afterwards the peptide aggregates
again; while the second hypothesis is that the peptide can interact
with the membranes already in an oligomerized state.
Tryptophan/tyrosine fluorescence emission analysis
We measured the intrinsic fluorescence of HB168–186 and
HB254–270 (due to the presence of a tryptophan residue in the
sequence of HB168–186 and two tyrosines for HB254–270) to
evaluate the degree of penetration of the peptides into the
membrane bilayer. We compared the fluorescence emission
spectra in DOPC/Chol vesicles with that in buffer (data not
shown). The quantum yield of aromatic residues of a peptide or
protein normally changes when the amino acid is located in a
more hydrophobic environment such as a phospholipid mem-
brane, normally increasing the intensity of the fluorescence
emission and shifting the maximal spectral position toward shorter
wavelengths (blue shift). Changes in the spectral properties were
observed for both peptides, suggesting that the single tryptophan
residue of HB168–186 and the two tyrosines of HB254–270 move
to a less polar environment upon interaction with lipids. Emission
intensity was enhanced and the maxima shifted to lower
wavelength. (Figure S1) Blue shifts of this magnitude are generally
observed when amphiphilic aromatic-containing peptides interact
with phospholipid bilayers and are consistent with the aromatic
moiety becoming partially immersed in the membrane, further
suggesting that the analysed peptides are capable of penetrating a
lipid bilayer [37].
The increase in fluorescence for tryptophan or tyrosines binding
to membrane phospholipids was used for the generation of binding
isotherms for HB168–186 and HB254–270, therefore partition
coefficients could be calculated. The concentrations of peptides
used were low enough to cause minimal aggregation in the
aqueous phase and were assumed not to disrupt the bilayer
structure. To determine the surface partition coefficient, the
fluorescence intensities were converted to moles of bound peptide
per moles of lipid and plotted as a function of the free peptide
concentration as described in material and methods (Figure 5). As
partition coefficients depend on the concentration of lipid
accessible to peptide, the curves obtained by plotting Xb* (the
molar ratio of bound peptide per 60% of the total lipid) vs Cf (the
equilibrium concentration of free peptide in the solution) are
referred to as the conventional binding isotherms. The shape of a
binding isotherm of a peptide can provide information on the
organization of the peptide within the membrane. A straight line
indicates a simple adhesion process. The shape of the binding
isotherm of all the peptides tested was not linear indicating that
peptide accumulation at the surface is not a simple phenomenon
without cooperative association. In particular, this behaviour is the
hallmark for peptides that self-associate at membrane surfaces
upon partitioning. If aggregation occurred only in the water but
not in the bilayer phase, the opposite course of the isotherms
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should be expected: a steep rise at the origin, followed by
pronounced flattening; thus, the shape of the isotherms obtained
could be interpreted as reflecting a process whereby peptides first
incorporate into the membrane and then aggregate there within.
Moreover, there was no evidence of significant aggregation in
water at the concentration used in this experiment (0.1 mM) for
HB254–270, although we have an indication of aggregation in
water for HB168–186 as shown in Figure 4C. In the isotherms
obtained, the total extent of incorporation (Xb
*) slowly increases
until a critical concentration is reached, where massive internal
aggregation apparently starts to develop.
The surface partition coefficients Kp were estimated by
extrapolating the initial slopes of the curves to Cf values of zero.
Curves are shown in Figure 5.
The Kp values for the peptides HB168–186 and HB254–270
are shown in Table 2. The Kp value obtained for HB168–186 is
2.5 104, indicating that the tryptophan in HB168–186 is able to
interact significantly with the bilayer and that most of the peptide
HB168–186 is located inside the liposomes. The Kp value for
HB254–270 is 3.2 104, indicating that the tyrosine residues present
in this peptide are located inside the liposomes and are stably
inserted.
Quenching of tryptophan/tyrosines by Acrylamide
The observed changes in the characteristics of the tryptophan/
tyrosine emission upon binding of peptides HB168–186 and
HB254–270 to lipid vesicles indicate their insertion into the
hydrophobic region of the bilayers. We also studied the
accessibility of the tryptophan/tyrosine residues of membrane-
bound peptides towards acrylamide, a neutral, water-soluble,
highly efficient quenching molecule, which is unable to penetrate
Figure 3. Ability of peptides to induce lipid mixing of inner-monolayer and membrane leakage. Peptide interactions with DOPC/Chol
LUVs (A–B), the dose dependence is reported and each trace represents an average of three independent experiments. A) Inner monolayer assay.
C) Leakage of ANTS/DPX.
doi:10.1371/journal.pone.0032186.g003
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into the hydrophobic core of the lipid bilayer. The more deeply a
tryptophan/tyrosine residue is buried, the less strongly it can be
quenched by acrylamide. Stern-Volmer plots for the quenching of
tryptophan by acrylamide, recorded in the absence and presence
of lipid vesicles, are depicted in Figure 6. Fluorescence of
tryptophan/tyrosine decreased in a concentration-dependent
manner by the addition of acrylamide to the peptide solution
both in the absence and presence of liposomes, without other
effects on the spectra. However, we can observe a substantial
difference between the two peptides. In the presence of liposomes,
a great decrease in fluorescence intensity was evident for HB254–
270, thus revealing that tyrosine residues are less accessible to the
quencher in the presence of LUVs. In fact, the values for Ksv were
lower (Table 3) in LUVs, suggesting that tyrosines were more
buried in the bilayers, becoming more inaccessible for quenching
by acrylamide. From Figure 6, it is evident that we can observe for
the peptide HB168–186 a low accessibility to the quencher both in
absence and presence of liposomes, indicating that the peptide has
a significant tendency to aggregate also in an aqueous solution.
ESR Results
The ESR spectroscopy, by using spin-labelled substances
(peptides and/or lipids) has been proved to give substantial
information on the interaction of peptide deriving from viral fusion
glycoproteins with lipid membranes [38–41]. In the present work,
the association of the two peptides, HB168–186 and HB254–270,
with lipid bilayers was investigated by analysing changes in ESR
spectra of spin-labelled phospholipids. The samples investigated
were phosphatidylcholine spin-labelled at different positions, n, in
the sn-2 chain (n-PCSL, n=5, 7, 10, 14) incorporated in DOPC/
Chol membranes (3/2), in the presence of the peptides.
Preliminarily, the spectra in the absence of the peptides were
registered. Inspection of Figure 7A (solid lines) shows that all the
spectra present a clearly defined axially anisotropic lineshape, an
evidence that, due to the high cholesterol content, the DOPC/
Chol bilayer is in the liquid-ordered state [42]. In an attempt to
quantitatively analyse the spectra, the outer hyperfine splitting,
2Amax, was calculated. The 2Amax variation, shown in Figure 7B,
is an evidence of the flexibility gradient in segmental acyl chain
mobility [38,43], indicating that the lipid bilayer presents a rigid
surface and relatively fluid interior [44–47].
Association of peptides to the lipid bilayer causes a significant
variation in the ESR spectra of spin-labelled phospholipids. In
Figure 7A, ESR spectra of 5-PCSL and 14-PCSL in DOPC/Chol
bilayers, in the presence of HB168–186, HB254–270 and HB168–
186:HB254–270 mixture at a lipid/peptide weight ratio of 1/1,
are also reported. The presence of two peptides induces significant
changes in the spin-label ESR spectra, which are mainly
detectable from the low- and high-field component position and
lineshape. In an attempt to quantify this evidence, the 2Amax
values were determined. Figure 7B shows the dependence of these
parameters on chain position, n, for the n-PCSL spin-labels in
DOPC/Chol membranes, in the absence and in the presence of
the peptides. In all cases, the flexibility gradient with the chain
position of the lipid bilayer membranes is preserved. However,
inspection of the figure reveals a significantly different behaviour
of the lipid chain mobility in the co-presence of the two peptides.
In fact, addition of HB168–186 or HB254–270 significantly
reduces the 2Amax value of 5-PCSL. In both cases, no changes in
the spectra of the spin-labels bearing the nitroxide group in the
more interior positions were observed. Strikingly, addition of the
HB168–186:HB254–270 mixture results in a strongly 2Amax
decrease for all the considered spin-labels. These results show a
cooperation of the peptides in perturbing the bilayer microstruc-
ture in that only in the presence of both of them the increase of
segmental mobility propagates along the whole acyl chains. Thus,
the contemporary interaction of both peptides with the lipid
membrane surface effectively perturbs the local order and
dynamics of the lipid leaflet they come in contact with.
Secondary structure in lipid bilayers
The CD spectra of the peptides in buffer and bound to LUVs
made of DOPC/Chol are shown in Figure 8. The binding of the
peptides to the membrane bilayer did not affect their structure.
The spectra are indicative of random conformation for both
peptides.
Discussion
Membrane fusion is of fundamental importance in the
biological life of a cell and is of particular interest during
enveloped virus infections. A common feature of all fusion events is
the involvement of the fusion peptide in these phenomena and the
key role played by lipids in the conformational changes leading to
the interaction of the fusion peptide with target membranes, and
in the membrane deformation following the initial peptide-
membrane interactions. Extensive research data on viral mem-
brane fusion proteins have disclosed the existence of several
protein domains involved in the viral fusion process. It is, thus, an
accepted view the presence of different membrane-active regions
in viral fusion glycoproteins, although their biological function is
still unclear. It has been hypothesised that these regions may have
a different role on either pore formation and stabilization, viral
budding or both of them.
In the present work we have investigated the role played by the
two fusion loops of HSV-1 gB in the mechanism of membrane
fusion. In particular, three important issues were addressed: the
ability of peptide analogues of the fusion loops to induce fusion of
liposomes, their ability to interact with the membrane bilayer
when alone and when used in equimolar concentrations and the
role of the target membrane composition. For herpesviruses,
cholesterol is thought to play a key role, in fact, lipid raft may act
as a platform allowing cell entry and potential coreceptors
clustering [32] or cholesterol may modulate the HSV entry
process regardless of its ability to promote lipids microdomains
[48]. In this work evidences have been obtained indicating the
ability of the two fusion peptide to induce fusion of liposomes in
vitro, their ability to strongly interact with a membrane bilayer
containing cholesterol and finally their different mode of
interaction with the bilayer indicating that although being both
involved in the fusion mechanism they may play a different role.
The two fusion loops constitute a structural subdomain wherein
key hydrophobic amino acids form a ridge that is supported on
both sides by charged residues. The two charged residues located
on both sides of the ridge represent a novel feature of viral fusion
peptides and probably enhance the ability of the hydrophobic
residues to interact with target membranes and to promote fusion.
Figure 4. Peptide aggregation. Fluorescence variation of ThT after addition of HB168–186 (A) and HB254–270 (B) peptides to an aqueous solution
and in the presence of LUVs of DOPC/Chol at a peptide concentration of 4 mM. (C) Percentage of aggregation as a function of peptide concentration
for HB168–186 and HB254–270 in buffer (closed symbols) and in LUVs (open symbols).
doi:10.1371/journal.pone.0032186.g004
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Figure 5. Tryptophan/tyrosine fluorescence emission analyses. Binding isotherms obtained plotting Xb
* versus Cf for HB168–186 and HB254–
270.
doi:10.1371/journal.pone.0032186.g005
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The analysis of the location of the fusion loops into the three-
dimensional structure of gB points out that the hydrophobic
residues do not appear to be able to insert deeply into a target
membrane. The hydrophilic residues on either side of the
hydrophobic ridge may help to stabilize insertion of gB into
cholesterol enriched membranes or more generally membranes
mimicking lipid rafts, but both fusion loops seem unable to deeply
penetrate into the hydrophobic core of the bilayer.
The fusion ability of the two peptides was analysed using LUVs
with different compositions. Membrane components, such as
anionic lipids (DOPG), unsaturated phospholipids (DOPC,
POPC), sphingolipid (SM) and cholesterol (Chol) were used in
this study. Lipid raft formation occurs by spontaneous aggregation
of certain naturally occurring lipids that aggregate in the plane of
the membrane and are characterized by a higher degree of
molecular order and by being thicker than the surrounding liquid-
disordered lipids in the membrane. To investigate lipid raft
characteristics in model membranes, Chol and SM are commonly
combined with phospholipids having unsaturated and therefore
kinked fatty acyl chains, such as POPC. Our results are consistent
with previous studies showing the specific association of gB with
cholesterol-rich rafts [32]. We found that gB peptides associate
with lower fusion ability with liposomes in the absence of
cholesterol. Our data further suggest that the cholesterol
dependence of gB is not necessarily dependent on a protein
receptor in rafts, but because cholesterol itself enhances insertion
of the fusion loops. In Semliki Forest virus fusion protein E1, a
class II fusion protein that inserts preferentially into membranes
enriched in cholesterol and sphingolipid [49], a point mutation in
the loop adjacent to the fusion loop confers increased cholesterol
independence [50,51].
Lipid mixing, inner-monolayer and leakage are three indepen-
dent experiments which describe different processes during the
interaction of peptides with liposomes. In particular, the lipid
mixing experiment evidences the fusion of both the inner and
outer monolayer, the inner monolayer experiment evidences the
eventual presence of fusion of the inner monolayer, while the
leakage describes the pore formation. Results were consistent
among the three experiments for both peptides, supporting the
hypothesis that the two peptides induce fusion of inner and outer
monolayers but not formation of pores whenever used alone or in
equimolar concentrations. The present results can be used as
qualitative indicators of bilayer perturbation due to its interaction
with the peptides and their superficially positioning. We have not
detected any significant pore formation; in fact, vesicle fusion
events were not accompanied by leakage of the aqueous contents
of the vesicle as also reported for other peptides in a study
published by Thoren et al. [52].
Table 2. Partition coefficient for the binding of peptides with
PC/Chol.
HB168–186 HB254–270
Kp (2.560.3)10
4 (3.260.2)104
doi:10.1371/journal.pone.0032186.t002
Table 3. Stern-Volmer (Ksv) quenching constant calculated
from the equation F0/F = 1+Ksv [Q] for HB168–186 and
HB254–270.
HB168–186 HB254–270
Ksv (M
21) in buffer 8.360.2 71.161.1
Ksv (M
21) in LUVs 6.460.4 8.560.1
doi:10.1371/journal.pone.0032186.t003
Figure 6. Quenching of tryptophan/tyrosines by Acrylamide. Stern-Volmer plots of acrylamide quenching of HB168–186 and HB254–270 in
buffer (closed symbols) and in LUVs (open symbols).
doi:10.1371/journal.pone.0032186.g006
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Another novel feature revealed in the present work is the
demonstration of oligomerization concomitant to fusion taking
place. Although a correlation between penetration and fusion
awaits further experimental support, our results suggest that
oligomerization is another parameter related to the nature of the
interaction of the peptide with the target membrane and plays a
key role in governing fusion activity. The peptide HB168–186
presents a high tendency to oligomerize both in aqueous solution
and inside the membrane. On the contrary, the peptide HB254–
280 is not oligomerized in aqueous solution but it is able to
oligomerize when interacting with the membranes.
Tryptophan and tyrosine side chains are often found at the
interface between charged phospholipids and hydrophobic fatty
acid chains of lipid membranes. The Kp values for the two
peptides are reported in Table 2. Since Kp values are all of the
same order (104), we concluded that the peptides have similar
membrane-binding affinities. The values of Kp obtained are within
the range of those obtained for membrane-permeating bioactive
peptides such as mellitin and its derivatives [53], the Staphylo-
coccus d-toxin [54], the antibiotic dermaseptin [55], pardaxin
analogues [56]. All the results obtained support a shallow insertion
of the two peptides that may expand the head-group region of one
of the monolayers and generate elastic stresses that are released by
bilayer deformation. Our results demonstrate that these two gB
peptides bind and interact with membranes and could thus be
directly involved in merging of the viral and cellular membranes
and might work cooperatively with other membrane active regions
present on herpesvirus glycoproteins to boost the fusion process.
These results improve the current understanding of the critical
features required for viral fusogenic peptides to cross the
membrane bilayer and seem promising for the development of
new carrier peptides that could exploit viral membranotropic
peptides for intracellular delivery [57–59].
HSV-1 might have several domains involved in the fusion
process which either directly or indirectly, might interact with
biological membranes, contributing to the viral envelope and cell
membrane merging. Although the detailed mechanism of
herpesvirus entry remains unclear, some important insights into
the interplay of the proteins involved in membrane fusion have
been gained recently, but there are still many unsolved questions
such as if the two fusion loops are the only HSV fusion peptide;
what triggers them to be inserted into the target membrane, what
is the role of gH in fusion and if fusion domains present in gH are
directly involved in fusion.
Materials and Methods
Materials
The Phospholipids: 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
choline (POPC), dioleoyl phosphatidylcholine (DOPC), dioleoyl
phosphatidylglycerol (DOPG), N-octadecanoyl-D-erythro-sphingo-
sylphosphorylcholine (SM), the fluorescent probes N-(7-nitro-
benz-2-oxa-1,3-diazol-4-yl)phosphatidylethanolamine (NBD-PE)
and N-(Lissamine-rhodamine-B-sulfonyl) phosphatidylethanol-
amine (Rho-PE) were purchased from Avanti Polar Lipids
(Birmingham, AL, USA), while cholesterol (Chol) and Triton-
6100 were from Sigma (St. Louis, MO, USA). All other reagents
were of analytical grade. Spin-labelled phosphatidylcholines (n-
PCSL) with the nitroxide group at different positions, n, in the sn-2
acyl chain were synthesized as described by Marsh [60]. The spin-
labels were stored at 220uC in ethanol solutions at a concentra-
tion of 1 mg/mL.
Peptide synthesis
Peptides were synthesised using standard solid-phase-9-fluor-
enylmethoxycarbonyl (Fmoc) method as previously reported [25].
All purified peptides (purity higher than 98%) were obtained with
good yields (30–40%). Table 1 shows the sequences of all the
synthesized peptides. Peptide stock solutions were prepared in
buffer with 2% dimethyl sulfoxide (DMSO).
Liposome preparation
Large unilamellar vesicles (LUVs) consisting of DOPG, DOPG/
Chol (3/2), DOPC, DOPC/Chol (3/2), POPC/Chol (3/2),
Figure 7. ESR Results. (A) ESR spectra of 5-PCSL and 14-PCSL spin-
labels in DOPC/Chol membranes in the absence of peptides (solid line)
and in the presence of HB168–186 (dotted line), HB254–270 (dashed
line) and HB168–186–HB254–270 mixture (dashed-dotted line). (B)
Dependence on spin-label position, n, of the outer hyperfine splittings,
2Amax, of the n-PCSL in DOPC/Chol bilayers in the absence (#) and in
the presence of HB168–186 (&), HB254–270 (N) or HB168–186: HB254–
270 (m) at T = 25uC.
doi:10.1371/journal.pone.0032186.g007
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POPC/Chol/SM (4/1/1), POPC/Chol/SM (2/1/1) and POPC/
Chol/SM (1/1/1), and when necessary containing Rho-PE and
NBD-PE, were prepared according to the extrusion method of
Hope et al. [61] in 5 mM HEPES, 100 mM NaCl, pH 7.4. Lipids
were dried from a chloroform solution with a nitrogen gas stream
and lyophilized overnight. For fluorescence and circular dichroism
experiments, dry lipid films were suspended in buffer by vortexing
for 1 h; then the lipid suspension was freeze-thawed 6 times and
extruded 20 times through polycarbonate membranes with 0.1 mm
diameter pores to produce LUVs. Lipid concentrations of
liposome suspensions were determined by phosphate analysis
[62]. For ESR spectroscopy, multi-lamellar vesicles (MLVs) were
prepared. In these samples, 1% (wt/wt) of the spin-label, dissolved
in ethanol, was added to the lipid mixture in organic solvent before
drying. MLVs suspensions were obtained by the same procedure
described above, excluding the extrusion step.
Lipid mixing assays
Membrane lipid mixing was monitored using the resonance
energy transfer assay (RET) reported by Struck et al. [63]. The
assay is based on the dilution of the NBD-PE (donor) and Rho-PE
(acceptor). Dilution due to membrane mixing results in an
increase in NBD-PE fluorescence. The change in donor emission
was monitored as aliquots of peptides were added to vesicles.
Vesicles containing 0.6 mol % of each probe were mixed with
unlabelled vesicles at a 1:4 ratio (final lipid concentration
0.1 mM). Small volumes of peptides in dimethylsulfoxide
(DMSO) were added; the final concentration of DMSO in the
peptide solution was no higher than 2%. The NBD emission at
530 nm was followed with the excitation wavelength set at
465 nm. A cut off filter at 515 nm was used between the sample
and the emission monochromator to avoid scattering interferenc-
es. The fluorescence scale was calibrated such that the zero level
corresponded to the initial residual fluorescence of the labelled
vesicles and the 100% value corresponding to complete mixing of
all lipids in the system was set by the fluorescence intensity of
vesicles upon the addition of Triton X-100 (0.05% v/v) at the
same total lipid concentrations of the fusion assay. Lipid mixing
experiments were repeated at least three times and results were
averaged. Control experiments were performed using a scrambled
peptide and DMSO. All the experiments were performed at
37uC.
Figure 8. Secondary structure in lipid bilayers. CD spectra of HB168–186 and HB254–270 in buffer and in DOPC/Chol LUVs.
doi:10.1371/journal.pone.0032186.g008
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Inner-monolayer phospholipid-mixing (fusion)
measurement
Peptide-induced phospholipid-mixing of the inner monolayer
was measured by a modification of the phospholipid-mixing
measurement reported elsewhere [64]. The concentration of each
of the fluorescent probes within the liposome membrane was 0.6%
mol. LUVs were treated with sodium dithionite 100 mM (from a
stock solution of 1 M dithionite in 1 M TRIS, pH 10.0) to
completely reduce the NBD-labelled phospholipid located at the
outer monolayer of the membrane, for approximately 1 h on ice in
the dark. Sodium dithionite was then removed by size exclusion
chromatography through a Sephadex G-75 50 DNA Grade
filtration column (GE Healthcare) eluted with a buffer containing
10 mM TRIS, 100 mM NaCl, and 1 mM EDTA, pH 7.4.
Measurements of ANTS/DPX leakage
The ANTS/DPX assay [34] was used to measure the ability of
the peptide to induce leakage of ANTS/DPX pre-encapsulated in
liposomes. Details of this assay can be found elsewhere [35]. To
initiate a leakage experiment, the peptide, in a stock solution at
pH 7.4 containing 5 mM Hepes and 100 mM NaCl, was added to
the stirred vesicle suspension (0.1 mM lipid) at 37uC.
Thioflavin T assays for peptide aggregation
Peptide aggregation was assayed using Thioflavin T (ThT).
ThT associates rapidly with aggregated peptides giving rise to a
new excitation maximum at 450 nm and an enhanced emission at
482 nm [36]. LUVs in 100 mM NaCl, 10 mM Tris–HCl, 25 mM
ThT, pH 7.4 (final phospholipid concentration of 0.1 mM) were
titrated with a peptide concentration of 1, 4, 8, 12, 16, 20 mM.
Fluorescence was measured before and after the desired amount of
peptide was added into the cuvette using a Varian Cary Eclipse
fluorescence spectrometer at 37uC. Samples were excited at
450 nm (slit width, 5 nm) and fluorescence emission was recorded
at 482 nm (slit width, 5 nm). Aggregation was quantified
according to the equation, %A= (Ff2F0)/(Fmax2F0)6100, where
Ff is the value of fluorescence after peptide addition, F0 the initial
fluorescence in the absence of peptide and Fmax is the fluorescence
maximum obtained immediately after peptide addition. Kinetic
data were obtained at a concentration of 4 mM.
Tryptophan and Tyrosine fluorescence measurements
Emission spectra of the peptides (1 mM) containing the
tryptophan and tyrosine residue in the absence or presence of
target vesicles (DOPC/Chol 1/1) were recorded: between 300 and
400 nm with an excitation wavelength of 295 nm for the peptide
HB168–186 and 290 and 350 with an excitation wavelength of
274 nm for the peptide HB254–270.The degree of peptide
association with lipid vesicles was measured by adding lipid
vesicles to 1 mM peptides and the fluorescence intensity was
measured as a function of the lipid/peptide molar ratio, in three to
four separate experiments. The fluorescence values were corrected
by taking into account the dilution factor corresponding to the
addition of microliter amounts of liposomes and by subtracting the
corresponding blank. The lipid/peptide molar ratio was 200:1.
The binding of hydrophobic peptides to membranes can be
described as a partition equilibrium: Xb=KpCf where Kp is the
apparent partition coefficient in units of M21, Xb is the molar ratio
of bound peptide per total lipid and Cf is the equilibrium
concentration of the free peptide in solution, as previously
suggested by Schwarz et al. [65]. F‘ was obtained by extrapolation
of a double reciprocal plot of the total peptide fluorescence vs the
total lipid concentration in the outer leaflet, i.e. 1/F vs 1/0.6CL.
The fraction of membrane-bound peptide, fb, was determined by
the formula fb = (F2F0)/(F‘2F0), where F represents the fluores-
cence of peptide after the addition of the vesicles and F0 represents
the fluorescence of the unbound peptide. fb allowed us to calculate
the equilibrium concentration of free peptide in the solution, Cf,
and the extent of peptide binding Xb. Assuming that the peptides
were initially partitioned only over the outer leaflet of the SUV
(60% the total lipid) [66], values of Xb were corrected as follows:
Xb
* =Xb/0.6.
The curve resulting from plotting Xb
* versus the concentration
of the free peptide, Cf, is the binding isotherm.
Tryptophan and Tyrosine quenching by Acrylamide
Aliquots of a 4 M solution of the water-soluble quencher were
added to the solution containing the peptide (1 mM) in the absence
or presence of liposomes at a peptide/lipid molar ratio of 1/200.
The maximal concentration of acrylamide is 0.2 mmol/ml.
Tryptophan fluorescence was measured with an excitation
wavelength of 295 nm, to reduce acrylamide absorbance (and
the resulting inner filter effect), and emission at a wavelength of
340 nm, to eliminate interference from the Raman band of water
[67] and tyrosine fluorescence was measured with an excitation
wavelength of 274 nm, and emission at a wavelength of 305. The
data were analyzed according to the Stern-Volmer equation [68],
F0/F= 1+Ksv [Q], where F0 and F represent the fluorescence
intensities in the absence and the presence of the quencher (Q),
respectively, and Ksv is the Stern-Volmer quenching constant,
which is a measure of the accessibility of tryptophan to acrylamide.
Acrylamide does not significantly partition into the membrane
bilayer [67], and the value for Ksv is a reliable reflection of the
bimolecular rate constant for collisional quenching of the aromatic
residues present in the aqueous phase. Accordingly, Ksv is
determined by the amount of non-vesicle-associated free peptide
as well as the fraction of the peptide residing at the surface of the
bilayer.
Electron Spin Resonance Spectroscopy
ESR spectra were recorded with a 9 GHz Bruker Elexys E-500
spectrometer (Bruker, Rheinstetten, Germany). The lipid suspen-
sions to be investigated were transferred into 25 mL glass
capillaries and flame sealed. The capillaries were placed in a
standard 4 mm quartz sample tube containing light silicone oil for
thermal stability. All the measurements were performed at 25uC.
Spectra were recorded using the following instrumental settings:
sweep width, 100 G; resolution, 1024 points; time constant,
20.48 ms; modulation frequency, 100 kHz; modulation ampli-
tude, 1.0 G; incident power, 6.37 mW. Samples containing the
peptides were prepared by hydrating the lipid film directly with the
peptide solution in buffer. In all samples, the peptide to lipid ratio
was set to 1:1 wt/wt. In samples containing both HB168–186 and
HB254–270, the total peptide to lipid ratio was maintained to 1:1
wt/wt, while the HB168–186:HB254–270 ratio was 1:1 wt/wt.
Several scans, typically 16, were accumulated to improve the
signal-to-noise ratio. Values of the outer hyperfine splitting, 2Amax,
were determined by measuring the difference between the low-
field maximum and the high-field minimum, through a home-
made, MATLAB-based, software routine. This parameter is a
useful empirical measure of the lipid chain dynamics and order in
both gel and fluid phases of lipid bilayers [44–46]. The main
source of error on the 2Amax value is the uncertainty in composition
of samples prepared by mixing few microliters of mother solutions.
For this reason, reproducibility of 2Amax determinations was
estimated by evaluating its value for selected independently
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prepared samples with the same nominal composition. It was
found to be 60.2–0.3 G.
Circular dichroism spectroscopy
CD spectra were recorded using a Jasco J-715 spectropolarim-
eter in a 1.0 cm quartz cell at room temperature. The spectra are
an average of 3 consecutive scans from 260 to 195 nm, recorded
with a band width of 3 nm, a time constant of 16 s, and a scan rate
of 10 nm/min. Spectra were recorded and corrected for the blank
sample. Mean residue ellipticities (MRE) were calculated using the
expression MRE=Obsd/(lcn), where Obsd is the ellipticity mea-
sured in millidegrees, l is the path length of the cell in cm, c is the
peptide concentration in mol/l, and n is the number of amino acid
residues in the peptide. Solutions of 4 mM of HB168–186 and
10 mM of HB254–270 with LUVs were prepared as described
previously [31]. The measurements were performed at peptide/
lipid ratios of 0.5 mol/mol.
Supporting Information
Figure S1 Fluorescence spectra of tryptophan and
tyrosine. Fluorescence spectra of HB168–186 and HB254–270
in buffer and in LUVs.
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gH625 is a membranotropic peptide able to transport different cargos (i.e. liposomes, quantum 
dots, polymeric nanoparticles) within and across cells in a very efficient manner. However, 
clear understanding of the detailed uptake mechanism remains elusive. In this work, the 
journey of gH625-functionalized polystyrene nanoparticles from the interaction with the cell 
membrane to their intracellular final destination has been investigated in detail in mouse brain 
endothelial cells in order to elucidate how gH625 affects nanoparticle behavior and their 
cytotoxic effect on an in vitro model of blood brain barrier. Results indicate that the 
mechanism of translocation of gH625 dictates nanoparticles’ fate and this has a relevant 
impact on the nanotoxicological profile of positively charged nanoparticles. 
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1. Introduction 
Nanotechnology plays a key role in future strategies for drug delivery and also an essential 
role in brain drug delivery. Nanoparticles are colloidal systems that range in size from 1 to 
100 nm. They can be fabricated by a variety of substances such as polymers, lipids, 
dendrimers, ceramics, and carbon nanotubes; and can be structurally adapted to deliver a wide 
variety of drugs, enhance delivery efficiency, and reduce side effects by targeted delivery [1, 
2]. Nanoparticles are increasingly demonstrating an advantage in effective transportation of 
various drugs, including temozolomide, loperamide, and doxorubicin, which are not normally 
able to reach the central nervous system (CNS)[3] in part due to the presence of the blood 
brain barrier (BBB). The BBB is formed by the endothelial cells of brain capillaries, and 
restricts the exchange of most endogenous molecules between the blood and the brain; the 
very tight regulation of brain homeostasis imposed by the BBB prohibits many therapeutic 
compounds from entering brain tissues[4]. Drugs that are intended to act in the CNS can be 
administered systemically, if they have the ability to circumvent the BBB or have to be 
introduced directly in the CNS by invasive methods[5]. The BBB represents the main 
challenge for the development of new neurotherapeutics, and various strategies are currently 
under development to enhance the uptake of therapeutic compounds into brain parenchyma. 
Among the others, the ever expanding use of nanoparticles is giving hope on achieving more 
efficient drug delivery into the brain but has also determined great concern about their 
potential risks to human and environmental health[3]. Toxicity of nanoparticles could vary 
with their physicochemical parameters. The dependence of cytotoxicity on particle size and 
surface coating has been widely investigated with smaller nanoparticles being more toxic than 
the larger ones. Moreover, recent works have demonstrated that nanoparticles essentially use 
the “classical” endocytic mechanism to enter cells. As a result of this route of cellular 
entrance, nanoparticles tend to accumulate and to remain inside lysosomal compartments. 
This accumulation leads to two important consequences: i) a low efficiency of BBB crossing 
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due to lysosomal storage[6] and ii) an increase of nanoparticle toxicological effects due to the 
lysosomal environment with a low pH and a high degradative potential. [7, 8] 
In this framework, NP surface modification may vary their intracellular fate and, therefore, 
their nanotoxicological profile. Indeed, using appropriate surface modification, nanoparticle 
carriers have been shown to represent promising strategies for delivery, having good cellular 
uptake and lower cytotoxicity in vitro and in vivo. Recently, nanoparticles with multiple 
surface modifications for delivery to the CNS have been developed such as decoration with 
poly(ethylene glycol) (PEG)[9], polysorbate-80[10], monoclonal antibody[11], and cationic 
cell-penetrating peptides[12]. More recently, great attention has been dedicated to the study of 
hydrophobic peptides that efficiently traverse biological membranes, promoting lipid 
membrane-reorganizing processes, such as fusion or pore formation, and thus involving 
temporary membrane destabilization and subsequent reorganization[13], which may be 
exploited for drug delivery purposes.[14-17] The nineteen-residue peptide gH625 is a 
membrane-perturbing domain derived from the glycoprotein H (gH) of Herpes simplex virus 
1[17]; gH625 interacts with model membranes, contributing to their merging[15] and is able 
to traverse the membrane bilayer and transport a cargo into the cytoplasm and across the 
BBB.[18-22] In particular, we previously reported the ability of gH625 to transport quantum 
dots,[18] liposomes,[20] nanoparticles,[21] and dendrimers.[22]  
We characterize here a novel theranostic platform that may be broadly applicable for the 
development of new therapeutics with increased brain penetration using nanoparticles 
conjugated with gH625. In particular, gH625 was coupled to the surface of fluorescent 
aminated polystyrene nanoparticles (NPs) via a covalent binding procedure and NP uptake 
mechanism and permeation across an in vitro BBB model were studied. We recently reported 
that the conjugation with gH625 facilitated the delivery of nanoparticles across the BBB, 
leading to significant higher cell uptake and crossing,  and, most importantly, a reduction of 
NP intracellular accumulation as large aggregates.[21] These previous observations suggest 
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that the efficient translocation across cell membranes and cell internalization of gH625-NPs 
do not involve exclusively “classical” endocytosis mechanisms. 
The surface functionalization with gH625 changed NP fate, thus providing a good strategy for 
the design of promising carriers to deliver drugs across the BBB for the treatment of brain 
diseases bypassing the endocytosis entrapment.  
Further characterization of the brain endothelial cell membrane translocation mechanism of 
this peptide platform and, hence, of its nanotoxicological impact are presented in this work. In 
particular, the interaction of gH625-NPs with brain endothelial cell membrane through atomic 
force microscopy and cholesterol depletion analyses, their intracellular trafficking and 
distribution as well as their cytotoxic effect compared to non-functionalized NPs, 
intracellularly delivered by “classical endocytosis” and by gene gun method [7] have been 
investigated. 
 
2. Results 
 
2.1 Interaction of gH625-NPs with the cell membrane 
gH625 enhances nanoparticles’ cellular uptake at early incubation time. In fact, we observed a 
2-fold increment of NP internalization within endothelial cells in presence of gH625 
compared to blank NPs already after 10 minute incubation.[21] Moreover, accordingly to 
cellular uptake kinetics, scanning electron microscopy (SEM) analyses indicated a better and 
more rapid adsorption of gH625-NPs on cell membrane, compared to blank-NPs after 10 min 
incubation, probably due to the membrane tropism of the peptide and, thus, an enhancement 
of gH625-NPs internalization.[21] 
To better elucidate the interaction of gH625-NPs with the cell membrane, coupling of 
conforcal laser scanning microscopy (CLSM) images with atomic force microscopy (AFM) 
was carried out. This analysis is very instructive on assessing the status of the NPs at the cell 
membrane.[23] Indeed, by matching topographical features of cell membrane with 
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fluorescence signal, we observed that, after 10 minute incubation, there is a partial co-
localization between NP fluorescence and cell membrane humps, suggesting that gH625-NPs 
are both on cell membrane and inside the cytoplasm (Figure 1 B). Moreover, NP deposition 
on the cell membrane was examined at different time points upon incubation with NPs. As 
shown by the chart in Figure 1 E, an overall increment of cell membrane roughness is 
observed upon 10 minute incubation with gH625-NPs compared to control cells (non-treated 
with NPs) and cells incubated with blank NPs. Conversely, no differences in cell membrane 
roughness are present among all samples after 24 h incubation, likely due to NP cellular 
uptake. These observations further confirm the better interaction of gH625-NPs with the cell 
membrane than blank NPs, in agreement with previously reported results.[21] 
gH625 assumes in membrane mimetic environments a helical structure that makes it 
particularly affine for lipids.[15] Indeed, we previously demonstrated its capability to hemi-
fuse liposomes and its tropism for cholesterol enriched membranes in vitro.[15] Therefore, we 
hypothesized that a similar mechanism could be used by gH625-NPs to bind the cell 
membrane and, thus, for their translocation within the cell. To address this issue, we treated 
cells with methyl beta cyclodextrin (MβCD) in order to deplete cholesterol from the cell 
membrane and investigate the effect of this treatment on nanoparticles’ cellular uptake. 
Results, reported in Figure 2 A-B, show no effects on intracellular distribution of blank NPs 
after 30 minute treatment with 10 mM MβCD. On the other hand, gH625-NP uptake is 
inhibited by cholesterol depletion (Figure 2 C and D). In particular, we observed a reduction 
of about 40% in cellular uptake for gH625-NPs after 30 minute of MβCD treatment compared 
to non-treated cells (Figure 2 E). Taken altogether these data suggest that the interaction with 
the cell membrane lipids plays a pivotal role in controlling the mechanism of gH625-NPs 
uptake. 
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2.2 gH625-NP intracellular behavior 
In order to confirm that the presence of gH625 affects the intracellular behavior of NPs by-
passing the endo-lysosomal pathway, we forced cell membrane crossing by shooting NPs with 
gene gun method.[7] 
As previously reported, [7, 21] once internalized by cells, blank NPs show prevalently a pearl-
on-a-string behavior, with a little percentage of random walk trajectories (Figure 3 A). On the 
contrary, if forced to enter cell by using gene gun method, shot blank NPs show almost 
exclusively random walk trajectories, suggesting very low NP confinement inside endo-
lysosomal compartments (Figure 3 B).[7] In the case of gH625-NPs, no significant changes in 
intracellular trajectories were observed upon delivery of NPs by using gene gun method 
(Figure 3 B). These data strongly suggest that gH625 allows NPs to by-pass/escape the endo-
lysosomal pathway.  
Furthermore, by increasing the incubation time, the percentages of random and pearl-on-a-
string trajectories remain almost the same for both blank and gH625-NPs (Figure 4 A and B). 
Interestingly, MPT analyses of later incubation times reveal the presence of a third category 
of trajectories that we did not consider for the calculation of trajectory percentages since they 
fit only partially the MSD equation described in the materials and methods section. More 
precisely, the first part of MSD curves of these trajectories shows a time coefficient  α ≤ 1, 
typical of random walk behavior, while the second part shows an α coefficient close to zero 
indicating a confined motion (Figure 4 C). In particular, the percentage of these trajectories is 
higher and increases with time for blank than gH625-NPs (data not shown). Therefore, we 
named this kind of trajectories “random caged” and hypothesized to be typical of 
nanoparticles confined inside the largest perinuclear lysosomes as their final destination. 
Further investigations are necessary to elucidate this issue. 
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2.3 gH625-NP intracellular distribution 
To further investigate the fate of gH625-NPs, we followed nanoparticles’ intracellular 
distribution by co-localization experiments within endocytic compartments, namely 
endosomes and lysosomes. After 10 minute incubation, both NPs are able to enter cells and 
partially co-localize with Rab5 protein, a marker of early endosomes, thus indicating that both 
NPs use vesicular structures to enter cells (Figure 5). In particular, at earlier incubation time, 
no significant differences of co-localization percentages are observed between blank and 
gH625-NPs. By increasing the incubation time, the percentage of co-localizationfor blank 
NPs increases up to 30 min and then decreases becoming about 4 % at 2h. Conversely, for 
gH625-NPs the percentage of co-localization with Rab5 protein remains almost constant with 
time. 
Already after 2h incubation, both blank and gH625-NPs partially co-localize with lysosomes, 
(Figure 6). However, the percentage of co-localization of blank NPs increases over time, 
reaching almost 80%. On the other hand, for gH625-NPs, the percentage of co-localization is 
lower than blank NPs and increases up to 6 h remaining almost constant after 24 h incubation. 
These observations suggest a partial lysosomal escape of gH625-NPs.  
The accumulation of NPs within the lysosomes also affects lysosome size distribution. Indeed, 
an increment in lysosome size up to 1.5 µm
2
 is observed after 24h incubation with blank NPs 
(Figure 7 A). Conversely, in presence of gH625-NPs, where a scarce co-localization is 
observed, lysosome size remains constant over time (Figure 7 B).  
2.4 gH625-NP cytotoxicity 
The capability to by-pass the lysosomal compartment can offer great advantages in terms of 
efficacy of nanocarriers to overcome biological barriers [21] and of reduced nanotoxicity. [7] 
Recent works reported on the cytotoxic effects of positively charged polystyrene NPs as a 
consequence of their localization in lysosomes and interaction with lysosomal components.[8, 
24] Therefore, we tested the effect of gH625 on cytotoxicity of positively charged polystyrene 
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nanoparticles and compared results to cells treated with blank NPs delivered by “classical” 
endocytosis and gene gun method, as positive and negative controls, respectively. We chose 
to work with 100 nm and 50 nm particles with a 35% functionalization degree, in order to 
evaluate the effect of size on NP cytotoxicity, and a particle concentration of 50 µg/ml NPs, 
reported in literature as cytotoxic[8] and corresponding in our experimental system to 6 × 10
4
 
NPs/cell for 100 nm NPs (Figure S2 A) and 2 × 10
5
 NPs/cell for 50 nm NPs (Figure S2 B). 
Data indicate a reduction of viability of cells treated with positively charged NPs, as expected 
(Figure 8). In particular, a higher cytotoxic effect is observed for 50 nm NPs than 100 nm NPs, 
likely due to the higher cellular uptake of smaller NPs (Figure S2). On the other hand, after 
NP shooting, no cytotoxic effect is observed for both 50 and 100 nm NPs, clearly indicating 
that the cytotoxicity is strongly dependent on NP intracellular localization. More interestingly, 
after incubation with gH625-NPs, a recovery of cell viability is observed, compared to 
endocytosed blank NPs. However, the reduction in cytotoxicity of gH625-NPs is less evident 
than shot blank NPs likely due to their partial co-localization with lysosomes as shown above 
(Figure 6). Moreover, the effect of gH625 in cytotoxicity reduction is higher for smaller (50 
nm) than bigger (100 nm) functionalized NPs, even though the first enter cells more than the 
second ones. These latter results could be attributed to a different conformation and/or density 
of peptide molecules on the NP surface. To address this issue, we first verified the secondary 
structure of the peptide bound to the nanoparticles by circular dichroism (CD) experiments. 
CD data confirmed that gH625 retains its structure (helical) when bound to both 50 nm and 
100 nm [21] -diameter nanoparticle surface (Figure S3). To further characterize the gH625-
NPs, we performed dynamic light scattering (DLS) measurements. After functionalization, the 
hydrodynamic size of nanoparticles with 35% of gH625 in aqueous medium at pH 7 was 
found to be 102.9 ± 0.6 nm with polydispersity index (PDI) of ca. 0.15 for 100 nm NPs, 
which is close to those previously obtained for the same preparation, indicating the 
reproducibility of the synthetic procedures, and 71.0 ± 9.3 nm (PDI 0.24) for 50 nm NPs 
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(Table S1). To confirm the colloidal stability of functionalized nanoparticles, which is a 
crucial parameter correlated to their functionalization, measurements of the zeta potential 
were also carried out. We confirmed previously obtained results. In particular, zeta potential 
values are around + 25 mV similar for both 100 and 50 nm gH625-NPs (Table S1). On the 
other hand, the density of peptide molecules on NP surface varies as a function of NP size 
being 4 peptides/nm
2
 for 100 nm NPs and 11 peptides/nm
2
 for 50 nm NPs. Taken altogether 
these data indicate that gH625 is able to retain its helical structure both on 100 nm and 50 nm 
NPs and suggest that its effect on cytotoxicity of polystyrene NPs with different size might 
depend on the density of peptide bound to the NP surface.   
3. Discussion 
Endocytosis is the major uptake mechanism of cells;[25] the cargos become entrapped in 
endosomes and are usually degraded by specific enzymes in the lysosomes; [8, 25-28] thus, a 
limiting step in achieving an effective biological based therapy is to facilitate endosomal 
escape and ensure delivery of therapeutics. The discovery that synthetic peptides can be used 
to deliver biologically active substances inside live cells has provided the basis for developing 
new effective strategies for drug delivery into the brain[29]. The data presented here further 
characterize a new drug-delivery platform designed to enhance brain penetration of drugs. In 
particular, we coupled polystyrene NPs to a membranotropic peptide (gH625) able to cross 
membrane bilayers. In previous validation studies, gH625 was shown to effectively enter cells 
and to efficiently transport small cargos by directly penetrating the membrane; although we 
could not completely exclude the partial involvement of endocytosis.[13, 18, 22] A primary 
objective of this study was to improve our understanding of the internalization mechanism 
and of its impact on the nanotoxicological profile of the nanoparticles. 
The uptake and subcellular localization of the NPs were investigated by exposing the in vitro 
BBB model to 100 nm polystyrene NPs. It is clear from our results that the majority of blank 
NPs end up in intracellular organelles, many of them lysosomes, similarly to several other NP 
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cell systems. [30, 31] As far as we can tell, they accumulate within the lysosomes. A 
significant number of blank NPs are observed associated with lysosomes and after 24 h the 
degree of lysosomal accumulation was around 80% indicating a significant fraction of NPs 
accumulates in lysosomes. Interestingly, gH625-NPs only slightly co-localize with lysosomes 
and their degree of lysosomal accumulation did not increase with time.  
The endothelial brain cells are rich in cholesterol and this may indicate an involvement of 
lipid rafts.[32] We previously demonstrated that gH625 is able to hemifuse liposomes 
containing a high percentage of cholesterol.[17] Here we wanted to verify if gH625-NPs were 
still able to cross the membrane of an in vitro model of the BBB depleted of cholesterol. Our 
hypothesis was confirmed by our results, showing that the depletion of cholesterol did not 
have any effect on the intracellular distribution of blank NPs but significantly reduced the 
uptake of gH625-NPs.  
gH625-NP interaction with the cell membrane plays a key role in controlling the uptake 
mechanism, as also demonstrated by the gene gun experiments, which show that blank NP 
intracellular behavior can be switched from pearl-on-a-string to random, while gH625-NP 
trajectories are not subject to any change.  
Collectively, the evidence of particle movement in the barrier and the information above do 
suggest that such true barrier crossing events occur for both blank-NPs and gH625-NPs but 
with different mechanisms that are related to the ability of gH625 to interact with membranes 
containing a high percentage of cholesterol. In particular, it may be hypothesized that gH625 
is able to carry NPs across the BBB with translocation mechanisms or, when endocytosis 
takes place, it is able to induce endosomal escape (Figure 9). 
This last point is extremely important as the cytotoxic effect of NPs is attributed to their 
localization in lysosomes and interaction with lysosomal components. In order to assess the 
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effect of the mechanism of uptake on the cytotoxicity, we used 100 nm and 50 nm NPs for 
their higher cytotoxic potential.[8] We found that when blank NPs are shot, we did not 
observe any cytotoxic effect; similarly if we decorate the NPs with gH625 we also observe a 
significant reduction of cytotoxicity compared to blank NPs. We thus, believe that the ability 
of gH625 to avoid accumulation into lysosomes (both by using uptake mechanisms not 
involving endocytosis mechanisms, and/or escaping from lysosomes) is responsible of the 
reduction of cytotoxicity. 
Data obtained on the transport mechanism of gH625 clearly indicate that it is able to switch 
the mechanism of uptake of the cargo and it is able to cross the BBB in a fashion that can be 
distinguished from other cell-penetrating peptides such as TAT and penetratin.[29] A variety 
of therapeutic approaches to cross the BBB have been examined previously, but most have 
been unsuccessful and/or inconvenient.[4] The gH625 platform provides a number of 
important advantages over these prior approaches. First, it involves only partially the 
endocytic pathway; second, it is able to facilitate the escape from endocytic vesicles; finally 
the absence of accumulation in lysosomes determines its lower toxicity.  
In conclusion, we have characterized the mechanism of uptake of NPs decorated on their 
surface with gH625 and their effect on cell viability. The results presented here and in earlier 
studies[21] suggest that the gH625 platform may have significant utility in overcoming this 
constraint and could be used as a safe and effective delivery system for the transport of drugs 
across the BBB. This platform presents high efficacy with extreme flexibility with unlimited 
targets and these are the first in vitro results showing that a membranotropic peptide could be 
used as a new brain delivery system. Further work is now underway with various therapeutic 
targets. 
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4. Conclusion 
In summary, this study demonstrated in greater detail the efficacy of gH625 peptide to deliver 
cargos across the brain endothelial cell membrane and its capability to avoid lysosomal 
accumulation of nanoparticles. This has got a particular relevance on the impact of 
nanoparticles in the cytotoxic response. Therefore, NP surface decoration with 
membranotropic peptides could be a valid strategy to design safe and effective nanocarriers 
for the treatment of CNS diseases. 
 
 
5. Experimental Section  
Materials: Orange fluorescent amine-modified polystyrene, 100 nm, nanoparticles (100 nm 
NPs) and blue fluorescent amine-modified polystyrene, 50 nm, nanoparticles (50 nm NPs) 
were purchased by Sigma-Aldrich. 
gH625 synthesis, nanoparticle conjugation and characterization of gH625-NPs: The peptide 
gH625 (Ac-HGLASTLTRWAHYNALIRAFGGG-COOH) was synthesized using the 
standard solid-phase-9-fluorenylmethoxycarbonyl (Fmoc) method as previously reported.[17] 
The peptide was obtained with good yields (30-40%).  
The conjugation of gH625 to amine-modified fluorescent polystyrene nanoparticles was 
performed as described previously[21]. A solution of the peptide, EDC (1-Ethyl-3(3-
dimethylamino-propyl)-carbodiimide, hydrochloride) and NHS (N-Hydroxysuccinimide) in 
molar ratio of 4:4:1 was prepared in PBS buffer at pH 7.4, at room temperature under stirring 
for 30 minutes. NPs were conjugated with the preactivated-peptide, in MES 0.1 M buffer at 
pH 5.5 for 3 hours at room temperature in presence of Tween 20 and the yield of the reaction 
was higher than 90%. The peptide-NPs were purified from the un-conjugated-NPs by 
exclusion chromatography on a 1 × 18 cm Sephadex G-50 (Amersham Biosciences) column 
pre-equilibrated in PBS buffer at pH7.4. The fluorescence spectra of peptide-NPs and un-
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conjugated NPs were measured in a Cary Eclipse Varian fluorescence spectrophotometer in 
the same condition. For both 50 and 100 PS NPs, 35 % of functionalization degree was used. 
The gH625-NPs were characterized by circular dichroism and measurements of size and zeta-
potential.  
CD spectra were recorded using a Jasco J-715 spectropolarimeter in a 1.0 or 0.1 cm quartz 
cell at room temperature. The spectra are an average of 3 consecutive scans from 260 to 195 
nm, recorded with a band width of 3 nm, a time constant of 16 s, and a scan rate of 10 nm/min. 
Spectra were recorded and corrected for the blank sample. Measurements of zeta potential and 
size of gH625 NPs and blank-NPs were made with a Zetasizer Nano-ZS (Malvern Instruments, 
Worcestershire, UK). The measurements were conducted at 25°C using a 3.6 × 10
10
 NP/ml 
suspension at pH 7. All measurements were performed in triplicate for each sample. 
Cell culture: Immortalized mouse cerebral endothelial cells, bEnd.3 cells (American Type 
Culture Collection, Manassas, VA) were grown in DMEM with 4.5 g/L glucose, 10% Fetal 
Bovine Serum (FBS), 3.7 g/L sodium bicarbonate, and 4 mM glutamine, 1% non-essential 
amminoacids, 100 U/ml penicillin and 0.1 mg/ml streptomycin in 100 mm diameter cell 
culture dish, in a humidified atmosphere at 37°C and 5% CO2. Cells used in all experiments 
were at passage 11–18. 
Atomic force microscopy (AFM): For atomic force microscopy, cells were incubated 10 
minutes with blank and gH625-NPs, washed twice to remove non internalized NPs and fixed 
with 4% paraformaldehyde for 20 min. Cells not incubated with NPs were used as a control. 
AFM (NanoWizard II, JPK, GMBH) analysis was performed in contact mode by using 
triangular tip with a nominal spring constant of 0.03 N/m (MLCT, Brukerprobes). 30 × 10 
µm
2 
images were taken at different size applying a force of 1.5 nN with a scan rate of 1 Hz 
and a resolution of 512 × 171. At least 10 images were used to calculate the mean roughness 
(RMS) and processed by JPK analysis software mapping the different regions of the whole 
cell surface.  
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Cholesterol depletion: To extract cholesterol from cell membrane, cells were incubated with 
10 mM MβCD for 30 minutes at 37°C as previously described.[33, 34] After MβCD 
treatment, NPs were added to cell culture medium and incubated with cells for 15 minutes at 
37°C. Then, cells were rinsed twice with PBS to remove non-internalized NPs and fixed with 
4% paraformaldehyde for 20 min. Finally, cell nuclei and membranes were stained with DAPI 
and red fluorescent wheat germ agglutinin (WGA), respectively. All samples were then 
observed at confocal microscope (SP5 Leica) with a 63× oil immersion objective. Confocal 
images were analyzed with ImageJ analysis software to quantify NP uptake. At least 20 cells 
of each three independent experiments were analyzed. Data were shown as mean ± standard 
deviation. 
Colocalization with endosomes and lysosomes: For co-localization experiments, after 100 nm 
PS NPs incubation, cells were firstly rinsed twice with PBS to remove non-internalized 
nanoparticles and fixed.  
For endosome staining, cells were fixed with 4% paraformaldehyde for 10 min at room 
temperature (RT). Then, cells were permeabilized with 0.01% saponin-PBS for 8 min and 
blocked with FBS-PBS 10% for 20 min at RT. Endosomes were localized with rabbit anti-
Rab 5 polyclonal (Abcam) primary antibodies and with AlexaFluor 633 goat anti-rabbit 
secondary antibodies (Molecular Probes, Invitrogen) 
For lysosomes staining, cells were fixed with 4% paraformaldehyde for 20 min at RT. Then, 
cells were permeabilized with 0.05% saponin-PBS for 20 min and blocked with FBS-PBS 
10% for 20 min at RT. Lysosomes were localized with rabbit anti-LAMP 2 polyclonal 
(Abcam) primary antibodies and with AlexaFluor 633 goat anti-rabbit secondary antibodies 
(Molecular Probes, Invitrogen). All samples were then observed at confocal microscope (SP5 
Leica) with a 63× oil immersion objective and dual-channel images were acquired.  
The co-localization analyses were performed by LAS AF (Leica) and ImageJ analysis 
softwares. Data were expressed as co-localization percentage. Moreover, Pearson’s 
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coefficient was also calculated by JACoP plugin[35] to have an estimation of the correlation 
among the pixels in the dual-channels images (Figure S1).   
Intracellular shooting of NPs by gene gun method: To have free NPs in the cytoplasm, a 
ballistic system (gene gun, BioRad) was used as described elsewhere.[7] Briefly, 50 and 100 
nm amine-modified polystyrene  NPs were suspended in 30 µl of distilled water at the final 
concentration of 2.9 × 10
13
 and 4.5 × 10
12
 NPs/ml, respectively, deposited and left to dry on a 
rupture disk under a sterile hood. After solvent drying, a 900 psi pressure was used to shoot 
NPs within cells. After shooting, cells were roughly rinsed with PBS to remove non-
internalized NPs and, the day after, the cells were recovered and 3×10
4
 cells were seeded in 
each fresh 35 mm culture dish. 
Multiple particle tracking (MPT): Images of shot and endo 100 nm NPs in End.3 cells were 
collected in time-lapse for 100 s with a sampling time of 1 second by using a wide field 
fluorescence microscope (Olympus Cell-R, 60x oil immersion objective, NA = 1.35). 
Tracking algorithm has been described in details elsewhere.[36] NP trajectories were built and 
then the mean square displacement (MSD) was calculated and correlated with the NP 
diffusion by the equation (1)   , 
MSD = 4Dt
α 
where D is the diffusion coefficient and α represents the time dependence. The MSD curve of 
each tracked NP was fitted by using equation (1), in order to gain information about the nature 
of particle motion into the cells. Briefly, we indicate as Brownian or sub-diffusive, NPs 
exhibiting MSD curve that undergoes a power law with exponent α = 1 and α < 1, 
respectively, and super-diffusive, particles presenting MSD, whose dependence on time was 
described by the power law with α > 1. NPs presenting a MSD curves with a time exponent α 
≤ 1 at low Δt and α ≈ 0 were classified as entrapped (random caged) in confined endo-
lysosomal regions and not computed. The percentages of randomly moving NPs (α ≤ 1) and 
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transported NPs (1<α < 2) were evaluated and compared for shooting and endocytosis as a 
function of NP surface functionalization with gH625 peptides. For each experiment, at least, 5 
cells were analyzed. 
Quantification of internalized nanoparticles: To evaluate the number of endo and shot NPs 
within cells, 7.3 × 10
11
 50 nm NPs/ml and 9.0 × 10
10
 100 nm NPs/ml were delivered by 
“classical” endocytosis and 2.9 × 1013 50 nm NPs/ml and 4.5 × 1012 100 nm NPs/ml were 
delivered by gene gun method. After NP incubation, cells were roughly rinsed with PBS, 
trypsinized and counted by Neubauer chamber. Afterward, cells were centrifuged and the 
pellets were lysed with lysis buffer. Cell lysates were analyzed by a spectrofluorometer 
(Perkin–Elmer, USA) to measure the amount of internalized NPs. Data were reported as NP 
number normalized to the number of cells. Samples that had the same number of NPs per cell 
were used and compared each other for cytotoxicity. 
In vitro cytotoxicity: bEnd.3 cell viability was quantified by Alamar Blue Assay and 
compared to non-treated cells, which were used as a control. Briefly, 3 × 10
4
 cells were 
seeded on a 35 mm cell culture dish and incubated 24 h with NP suspensions to allow 
endocytosis. Conversely, for NP shooting, cells were shot with NPs by gene gun, washed 
roughly with PBS and, then, allowed to recover for 24 h at 37°C. After recovery, cells were 
trypsinized, counted and seeded on fresh 35 mm cell culture dishes. Alamar Blue Assay was 
performed according to the manufacturer’s procedure at 1 day after NP exposure. Absorbance 
of Alamar Blue reagent solution was read at 570 nm and 600 nm by a plate reader 
(Perkinelmer). Data were reported as percentage of viable cells normalized to non-treated 
cells.  
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Figure 1. AFM/CLSM coupling analysis. CLSM z-sectioning maximum projection of bEnd.3 
cells incubated for 10 min at 37°C with gH625-NPs (a) and blank NPs (c). Red fluorescence: 
cell membrane staining with WGA; green fluorescence: NPs; the dashed squares indicate the 
zoomed areas in b (scan area is about 3 × 8 µm) and d (scan area is about 14 × 25 µm). 
Transparence image merge of CLSM image and AFM scanning of cell membrane (b and d).  
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Figure 2. Blank and gH625-NP cellular uptake upon cholesterol depletion treatment. 
Confocal microscope images of bEnd.3 cells incubated with blank (a and b) and gH625- (c 
and d) NPs; b and d represent cells treated with 10 mM MβCD. Cell membranes are stained 
with red fluorescent WGA, cell nuclei are stained with DAPI and green spots are fluorescent 
NPs. Scale bar 20 µm. Quantification of NP uptake inhibition (e). Data are reported as mean ± 
standard deviation. p < 0.05 is considered statistically significant (*). 
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Figure 3. Intracellular trajectories of endocytosed (endo) (a) and shot (b) NPs analysed by 
MPT technique. The number of analyzed trajectories was 226 for endo blank NPs, 216 for 
shot blank NPs, 38 for endo gH625-NPs and 101 for shot gH625-NPs. 
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Figure 4. Intracellular trajectories of blank (a) and gH625-NPs (b) over time analysed by 
MPT technique. The number of analyzed trajectories were 105, 108, 64 for blank NPs at 2, 6 
and 24h, respectively, and 34, 113, 87 for gH625-NPs at 2, 6 and 24h, respectively. 
. 
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Figure 5. Co-localization of blank and gH625-NPs with endosomes over time. Confocal 
images of blank (a and c) and gH625-NPs (b and d) upon 10 min (a and c) and 1 h (b and d) 
of incubation. Scale bar 20 µm. Quantification of colocalization by ImageJ analysis software 
(e). 
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Figure 6. Co-localization of blank and gH625-NPs with lysosomes over time. Confocal 
images of blank (a and c) and gH625-NPs (b and d) upon 2 h (a and c) and 24 h (b and d) of 
incubation. Scale bar 20 µm. Quantification of colocalization by ImageJ analysis software (e).  
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Figure 7. Lysosome size distribution of bEnd.3 cells upon incubation with blank (a) and 
gH625 (b) NPs over time measured by ImageJ software.  
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Figure 8. Cytotoxicity of 100 nm and 50 nm gH625-NPs compared to non-treated control 
cells (ctrl) and cells incubated for 24 h with blank NPs delivered by “classical” endocytosis 
(endo-NPs) and by gene gun method (shot-NPs). Data are expressed as the average 
percentage of cell viability normalized to non-treated cells (ctrl) ± standard deviation. p  < 
0.05 is considered statistically significant (*) (n= 6). 
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Figure 9. Schematic representation of the hypothesized mechanisms of gH625-NP uptake and 
intracellular trafficking. gH625 may be able to carry NPs across the cell membrane with 
translocation mechanisms (route 2) or, when endocytosis takes place, it is able to induce 
endosomal escape (route 1). The ability of gH625 to avoid accumulation into lysosomes (both 
by using uptake mechanisms not involving endocytosis mechanisms, and/or escaping from 
lysosomes) is responsible of the reduction of cytotoxicity. 
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TOC. 
gH625 functionalized nanoparticle (gH625-NP) uptake mechanisms are characterized in 
brain endothelial cells. No lysosomal accumulation of gH625-NPs compared to blank non-
functionalized nanoparticles has relevant consequences in cytotoxicity profile of nanoparticles. 
As a result, this platform pave the way to design safe and effective nanocarriers for drug 
delivery to the central nervous system.  
 
 
  
29 
 
 
 
Copyright WILEY-VCH Verlag GmbH & Co. KGaA, 69469 Weinheim, Germany, 2013. 
 
Supporting Information  
 
 
Surface decoration with membranotropic peptides as a method to escape endo-lysosomal 
compartment and reduce nanoparticle toxicity. 
 
Daniela Guarnieri
1
, Ornella Muscetti
1
, Annarita Falanga
2
, Sabato Fusco
1
, Valentina Belli
1
, 
Emiliana Perillo
2
,
 
Edmondo Battista
1
, Valeria Panzetta
1
, Stefania Galdiero
2,*
, Paolo A. 
Netti
1,3,*
 
 
 
Dr. D. Guarnieri, Dr. O. Muscetti, Dr. S. Fusco, Dr. V. Belli, Dr. E. Battista, Dr. V. Panzetta, 
Prof. P.A. Netti 
Center for Advanced Biomaterials for health Care (CABHC), Istituto Italiano di Tecnologia, 
Largo Barsanti, Napoli, Italy 
Centro di Ricerca Interdipartimentale sui Biomateriali (CRIB), Università di Napoli Federico 
II, Piazzale Tecchio 80, Napoli, Italy 
*E-mail: nettipa@unina.it    
Dr. A. Falanga, E. Perillo, Prof. S. Galdiero 
Dipartimento di Farmacia, Università di Napoli Federico II, Via Domenico Montesano 49, 
Napoli, Italy 
*E-mail: sgaldier@unina.it  
 
 
  
30 
 
 
Table S1. Size and zeta-potential of 50 and 100 nm NPs with and without gH625 
functionalization at pH7.  
 Zeta-
potential 
(mV) [a] 
Size 
(d.nm) [a] 
PDI 
50 nm NP + 42.8 ± 6.7 60.0 ± 5.4 0.16 
50 nm gH625-NP + 23.4 ± 3.0 71.0 ± 9.3 0.24 
100 nm NP + 56.7 ± 1.1 104.4 ± 0.3 0.11 
100 nm gH625-NP + 26.9 ± 1.0 102.9 ± 0.6 0.15 
[a] (mean value ±SD, n=3) 
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Figure S1. Pearson’s coefficients of co-localization experiments of blank and gH625-NPs 
with Rab5 (A) and LAMP2 (B) calculated by JACoP ImageJ plugin. 
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Figure S2. Quantification of 100 nm (A) and 50 nm (B) NP uptake upon endocytosis (endo) 
and shooting (shot). 
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Figure S3. Circular dichroism of 50 nm NPs (panel A) and 100 nm NPs (panel B) with 35% 
of gH625 functionalization. 
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Abstract  
The present work investigates in vitro the delivery of the anticancer drug mitoxantrone (MTX) to HeLa 
cancer cells by means of polyethylene glycol (PEG) liposomes functionalized with the novel cell penetrating 
peptide gH625. This hydrophobic peptide enhances the delivery of doxorubicin (Doxo) to the cytoplasm of 
cancer cells, while the mechanism of this enhancement has not yet been understood. Here, in order to get a 
better insight into the role of gH625 on the mechanism of liposome-mediated drug delivery, we treated HeLa 
cells with liposomes functionalized with gH625 and loaded with MTX; functionalized and not liposome 
were characterized in terms of their physico-chemical properties and drug release kinetics. To quantify the 
MTX uptake and to study the subcellular drug distribution and interaction, we took advantage of the intrinsic 
fluorescence of MTX and of the fluorescence-based techniques like fluorescence-activated cell sorting 
(FACS) and confocal spectral imaging (CSI). FACS data confirmed that gH625 increases the total 
intracellular MTX content. CSI data indicated that when liposomes are decorated with gH625 an enhanced 
staining of the internalized drug is observed mainly in hydrophobic regions of the cytoplasm, where the 
increased presence of an oxidative metabolite of the drug is observed. The cytotoxicity on HeLa cell line was 
higher for functionalized liposomes within 4-6 h of treatment. To summarise, the MTX delivery with gH625-
decorated nanoliposomes enhances the quantity of both the intracellular drug and of its oxidative metabolite 
and contributes to higher anticancer efficacy of the drug at the delay of 4 to 6h. 
Highlights 
 We report on the delivery of gH625 decorated liposomes 
 An enhanced quantity of MTX is delivered  
 The formation of an oxidative metabolite of MTX is proposed 
 
Keywords: nanoliposomes, polyethylene glycol (PEG), cell penetrating peptide (CPP), gH625, anticancer 
drug mitoxantrone (MTX). 
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1. Introduction  
Cancer remains a leading cause of death in the western world. Cancer chemotherapies usually involve the 
use of cytotoxic molecules which kill highly proliferative cancer cells but also other proliferative cells in 
bone marrow, the gastrointestinal tract and hair follicles leading to common side effects such as 
compromised immune system, hair loss etc. [1]. Mitoxantrone (MTX) is a synthetic anthracenedione 
antineoplastic agent derived from the anthraquinone dye ametantrone [2]. It is structurally similar to the 
anthracycline agent doxorubicin (Doxo), both drugs having a planar aromatic ring structure which enables 
them to interact with DNA by intercalation between base pairs. MTX can inhibit the activity of nuclear 
enzyme DNA topoisomerase (II), interfere with RNA and cause the crosslink of DNA and strand breaks and 
produce reactive oxygen species. MTX is believed to lack cell cycle phase specificity because it has 
cytocidal effects both on proliferating and non-proliferating cells [3]. Similar to Doxo, its main side effect is 
cardiotoxicity; although also neutropenia, bone marrow suppression and secondary acute myelogenous 
leukemia have been reported in patients treated with MTX [4]. However, MTX has been shown to produce 
free radicals to a much lesser degree than Doxo [5].  
Actual treatments of cancer disease remains an elusive alternative, offering limited efficacy with extensive 
secondary effects as a result of severe cytotoxic effects in healthy tissues. The advent of nanotechnology 
brought the promise to revolutionize many fields including oncology, proposing advanced systems for cancer 
treatment. Drug delivery systems are among the most successful examples of nanotechnology and allow the 
reduction of unwanted side effects of systemic delivery, while increasing drug accumulation in tumours and 
improving the therapeutic efficacy. A delivery tool should transport the drug to the target cells not only with 
high efficacy, but also with minimal toxicity and immune response avoiding its degradation and entrapment 
in endosomes. The development of a broad range of nanoparticle platforms with the ability to tune size, 
composition and functionalities has provided a significant resource for nanomedicine. 
Liposomes play a key role as drug carriers and represent a relatively simple form of nanovectors, especially 
for the delivery of antineoplastic drugs [6,7]; in fact, they modify the pharmacokinetics and biodistribution of 
the drug, thus resulting in lower toxicity and higher efficacy. Liposomes are able to selectively deliver the 
drug into malignant areas due to enhanced permeability and retention effects (EPR). As a result, the exposure 
of healthy tissues to toxic drugs is reduced and therapeutic indexes are improved. Unfortunately, following 
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intravenous injection, many nanoliposomes are easily recognized by the reticulo endothelial system (RES) 
resulting in rapid clearance and nonlinear pharmacokinetics. To reduce this effect, polyethylene glycol (PEG) 
has been introduced on the surface of liposomes. This modification is a milestone breakthrough in the field 
of drug delivery and is widely known as stealth technology. PEG-coated liposomes display a good 
pharmacokinetic profile and reduced systemic toxicity; however, their uptake in cells is delayed. In order to 
facilitate the interaction between liposomes and cells, the liposome surface can be functionalized with cell 
penetrating peptides (CPPs). CPPs have received much attention because of their ability to enable several 
kinds of cargoes to cross cell membranes both in vitro and in vivo [8,9]. CPPs are short and usually basic 
amino acid rich peptides originating from proteins like the viral TAT protein that are able to cross biological 
barriers. The CPPs uptake mechanism is highly debated and is thought to involve mainly the endocytic 
pathway. Trapping the conjugated cargo in endosomes, eventually landing in lysosomes where common 
enzymatic degradation mechanisms take place, often leads to a limited delivery of therapeutic agents to 
targets[10]. 
Hydrophobic peptides, that efficiently traverse biological membranes, promote lipid-membrane reorganizing 
processes and involve temporary membrane destabilization [9,11,12,13], are able to avoid endosomal 
entrapment either favouring the escape from the endosome or by translocating directly into the cytosol, thus 
favouring energy independent processes. This idea has been exploited to design the drug delivery tool called 
gH625 [12,14], which can be efficiently linked to different potential therapeutic molecules and/or 
nanovectors and represents an extremely powerful tool to increase their uptake. gH625 is a peptide derived 
from glycoprotein H of Herpes simplex virus type I, which has been shown to have many applications, from 
membrane fusion [15], to viral inhibition [16,17] and drug delivery [13]. gH625 has the ability to penetrate 
deep into the bilayer as a helix without causing significant bilayer perturbations.This ability may help 
explaining its translocation across the bilayer. It has been recently demonstrated that gH625 is able to 
transport into the cytosol several compounds, such as QDs [18], liposomes [19], NPs [20], dendrimers 
[21,22], and proteins [23].  
The cellular uptake of liposomes or other nanosystem decorated on their surface with gH625 has been 
previously determined by flow cytometry (Fluorescence-activated cell sorting - FACS) and confocal 
fluorescence microscopy [18,19]. It has been shown that the mechanism of nanosystem uptake could be 
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modified by the presence of the peptide and that the internalization of functionalized nanosystems is mainly 
not energy-dependent. However, the analysis was limited to the overall detection of the drug used and did not 
account for the subcellular fluorescence changes, depending on the drug environment/interaction. Confocal 
spectral imaging (CSI) represents an alternative technique based on measurement, at different points of a 
cell, of the fluorescence spectra, which provides the opportunity to distinguish different molecular states of 
the intracellular drug [24]. Thus, CSI is a powerful tool for mapping the MTX molecular interactions within 
compartments of living cells. 
In this work, in order to get a better insight into the role of gH625 on the mechanism of liposome-mediated 
drug delivery, we have performed a comparative study of HeLa cells treated with MTX-loaded PEGylated 
liposomes (LMTX) and from LMTX functionalized with gH625 (LMTX-gH625).Prior to cellular 
experiments, the liposomes were carefully characterized in terms of their physical properties (hydrodynamic 
size, surface charge), chemical composition (MTX content, gH625 conformation) and drug release kinetics. 
Both the FACS data on the quantity of total intracellular MTX, the CSI data on the subcellular drug 
distribution/interaction and the cytotoxicity assay data indicate that the functionalization of liposomes with 
the peptide gH625 affects the drug delivery qualitatively and quantitatively. 
 
2 Material and methods 
2.1 Materials 
Fmoc-protected amino acid derivatives, coupling reagents, and Rink amide p-methylbenzhydrylamine 
(MBHA) resin were purchased from Calbiochem-Novabiochem (Laufelfingen, Switzerland). Fmoc-l-
propargylglycine (Fmoc-Pra-OH) was purchased from Polypetide (Strasbourg, France). Mitoxantrone and 
other chemicals were purchased from Sigma–Aldrich, Fluka (Buchs, Switzerland), or LabScan (Stillorgan, 
Ireland) and were used as received, unless otherwise stated. 1,2-Dioleoyl-sn-glycero-3-
phosphocholine(DOPG) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene 
glycol)-2000] (ammonium salt) were purchased from Avanti Polar Lipids (Alabaster, AL). HeLa,cervical 
cancer cell of an African-American woman were purchased from ATCC, Rockille, (MD, USA), Dulbecco’s 
Minimal EssentialMedium was obtained from Gibco, Invitrogen Co., (Carlsbad, CA, USA), fetal bovine 
serum was obtained from Euroclone, Milan, Italy, 100 mg / ml sodium pyruvate, 100 g / ml of nonessential 
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aminoacids, 100 g / ml penicillin / streptomycin and 100 U / ml glutamine was bought from Invitrogen Life 
technologies, Italy and Hank’s Balanced Salt Solution from Fisher Bioblock Scientific, Illkirch, France. 
Other reagents were all of analytical grade. 
2.2 Solid-phase peptide synthesis 
gH625 was synthesized using standard solid-phase 9-fluorenylmethoxycarbonyl (Fmoc) procedures with a 
Syro I MultiSynThec GmbH (Wullener, Germany) automatic synthesizer, as previously reported[15]. 
The Rink amide MBHA resin (substitution 0.51 mmol/g) was used as the solid-phase support, and syntheses 
were performed on a scale of 20 µmol. The peptide was synthesized by consecutive deprotecting and 
coupling step. Coupling: Fmoc-protected amino acids (4 equivalents relative to resin loading) HBTU (0.5 M 
in DMF, 4 equiv), HOBt (0.5 M in DMF, 4 equiv), and DIPEA (2 M in DMF, 8 equiv). Deprotection: 30% 
piperidine in DMF (v/v).  
The gH625-Pra was synthetized to allow binding to preformed-liposomes. Fmoc-Pra-OH was coupled once 
for 45 min with 2 equivalents of PyBop/HOBt and 4 equivalents of DIPEA. The peptide was fully 
deprotected and cleaved from the resin with a solution of TFA/water/anisole/thioanisole93.5/2.5/2.0/2.0, at 
room temperature for 300 min. Then, it was precipitated with ice-cold ethyl ether, filtered, dissolved in water, 
and lyophilized. Purification was performed by RP-HPLC on a LC8 Shimadzu HPLC system (Shimadzu 
Corporation, Kyoto, Japan) equipped with a UV lambda-Max Model 481 detector using a Phenomenex 
(Torrance, CA) C18 (300 Å, 250 × 21.20 mm, 5 µ) column eluted with H2O/0.1% TFA (A) and CH3CN/0.1% 
TFA (B) from 20–80% over 20 min at a flow rate of 20 mL/min. Purity and identity were assessed by 
analytical LC-MS analyses using a Finnigan Surveyor MSQ single quadrupole electrospray ionization 
(Finnigan/Thermo Electron Corporation San Jose, CA), column: C18-Phenomenex eluted with H2O/0.1% 
TFA (A) and CH3CN/0.1% TFA (B) from 20–80% over 10 min at a flow rate of 0.8 mL/min. The final yield 
of purified peptide ranged between 30 and 40%. Azide-AdOO-Lys(C(O)CH2CH2C(O)N-(C18H37)2)-amide 
((C18)2L-N3) monomer was synthesized on solid phase under standard conditions using the Fmoc/tBu 
strategy as previously reported [19].  
2.3 Liposomes preparation 
Liposomes were prepared by the thin lipid film hydration procedure. Mixed aggregates of DOPG/DSPE-
PEG/(C18)2L-N3 (85:5:10 molar ratio) were prepared by dissolving the lipids in a small amount of 
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chloroform, and subsequently evaporating the solvent by slowly rotating the tube containing the solution 
under a stream of nitrogen and eventually lyophilized overnight. A thin film of amphiphiles was obtained. 
The dry lipid film was suspended in HEPES-NaCl buffer (5 mM-100mM) at pH 7.4 by vortexing; then the 
lipid suspension was freeze–thawed ten times and extruded ten times thought a polycarbonate membrane 
with 100 nm pore size using a thermobarrel extruder(Northern Lipids Inc, Canada).  
2.4 Functionalization of liposomes with gH-625 
The click reaction was carried out on DOPG/DSPE-PEG/(C18)2L-N3 liposomes adding CuSO4•5H2O (4.4 
equiv), ascorbic acid (6.7 equiv), and the peptide derivative (1 equiv) with respect to the azido moiety. In 
particular, solutions containing CuSO4•5H2O (60.5 mM, solution A), ascorbic acid (81.4 mM, solution B), 
and the alkyn-modified peptide (1 mM, solution C) were freshly prepared in water.  
Solution A (11.6 µL), solution B (13.2 µL), and solution C (145.4 µL) were added to a suspension of azido-
functionalized preformed liposomes in HEPES-NaCl buffer (400 µL). The concentration of solution C was 
determined measuring the tryptophan absorbance at 280 nm on a UV/Vis Jasco V-5505 spectrophotometer. 
The reaction mixture was stirred at 40°C for 30 min and then left overnight at room temperature. After the 
conjugation step the liposomes were purified by exclusion chromatography on a 1×18 cm Sephadex G-50 
(Amersham Biosciences) column pre-equilibrated with HEPES buffer. 
2.5 MTX encapsulation in liposomes 
MTX was remote-loaded in DOPG/DSPE-PEG/(C18)2L-N3 liposomes through an ammonium sulphate 
gradient method. Briefly, a liposomal solution was prepared as reported above in an ammonium sulphate 
solution (250 mM) at pH 5.5. Next, the external buffer was removed by ultracentrifugation at 151332 g, at 
4°C for 3h, and the liposomes were resuspended in 400 µL of HEPES-NaCl buffer (5 mM-100mM) at pH 
7.4. A MTX solution (18µL at 2mg/mL) in water was added to the liposomal solution, to achieve a final lipid 
to drug weight ratio of 10:1. This suspension was stirred for 30 min at 60°C. Unloaded MTX was removed 
with a Sephadex G50 column for determination of entrapment efficiency. The MTX concentration was 
determined by UV spectroscopy measuring the drug absorbance at λ=655 nm. The Drug Loading Content 
(DLC, defined as the weight ratio of encapsulated drug vs. the amphiphilic moieties) was quantified by 
subtracting the amount of MTX removed from the total amount loaded. Finally, the MTX pre-loaded 
liposomes were modified with gH625 by using the click-chemistry reaction procedure, as reported above. 
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2.6 Quantification of MTX loaded into the liposomes 
The presence of copper in Lipo-MTX-gH625 determines the formation of a complex between copper and 
MTX which quenches fluorescence and absorbance of the drug. In order to verify that the quantity of MTXin 
both liposomes conjugated or not with the peptide were equal, both preparations were treated with 0.2% 
Triton X-100 and then with EDTA (10 mM, 91 µL) with incubation for 1 h at 37 °C. Finally, the drug 
absorbance measured at 655 nm was used to determine its concentration according to the previously 
established calibration curve. 
2.7 Particle size and zeta potential analyses 
The hydrodynamic diameter (DH) and the polydispersity index (PDI) of LMTX andLMTX-gH625 were 
measured using dynamic light scattering (DLS) method (Malvern Nanosizer Nano ZS, Malven, UK). The 
zeta potential was determined using Malvern Nanosizer NanoZS (Malvern, Malven, UK). The instrument use 
a He–Ne laser 4mW source operating at 633 nm with thescattering angle fixed at 173°. Each measurement 
was performed at 25°C, at least in triplicate. 
2.8 gH625 conformation monitoring by circular dichroism (CD) 
CD spectra in the range from 260 to 195 nm were recorded with a Jasco J-810 spectropolarimeter equipped 
witha NesLab RTE111 thermal controller unit. For the measurements, liposomes decorated with gH625 were 
diluted 10 times in a H2O and placed in a 10 mm quartz cellstabilized at 25°C.Other experimental settings 
were: scan speed of 10 nm min
-1
, sensitivity of 50 mdeg, time constant of 16 s, bandwidth of 1 nm. Each 
spectrum was obtained through averaging three scans, subtracting the contributionsfrom other species 
present in solution, and converting the signal to mean molar ellipticity. 
2.9 In vitro drug release 
The in vitro release kinetics of MTX from liposomes was determined using UV-visible spectrophotometry. 
LMTX and LMTX-gH625 at equivalent MTX concentration were placed into2 mL of HEPES-NaCl buffer 
and into under continuous stirring at 37°C. The release studies were carried out in triplicate. At 
predetermined time intervals, 200 µL aliquots were withdrawn and replaced with equal volume of fresh 
medium. The free drug was collected by a Sephadex G50 column and MTX was quantitated based on the 
UV-Vis absorbance at 655 nm using a previously established calibration curve. The cumulative amount of 
MTX released over 24h was quantified, and results were plotted against incubation time.  
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2.10 In vitro cytotoxicity Studies 
The estimation of cell viability was performed by staining with Trypan Blue (TB) (Invitrogen). This marker, 
added to a cell suspension, is able to cross cell membranes that have been changed significantly. The TB 
penetrates only into damaged cells giving them a blue colour observable under anoptical microscope. The 
viable cells, which are not permeable to the marker, remain colourless. This assay was performed on HeLa, 
cervical cancer cell of an African-American woman(ATCC, Rockille, MD, USA, CCL-2) grown as 
monolayers in Dulbecco’s Minimal EssentialMedium (Gibco BRL, Invitrogen Corporation, Carlsbad, CA, 
USA), supplemented with 10% fetal bovine serum.(FBS - Euroclone, Milan, Italy), 100 mg / ml sodium 
pyruvate, 100 g / ml of nonessential aminoacids, 100 g / ml penicillin / streptomycin and 100 U / ml 
glutamine (Invitrogen - Life technologies, Italy). These cells were cultured at 37° C, in a humidified 
incubator in presence of 5% CO2, using sterile flasks. After reaching the confluence of the flask, the medium 
was removed and the cells were washed with phosphate buffer saline (PBS). Subsequently, the cells were 
incubated with a solution of trypsin (0.05% trypsin, 0.0022% EDTA) and PBS at 37 ° C in the presence of 
5% CO2 for 3 minutes. Finally, the cells detached from the flask were transferred into a sterile tube (Falcon) 
and centrifuged at 325 g for 10 minutes. The cell pellet obtained was resuspended in fresh culture medium 
and the cells were seeded in 12 well plates (Falcon) in complete medium at a concentration of 350.000 - 
400.000 cells / well. The following day, the cells were treated with different concentrations of LMTX and 
LMTX-gH625; controls were used as untreated cells (negative control) and cells treated with H2O2 (positive 
control). At the end of the treatments of 1, 4, 6, 12, 24, 48 and 72 hours, the cells were washed three times 
with PBS to remove the liposomes in excess, and then trypsinized. The cells completely detached were 
transferred in falcon tubes and 25μl of the cell suspension were mixed with 475μl of TB. The cells were 
counted using the appliance Countess® Cell Counter (Invitrogen). The results were expressed as percentage 
of control. 
2.11 In vitro cellular uptake by flow cytometry  
The cellular uptake of MTX-loaded liposomes was analysed by flow cytometry. HeLa cells, cultured in 
Dulbecco’s Minimal Essential Medium supplemented with 10% fetal bovine serum, were seeded into six-
well at a density of 3 × 10
5
 cells per mL at 37 °C for 48 h. Then, cells were treated with a final concentration 
of 5 μM of LMTX and LMTX-gH625 in PBS medium for 1 and 4 hours in a volume of 1 mL. Thereafter, 
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cells were washed three time, trypsinized, harvested and then resuspended in 0.5 mL of PBS. The MTX 
fluorescence associated to the cells was measured by FACs analysis (BD Accuri), using FL4 channel 675/25 
nm. The events collected were ten thousand and BD Accuri C6 software was used to calculate mean 
fluorescence intensity (MFIs) for each sample. MFIs values were reported as histogram. 
2.12 In vitro cellular uptake and distribution by confocal spectral imaging (CSI) 
HeLa cells were plated at a density of 4 × 10
4
 cells/well in 24-well plates onto cover glasses for 48h in 
DMEM media supplemented with 10 % serum. HeLa cells were then incubated with either LMTX orLMTX-
gH625 at drug concentration of 1 µM for 1 and 4 h at 37 °C in DMEM media without serum. After the 
incubation with the liposomes, the medium was removed and the cells were washed three times with fresh 
HBSS (Hank’s Balanced Salt Solution, Fisher Bioblock Scientific, Illkirch, France).Washed cells were 
placed between slide and slip cover. Fluorescence measurements were carried out using a LabRam confocal 
microspectrometer (Horiba, Villeneuve d’Ascq, France). The MTX fluorescence was excited with a 632.8 
nm line of an internal, air-cooled, helium-neon laser. The power on the samples was ~30 µW, the acquisition 
time was 0.02 or 0.05 s/spectrum. After the acquisition, all the spectra were normalized to an intensity 
corresponding to the same acquisition duration. Treatment of spectral maps was made using LabSpec 4.18 
software (Horiba Villeneuve d’Ascq, France). 
 
3. Results 
3.1. Physico-chemical properties of liposomes 
3.1.a. Synthetic components. The liposome component (C18)2L-N3 and the peptide gH625 bearing a 
propargylglycine moiety (gH625-Pra) were synthesized by the standard solid phase peptide synthesis (SPPS) 
protocols with Fmoc/tBu (tBu=tert-butyl) chemistry. The alkyne moiety was introduced at the C-terminus of 
the peptide as an L-propargylglycine. The compounds identity and the purity were confirmed by mass 
spectrometry, 
1
H and 
13
C NMR spectroscopy (for (C18)2L-N3), and LC-MS[19].Both gH625-Pra and (C18)2L-
N3 were collected in good yields (30–40% and 85%, respectively) after HPLC-RP purification.  
3.1.b. Blank liposomes. Liposomes coated with PEG (DOPG/DSPE-PEG/(C18)2L-N3liposomes) were 
generated according to classical procedures [25]. Briefly, the lipid mixture was dissolved into ammonium 
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sulphate buffer and then the suspension was extruded ten times through a polycarbonate membrane (100 
nm).  
3.1.c. MTX-loaded liposomes.To obtain the MTX-loaded liposomes (LMTX) we used the well-assessed 
procedures based on an ammonium sulphate gradient [26]; in particular, a solution containing MTX was 
incubated with liposomes under stirring for 30 min at 60°C. Subsequently, unloaded MTX was removed 
usinga Sephadex G50 column pre-equilibrated with HEPES-NaCl buffer (5 mM-100mM) at pH 7.4. The 
drug/lipid weight ratio chosen for the loading experiments was 0.1. The resulting LMTX were used as it or 
were modified with the gH625-Pra peptide (to become LMTX-gH625) via click-chemistry reaction 
performed in aqueous medium. The coupling of the Pra moiety of the gH625 to the liposomes surface was 
obtained due to a copper
(I)-
catalyzed Huisgen 1,3-dipolar cycloaddition reaction of azides and alkynes [27]. 
Cu
I
 catalyser was generated in situ by reduction of CuSO4 with ascorbic acid [28]. The LMTX-gH625 were 
obtained with a yield higher than 90% after 12 h at room temperature. Circular dichroism (CD) spectra 
showed that gH625 when conjugated to liposomes at a concentration of 1.25x10
-6
M adopts an α helical 
conformation (Figure 1), while the peptide alone in buffer adopts a random coil structure; suggesting that the 
coupling on the surface of the liposomes was sufficient to induce the secondary structure which is probably 
playing a key role in translocation across the membrane bilayer.  
 
Figure 1. Circular dichroism spectrum of gH625 conjugated to blank liposomes and of gH625 alone. 
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Dynamic light scattering (DLS) data on LMTX and on LMTX-gH625dispersed in aqueous medium at pH 7 
(Table 1) showed that the liposome functionalization with gH625 only slightly increased their average 
hydrodynamic diameter, from ca. 112 to122 nm. The polydispersity index changed from ca. 0.09 to ca. 0.19, 
indicating that the distribution of the liposome size remained rather narrow and there are no signs of 
aggregation. These parameters should favour both the effective extravasation of liposomes and their longer 
retention in tumour tissues.  
The surface charge of the liposomes, as determined by measurement of their zeta potential, was also slightly 
reduced on going from LMTX toLMTX-gH625, from ca. -26 to -21 mV (Table 1). It is widely accepted that 
at high values of ξ-potential (over 20 mV, positive or negative) the electrostatic repulsions between particles 
are strong enough to ensure their colloidal stability. At smaller values of ξ-potential, particles can flocculate, 
except if they have sterical repulsion like in the case of PEG coating. Anyhow, the aqueous suspensions of 
both LMTX toLMTX-gH625 appear as stable colloids.  
Table 1. Colloidal characteristics of LMTX and LMTX-gH625 
Liposome type Hydrodynamic 
diameter, nm 
Polydispersity Index  Zeta potential, mV 
LMTX 111.80±1.42 0.09±0.01 -26.30±1.01 
LMTX-gH625 122.00±1.05 0.19±0.07 -21.30±1.10 
Data obtained for three independently prepared batchesof each liposome type, with at least 13runsper 
batch. 
 
3.1.d. MTX loading efficiency and release kinetics. The drug loading efficiency calculated from the 
unloaded MTX absorbance at λ=655 nm was found at least as high as 97% of the total amount incubated and 
it was nearly the same in both LMTX-gH625 and LMTX. 
In spite of the same concentration inside the liposomes, the MTX fluorescence intensity from LMTX in 
aqueous suspension was about 5.7 times higher than in LMTX-gH625. The MTX fluorescence in gH625 
should be partially quenched by Cu ions used to catalyse the peptide coupling to the liposomes. This 
hypothesis was confirmed by the experiment described below. Both LMTX and LMTX-gH625 were 
dissolved by treatment with 0.2% of Triton X-100 and incubation for 1 h with EDTA (10 mM) at 37 °C. This 
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treatment brought to a full restoration of MTX absorbance intensity of MTX released from LMTX-gH625, 
while for LMTX, which did not contain copper, the absorbance intensity of the released drug was not 
affected (Figure 2). Therefore, copper ions are able to penetrate LMTX-gH625and to quench there the loaded 
MTX fluorescence and absorbance; however, once the drug escapes from the liposomes, the quenching is no 
more active. 
 
Figure 2. Effect of combination of Triton and EDTA on LMTX and LMTX-gH625. Both liposomes were treated by 
Triton X-100 (TX-100) and 10 mM of EDTA at 37°C. The presence of EDTA brought full restoration of MTX 
absorbance intensity in LMTX-gH625, while on LMTX had not effect. 
 
There were no pronounced differences between LMTX and LMTX-gH625 from the point of view of the drug 
release kinetics in vitro, in HEPES-NaCl buffer (Figure 3). Less than 30% of loaded MTXwas released 
within 24 h, indicating the good stability of liposomes. 
 
Figure 3. Kinetics of in vitro release of MTX from LMTX and LMTX-gH625. 
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3.2 Biological activity of LMTX and LMTX-gH625 in HeLa cells in vitro  
The cytotoxicity of liposomes was evaluated staining Triptan Blue on HeLa cells. Within 4 and 6 h treatment 
duration, cytotoxicity  was higher for LMTX-gH625 than LMTX (Figure 4A). At  48 and 72 h we did not 
notice significant differences between the two types of liposomes; indicating that at high incubation times 
both are significantly toxic to the cells. 
Flow cytometry allowed us to compare quantitatively the MTX uptake by HeLa cells treated with LMTX-
gH625 or with LMTX (Figure 4B). We clearly observed an increased uptake of MTX from liposomes 
decorated with gH625. 
For better understanding of the observed cytotoxicity and uptake details, we determined the subcellular 
distribution and interaction of the delivered MTX in live HeLa cancer cells using confocal spectral imaging 
(CSI) technique. As described above, the CSI approach consists in recording the complete fluorescence at 
each scanned point of the cell and therefore exploiting both the spectral shape and intensity.  
Full fluorescence spectra (in the 640-920 nm range) were then recorded via point-by-point scanning of the 
equatorial optical section of the treated cells (see the Experimental section). From these spectra, the 
parametric maps were generated using either total fluorescence intensity (area of the whole spectrum) or  
coefficients determined from fitting each experimental spectrum with spectra characteristic of 3 intracellular 
molecular interactions of the drug: (i) MTX at lipophilic environment, where the spectrum is very close in 
shape to that of the drug in LMTX in suspension (blue zones and spectra in Figure 5); (ii) MTX in nucleus, 
where a significant bathochromic shift of the spectrum is observed due to the drug intercalation between 
DNA base pairs (green zones and spectra); and (iii) an oxidative metabolite of the drug stained in the low 
polarity environment, with the blue-shifted spectrum  (red zones and spectra). These characteristic spectra 
are consistent with those we previously reported for the MTX incubated as aqueous solution to MDA-MB-
231 and MCF-7 cancer cell lines [29].  
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Figure 4 Cytotoxicity of liposomes on HeLa cells at several times of incubation.(panel a)Flow cytometry data on the 
MTX uptake by HeLa cells (panel b).  
 
In the present study, the fact that not only the blue spectra but also the shifted ones were observed indicates 
that the drug was released, at least in part, from the liposomes and was able to reach the nucleus. 
Interestingly, the blue and red spectra were highly co-localized in some perinuclear regions, indicating that 
the lipophilic locations favour the drug oxidative metabolism. In our previous study, [29] we found the 
metabolite to be co-localized with the fluorescent label of endoplasmic reticulum and its presence correlated 
with higher sensitivity of cancer cells to chemotherapeutic drug MTX. From the point of view of the 
fluorescence intensity, it is difficult to establish the exact quantum yields (QY) in these three subcellular 
situations. Nevertheless, it is commonly believed that the lower polarity environment of fluorophore favours 
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higher QY, while the DNA intercalation leads to a partial quenching of the drug fluorescence. In this 
consideration, the intensities used in Figure 5 allow only a comparative discussion, but could be calibrated to 
concentrations once the QY are established (it was not a subject of the present study). 
 
Figure 5. In vitro study of subcellular interaction and distribution of MTX delivered from LMTX and LMTX-gH625to 
live HeLa cancer cells. Left panel: representative images of individual cells, i.e. merge of the white light images with 
the fluorescence spectral maps showing either total spectral intensity (yellow zones) or merged spectral maps 
characteristic of 3 intracellular molecular interactions of the drug: MTX at lipophilic environment (blue zones and 
spectra), MTX-DNA complex in nucleus (green zones and spectra) and presence of an oxidative metabolite of the drug 
(red zones and spectra). Average spectra of the respective cells are shown in the middle column. Right panel: statistical 
summary of the data over a population of at least 6 cells. 
 
The results shown in Figure 5 allow to analyse two effects, that of incubation duration (1h vs 4h) and that of 
the liposomes functionalization with gH625. The spectral maps show that the increase of the incubation 
duration from 1h to 4h, determines a significant increase of the total intracellular drug fluorescence (2 to 5 
fold, see the statistical summary in Figure 5). Similar total fluorescence intensity was reached with both 
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types of nanosystems. In contrast, for the LMTX and not for the LMTX-gH625, 4h vs 1h incubation resulted 
in a subcellular redistribution of the MTX fluorescence: the relative fractions of lipophilic vs nuclear 
locations were inversed. The analyses of this inversion together with the nearly 2-fold increase of total 
intensity in LMTX between 1 and 4h, leads one to the supposition that the total drug in the nucleus is 
probably not decreased while the drug presence in the perinuclear locations is more pronounced. For the 
LMTX-gH625, the drug fluorescence from the hydrophobic perinuclear regions was dominant even after 
only 1h of incubation and the subcellular distribution remained nearly constant between 1h and 4h of 
incubation. The latter means that the 5-fold increase of the intracellular fluorescence intensity for the gH625-
modified liposomes is related to the increased uptake of the liposomes and not to the QY changes.  
The subcellular distribution of MTX delivered with liposomes was different from that of MTX in solution: 
while the drug solution was mainly and rapidly stained in nucleus of cancers cells[29], liposomes mainly 
directed the drug to the perinuclear zones where the metabolite production/staining by the cells was also 
more significant than with solutions. This could be the effect of the liposomal delivery of MTX. 
The above described results lead to the following conclusions about the effect of the liposomes 
functionalization with gH625: (i) it makes the MTX uptake to the hydrophobic perinuclear staining zones 
even more efficient; (ii) it favours even more the presence of an oxidative metabolite of the drug in the same 
perinuclear regions.  
 
4 Discussion  
Cell penetrating peptides (CPPs) have recently attracted much interest as very efficient agents to enhance 
drug delivery into target cells. Among the CPPs, gH625 represents a novel sequence with great possibility of 
overcoming the known limits of classical CPPs. In previous studies, we have demonstrated that gH625 acts 
as a potent vector for the cell delivery of molecules and nanosystems [12]. It is widely accepted that drug 
intracellular distribution changes when they are bound to CPPs [19,30]. The clarification of the mechanism 
of internalization could be useful to improve the design of anticancer delivery tools that may determine an 
increase of internalization and may also help in overcoming resistance problems. The purpose of this study 
was to explore the possibility of using nanoliposomes decorated on their external surface with a novel CPP 
gH625 to change and enhance the internalization of MTX. We used CSI to distinguish very fine 
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modifications of MTX intrinsic fluorescence within different intracellular microenvironments. 
The obtained results clearly show that the presence of gH625 on the surface of liposomes is favouring their 
uptake in HeLa cells: in fact, a greater quantity of MTX is internalized (Figure 4B). This correlates well with 
toxicity data (Figure 4A). Within 4 h, the LMTX-gH625 was more active than LMTX. The gH625 peptide 
probably induced a greater and more rapid internalization, which could contribute to the earlier cytotoxicity 
of LMTX-gH625 compared to LMTX. It has also been reported in literature that a fast cytoplasmic delivery 
of the drug can be related to a better chance to overcome drug resistance [31]. Nevertheless at high 
incubation times there were no significant differences. 
From the CSI spectra, we detected 3 intracellular molecular situation for the drug: MTX at lipophilic 
environment, MTX in nucleus and an oxidative metabolite of the drug stained in the low polarity 
environment. The spectra observed indicate that the drug was partially released from the liposomes and was 
able to reach the nucleus; moreover, the effect of gH625 consists also in an increased presence of an 
oxidative metabolite of the drug which we previously demonstrated to be correlated with sensitivity of 
cancer cells to chemotherapy by MTX [29].We observed that Cu is able to lead to a partial fluorescence 
quenching for MTX loaded in LMTX-gH625. If we assume that a fraction of subcellular MTX found in 
lipophilic environment is still encapsulated in liposomes, it means that the real amount of internalized LMTX 
in presence of gH625 is even higher than what was estimated. 
Our results support the view that, in addition to the nuclear one, several mechanisms may be involved in the 
cytotoxicity of LMTX-gH625 internalization. 
5 Conclusions  
To summarise, gH625 modifies the internalization of liposomes and therefore the drug transport to the cells. 
Although the liposome-mediated drug delivery to the nucleus is delayed compared to the drug solution, it 
could be compensated by complementary mechanisms of cytotoxicity taking place into the cytosol, namely 
those involving the oxidative metabolism of the drug. These mechanisms are of particular interest for the 
anticancer activity evaluation of the nanosystems for drug delivery. 
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Abstract 
The success of pharmacological treatments is often hampered by the onset of the drug 
resistance. New delivery systems including liposomes have been developed to circumvent 
drug resistance. To enhance the antitumor efficacy of liposomes encapsulating anti-cancer 
agents, we have used liposomes externally conjugated to the 20 residue peptide gH625, 
previously identified as a membrane-perturbing domain in the gH glycoprotein of Herpes 
simplex virus type I. Physicochemical characterization of the liposome system revealed a 
size of 140 nm with uniform distribution and high doxorubicin encapsulation efficiency. We 
have evaluated the growth inhibition on either wild type (A549) or doxorubicin-resistant 
(A549 Dx) human lung adenocarcinoma cell lines treated with increasing concentrations of 
liposomes encapsulating Doxo (LipoDoxo), liposomes encapsulating Doxo conjugated to 
gH625 (LipoDoxo-gH625 ), empty liposomes (Lipo) or free Doxo for 72 h. We found that 
the growth inhibition induced by LipoDoxo-gH625 was higher than that caused by 
LipoDoxo with an IC50 of 2.7 and 5µM, respectively, in A549 and A549 Dx cells. The data 
on cell growth inhibition were paralleled by an increased uptake of Doxo induced by 
LipoDoxo-gH625 compared to LipoDoxo in A549 Dx cells. Cytometric analysis revealed 
that the antiproliferative effects of each drug treatment were mainly due to the induction of 
apoptosis. Moreover, the data obtained on oxidative stress suggested a greater internalization 
of LipoDoxo-gH625 than LipoDoxo in A549 Dx after 72h of treatment. In conclusion, 
liposomes armed with gH625 are able to overcome resistance in lung adenocarcinoma cell 
lines. 
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Introduction  
One of the most important goals in cancer treatment is the achievement of pharmacologically 
active concentrations of chemotherapeutics in cancer tissues, avoiding drug distribution in 
healthy tissues. In fact, up-to-date a plethora of pharmacological weapons are available in 
order to control cancer growth but for none of these selectivity toward cancer cells 
1
 was 
demonstrated. An additional challenge is represented by the intracellular targeting of key 
molecules involved in cancer cell regulation once the efficacious delivery of drugs in cancer 
cells is achieved. The encapsulation of drugs in nanometric scaled biocompatible materials is 
a potential strategy for the accumulation of the drugs in the inflamed or tumor tissues 
through the use of the so-called and well-known enhanced retention and permeation effect 
(EPR)1. Once accumulated in tumor tissues nanocarriers can release the drug or can be 
internalized in cancer cells through endocytosis mechanism, resulting in intracellular 
trafficking in endosomes. Therefore, cleavage of the drugs out of nanocarriers and escape 
from the endosomes are further critical steps. A complication of cancer therapy is the 
potential development of chemoresistance that is due to the selection of cancer cell clones 
expressing molecules that protect tumour cells from anti-cancer agents 2,3. In this light, the 
overexpression of ATP binding cassette (ABC) transporters - such as P-glycoprotein 
(Pgp/ABCB1), multidrug resistance related proteins (MRPs/ABCCs) and breast cancer 
resistance protein (BCRP/ABCG2) - limits the intracellular retention and cytotoxicity of 
different chemotherapy drugs, conferring to tumor cells a multiple and cross-resistant 
phenotype known as multidrug resistance (MDR)
4 
. Therefore, after the crossing of the 
fenestrated vessels, that are typical of cancer tissues, nanoparticles have also to overcome 
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cell membrane barriers, release and retain the drug intracellularly at therapeutic levels for a 
desired time. Based on these, cancer cell membranes represent another critical barrier that 
affects both drug internalization and retention in cancer cells.  
Among nanosystems used for drug delivery, liposomes have attracted great attention since 
they are deemed ideal for loading and delivery of different molecules, therefore, offering 
novel opportunities for cancer treatment 5-7. Benefits associated with liposomal drugs can 
derive from: i) protection of encapsulated drugs from chemical and biological degradation 
into the blood stream; ii) controlled release and reduced toxicity through decreased exposure 
of healthy tissues to anti-cancer drugs; iii) increased anti-tumor activity resulting from a 
relatively long systemic circulation time (especially in the case of PEGylated liposomes)8-10; 
iv) subsequent extended exposure and accumulation in growing tumor sites. To enhance the 
antitumor efficacy of liposomal drugs and to overcome the obstacle of the membrane barrier 
of cancer cells, many research groups are actively investigating how to improve liposome 
cell internalization through the addition of surface ligands. Recently, several cell penetrating 
peptides (CPPs) such as penetratin and Tat have been successfully used for the intracellular 
delivery of liposomes 5,11,12. CPPs are a group of short, positively charged peptides with a 
potent ability to penetrate the membrane bilayer, which are well suited as drug delivery 
vehicles able to cross the biological barriers. The advantages of peptides as delivery 
enhancers include: i) their relatively small molecular weight, ii) easy synthesis, iii) relatively 
low cytotoxicity and immunogenicity, and iv) in vivo degradation13. Cationic cell-penetrating 
peptide-mediated endocytosis is one of the mechanisms by which drug carriers cross the 
membrane bilayer 14; subsequently, the cargo is trapped in endosomes, eventually landing in 
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lysosomes where its intracellular bioavailability is decreased. In order to avoid the endocytic 
pathway, it is of great importance to discover new molecules exploiting different 
mechanisms of uptake. Hydrophobic peptides that efficiently cross biological membranes, 
promoting lipid membrane-reorganizing processes represent a powerful alternative15-17. 
Viral-derived peptides, especially those derived from viral entry proteins, can be useful as 
Trojan horses due to their intrinsic properties of inducing membrane perturbations16-18.  
The twenty residue peptide gH625, previously identified as a membrane-perturbing domain 
in the glycoprotein H (gH) of Herpes simplex virus 1 (HSV-1), is able to cross the membrane 
bilayer19 and has been extensively used for vector-mediated strategies in vitro, which only 
partially involves the endocytic pathway20-24. We previously showed the drug carrier ability 
of gH625 functionalized DOPG based liposomes encapsulating Doxo and revealed 
differences between the uptake mechanisms of free and encapsulated Doxo22 . Nuclear 
accumulation of free Doxo was attributed to drug diffusion, while encapsulated Doxo 
remained mostly in the cytoplasm with negligible nuclear accumulation 22.  
Here, we investigated the in vitro anti-cancer activity of Doxo-encapsulating liposomes, 
constituted by soy phospholipids, cholesterol and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG), in order to 
improve biocompatibility and lead to a prolonged presence in the systemic circulation. 
The antiproliferative activity of gH625 functionalized or not functionalized with gH625 
liposomal formulations was investigated on non small cell lung cancer (NSCLC) A549 cells 
either sensitive or resistant to Doxo. The differential accumulation and the oxidative stress 
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caused by the two different formulations in resistant and parental A549 cells were also 
evaluated.  
 
Material and Methods 
Materials 
Fmoc-protected amino acid derivatives, coupling reagents, and Rink amide p-
methylbenzhydrylamine (MBHA) resin were purchased from Calbiochem-Novabiochem 
(Laufelfingen, Switzerland). Fmoc-l-propargylglycine (Fmoc-Pra-OH) were purchased from 
Polypeptide (Strasbourg, France). Doxorubicin hydrochloride, and the other chemicals were 
purchased from Sigma–Aldrich, Fluka (Buchs, Switzerland), or LabScan (Stillorgan, Ireland) 
and were used as received, unless otherwise stated. All phospholipids were purchased from 
Avanti Polar Lipids (Alabaster, AL); in particular the soybean phospholipid mixture is 
composed of Soy PC (3.8mg) Soy PE (3.0mg) Soy PI (1.8mg) Soy PA (0.7mg) Soy LPC 
(0.7mg) with 0.1% butylated hydroxytoluene (BHT). Culture medium DMEM, fetal bovine 
serum and tissue culture plasticware were purchased from Microtech (Naples, Italy). 
Annexin V-FITC Apoptosis Detection Kit was purchased from eBioscience (San Diego, CA, 
USA). Dihydroethidium (DHE) was purchased from Sigma-Aldrich (Milan, Italy). 
 
Solid-phase synthesis of gH625 and Azide-AdOO-Lys(C(O)CH2CH2C(O)N-
(C18H37)2)-amide 
The peptide was synthesized using standard solid-phase 9-fluorenylmethoxycarbonyl (Fmoc) 
procedures with a Syro I MultiSynThec GmbH (Wullener, Germany) automatic synthesizer 
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using a Rink amide MBHA resin (substitution: 0.51 mmol/g; synthesis scale: 20 µmol). The 
peptide was obtain by repeated cycles of deprotection and coupling. Coupling: 4 equiv of 
Fmoc-protected amino acids relative to resin loading, HBTU (0.5 M in DMF, 4 equiv), HoBt 
(0.5 M in DMF, 4 equiv), and DIPEA (2 M in DMF, 8 equiv). Deprotection: 30% piperidine 
(v/v) in DMF for 10 min (2 times) . All couplings were performed twice for 0.5 h. Fmoc-Pra-
OH was coupled once for 45 min with 2 equivalents of PyBop/HOBt and 4 equivalents of 
DIPEA. The peptide was fully deprotected and cleaved from the resin with a solution of 
TFA/water/anisole/thioanisole 93.5/2.5/2.0/2.0 at room temperature for 300 min, and then 
precipitated with ice-cold ethyl ether, filtered, dissolved in water, and lyophilized. The crude 
peptide was purified by RP-HPLC on a LC8 Shimadzu HPLC system (Shimadzu 
Corporation, Kyoto, Japan) equipped with a UV lambda-Max Model 481 detector using a 
Phenomenex (Torrance, CA) C18 (300 Å, 250 × 21.20 mm, 5 µ) column eluted with 
H2O/0.1% TFA (A) and CH3CN/0.1% TFA (B) from 20–80% over 20 min at a flow rate of 
20 mL min-1. Purity and identity were assessed by analytical LC-MS analyses using Finnigan 
Surveyor MSQ single quadrupole electrospray ionization (Finnigan/Thermo Electron 
Corporation San Jose, CA), column: C18-Phenomenex eluted with H2O/0.1% TFA (A) and 
CH3CN/0.1% TFA (B) from 20–80% over 10 min at a flow rate of 0.8 mL min
-1. The final 
yield of purified peptide was ~40%. Azide-AdOO-Lys(C(O)CH2CH2C(O)N-(C18H37)2)-
amide ((C18)2L-N3) monomer was synthesized on the solid phase under standard conditions 
using the Fmoc/tBu strategy as previously reported 22. 
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Liposomes preparation 
Liposomes were prepared by the thin lipid film hydration procedure. Mixed aggregates of 
soy phospholipid mixture/cholesterol/DSPE-PEG/(C18)2L-N3 (57:28:5:10 molar ratio) were 
prepared by dissolving the lipids in a small amount of chloroform, and subsequently 
evaporating the solvent by slowly rotating the tube containing the solution under a stream of 
nitrogen and lyophilized overnight. In this way a thin film of amphiphiles was obtained. The 
dry lipid film was suspended in HEPES-NaCl buffer (5 mM-100mM) at pH 7.4 by vortexing 
for 1 h; then the lipid suspension was freeze–thawed ten times and extruded ten times 
thought a polycarbonate membrane with 100 nm pore size using a thermobarrel extruder 
(Northern Lipids).  
 
Functionalization of liposomes with gH625 
The click reaction was carried out on preformed soy phospholipid 
mixture/cholesterol/DSPE-PEG/(C18)2L-N3 liposomes adding CuSO4•5H2O (4.4 equiv), 
ascorbic acid (6.7 equiv), and the peptide derivative (1 equiv). In particular, solutions 
containing CuSO4•5H2O (60.5 mM, solution A), ascorbic acid (81.4 mM, solution B), and 
the alkyn-modified peptide (1 mM, solution C) were freshly prepared in water.  
Solution A (11.6 µL), solution B (13.2 µL), and solution C (145.4 µL) were added to a 
suspension of azido-functionalized liposomes in HEPES buffer (400 µL). The concentration 
of solution C was determined measuring the absorbance with a UV/Vis Jasco V-5505 
spectrophotometer. 
The reaction mixture was stirred at 40°C for 30 min and left overnight at room temperature. 
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After the conjugation step the liposomes were purified by exclusion chromatography on a 1 
× 18 cm Sephadex G-50 (Amersham Biosciences) column pre-equilibrated with HEPES 
buffer. 
 
Doxo encapsulation in liposomes 
Doxorubicin was remote-loaded in soy phospholipid mixture/cholesterol/DSPE-PEG/( 
C18)2L-N3 liposomes through the ammonium sulphate gradient method and the free Doxo 
was removed by gel filtration. Briefly, the liposomal film was suspended in an ammonium 
sulphate solution (250 mM) at pH 5.5. The external buffer was removed by 
ultracentrifugation at 40000 rpm (Beckman Optima L-70 Ultracentrifuge) at 4°C for 3h, and 
liposomes were resuspended in HEPES-NaCl buffer (5 mM-100mM) at pH 7.4. A Doxo 
solution in water was added to the liposomal solution. This suspension was stirred for 30 min 
at 60°C. The unloaded Doxo was removed using a Sephadex G50 column and the Doxo 
concentration was determined by UV spectroscopy measuring the absorbance at λ=480 nm. 
The drug loading content (DLC, defined as the weight ratio of encapsulated Doxo vs. the 
amphiphilic moieties) was quantified by subtraction of the amount of Doxo removed from 
the total amount of Doxo loaded. Finally, Doxo pre-loaded liposomes were modified with 
gH625 using the click-chemistry reaction procedure, as reported above. 
Particle size and zeta potential analyses 
The hydrodynamic diameters (DH) and polydispersity index (PDI) of liposomes (Lipo), 
Doxo-loaded liposomes (LipoDoxo) and Doxo-loaded liposomes-gH625 (LipoDoxo-gH625) 
were measured using dynamic light scattering (DLS) (Malvern Zetasizer Nano ZS, Malven, 
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UK). The zeta potential of LipoDoxo-gH625 was determined using a Malvern NanoZ 
(Malvern Zetasizer Nano ZS, Malven, UK). The analysis were performed with He–Ne laser 
4mW operating at 633 nm at scattering angle fixed at 173° and at 25°C. The results were 
determined three times for each sample and each measurement was performed at least in 
triplicate. 
In vitro Doxo release from liposomes  
The in vitro release of Doxo from LipoDoxo and LipoDoxo-gH625 was determined using a 
dialysis method. Briefly, free Doxo and Doxo-loaded liposomes (with free Doxo removed) 
were placed in a dialysis bag (MW cut off of 1000 Da) and dialyzed against HEPES-NaCl 
and HEPES-NaCl with 50% fetal bovine serum under continuous stirring at 37°C. At 
predetermined time intervals, aliquots were withdrawn and replaced with an equal volume of 
fresh medium. The Doxo concentrations were calculated based on the fluorescence 
absorbance intensity of Doxo excited at 485 nm using a previously established calibration 
curve. The cumulative amount of Doxo released over the 72 h was quantified, and results 
were plotted against time.  
Cell culture 
Human lung adenocarcinoma cell line wild type (A549) and doxorubicin (Doxo)-resistant 
(A549 Dx) were kindly provided by Chiara Riganti, MD (Department of Genetics, Biology 
and Biochemistry, University of Turin, Italy). Both cell lines were grown in DMEM 
supplemented with 10% heat-inactivated fetal bovine serum, 20 mM HEPES, 100 U/mL 
penicillin, 100 mg/mL streptomycin, 1% L-glutamine and 1% sodium pyruvate. The 
resistance to Doxo in A549 Dx cell line was maintained by administering 10 nM of Doxo in 
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alternating steps. A549 and A549 Dx cells were cultured at a constant temperature of 37°C in 
a humidified atmosphere of 5% carbon dioxide (CO2). 
Cell proliferation assay 
The evaluation of cell proliferation was performed on human lung adenocarcinoma cell line 
wild type and doxorubicin resistant in the presence of increasing concentrations of 
LipoDoxo, LipoDoxo-gH625 and Lipo in a range of 5-0.04 µM or free Doxo in a range of 3-
0.02 µM. A549 and A549 Dx cells were seeded in 96-well plates in a number of 25 x 102 per 
well. The growth inhibition was assessed by MTT viability assay after 72 h of treatment as 
previously described 25. Then the concentrations inhibiting 50% of cell growth (IC50) were 
obtained and these values were used for subsequent experiments. MTT assay was carried out 
by triplicate determination on at least three separate experiments. All data are expressed as 
mean ± SD. 
Flow cytometric analysis of Doxo accumulation  
The accumulation of Doxo was analyzed by FACSAria™ (BD Bioscences) after treating 
A549 and A549 Dx cells with a fixed concentration (10 µM) of Lipo, LipoDoxo, LipoDoxo-
gH625 and Doxo. Briefly, A549 and A549 Dx cells were seeded in 6-well plates in a number 
of 2 x 105 cells per well and were treated 24h later with each formulation and free Doxo. 
After 3, 6, 12 and 24 h of treatment cells were trypsinezed, washed twice with PBS 1X and 
pellets were resuspended in 500 μL of PBS 1X. Doxo fluorescence associated to the cells 
was measured using FL2 channel and calculated as mean fluorescence intensity (MFIs) for 
each sample. For each sample, 2 x 104 events were acquired. Analysis was carried out by 
triplicate determination on at least three separate experiments.  
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Flow cytometric analysis of oxidative stress 
The evaluation of ROS accumulation was detected using dihydroethidium (DHE), a specific 
marker for the determination of reactive oxygen species, in detail superoxide anion. Once 
oxidized within the cell, DHE is converted into ethidium (HE) and emits at the wavelength 
of 605 nm. Briefly, A549 and A549 Dx cells were seeded in 6-well plates in a number of 2 x 
105 cells per well and were treated 24 h later with concentration inhibiting 50% of cell 
growth of each formulation and Doxo. A549 and A549 DX cells were also treated with 500 
µM of H2O2, which is able to induce superoxide anion formation, 2000 µM of N-
acetylcysteine (NAC) as antioxidant agent, and H2O2 in combination with NAC. At the end 
of treatments, A549 and A549 Dx cells were incubated for 1 h with 20 ng/mL DHE stock 
solution (2,5 mg/mL). At the time of processing, cells were trypsinized, washed twice with 
PBS 1X and the pellet was resuspended in 500 µl of PBS 1X. The dye accumulation was 
analysed by BD FACSAria™ (BD Bioscences). For each sample, 2 x 104 events were 
acquired. Analysis was carried out by triplicate determination on at least three separate 
experiments.  
 
Flow cytometric analysis of apoptosis 
Apoptotic cell death was analysed by Annexin-V–FITC staining and by propidium iodide 
(PI) detection systems (eBioscences, Vienna, Austria). Briefly, A549 and A549 Dx cells were 
seeded in 6-well plates in a number of 2 x 105 cells per well and were treated 24 h later with 
concentration inhibiting 50% of cell growth of LipoDoxo, LipoDoxo-gH625, Doxo and 5µM 
of Lipo (concentration proved to be not toxic). After 3h-6h-12h-24h of treatment cells were 
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trypsinezed, washed twice with PBS 1X and pellets were resuspended in 200 μL Binding 
Buffer 1X. Then, 5 μL Annexin V-FITC were added to 195 μL cell suspension, mixed and 
incubated for 10 min at room temperature. Cells were washed with 200 μL Binding Buffer 
1X, resuspended in 190 μL Binding buffer 1X and 10 μL Propidium Iodide (20 μg/mL) was 
added. The detection of viable cells, early apoptosis cells, late apoptosis cells and necrotic 
cells were performed by FACSAria™ (BD Bioscences). For each sample, 2 x 104 events 
were acquired. Analysis was carried out by triplicate determination on at least three separate 
experiments.  
Evaluation of intracellular distribution of  Doxo by confocal microscopy 
After 6 and 24 of incubation of A549 and A549 Dx cells with fluorescent Lipo, cells 
were fixed for 20 minutes with a 3% (w/v) paraformaldehyde (PFA) solution and 
permeabilized for 10 minutes with 0.1% (w/v) Triton X-100 in phosphate-buffered saline 
(PBS) at room temperature. To prevent nonspecific interactions of antibodies, cells were 
treated for 2 h in 5% bovine albumin serum (BSA) in PBS, then cells were incubated with a 
specific mouse monoclonal Ab raised against vimentin (1:1,000 in blocking solution, 3% 
(w/w) BSA in TBS-Tween 0.1%, Sigma) for 2 h at 37 ° C. After several washes, cells were 
incubated with a secondary IgG goat anti-mouse antibody (Alexa Fluor 488, Life 
Technologies, Carlsbad, CA) diluted 1:1,000 in blocking solution for 1 h at room 
temperature. The slides were mounted on microscope slides by Mowiol. The analyses were 
performed with a Zeiss LSM 510 microscope equipped with a plan-apochromat objective X 
63 (NA 1.4) in oil immersion. The fluorescences of the Doxo and Alexa Fluor 488 were 
collected in multi-track mode using BP550-625 and LP650 as emission filters, respectively. 
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Statistical analysis.  
All data are expressed as mean ± SD. Statistical analysis was performed by analysis of 
variance (ANOVA) with Neumann-Keul's multiple comparison test or Kolmogorov-Smirnov 
where appropriate. 
 
 
 
Results and Discussion 
Peptide synthesis and conjugation of gH625 to liposomes surface. 
The peptide gH625-Pra and the liposome component (C18)2L-N3 were synthesized according 
to standard solid phase peptide synthesis (SPPS) protocols with Fmoc/tBu (tBu=tert-butyl) 
chemistry. The alkyne moiety of gH625-Pra was introduced in the peptide sequence at the C-
terminal position as L-propargylglycine. (C18)2L-N3 was synthesized on solid phase 
following a modified protocol of the classical Fmoc/tBu strategy 22. Both gH625-Pra and 
(C18)2L-N3 were collected in good yields (~ 40% and 85%, respectively) after HPLC-RP 
purification, and analyzed by mass spectrometry, 1H and 13C NMR spectroscopy (for 
(C18)2L-N3), and HPLC to confirm the compound identity and the purity.  
The coupling of gH625 on the surface of preformed liposomes was performed by click 
chemistry (Figure 1). This procedure involves a copper(I)-catalyzed Huisgen 1,3-dipolar 
cycloaddition reaction of azides and alkynes yielding 1,4-disubstituted 1,2,3-triazole-linked 
conjugates 26. The click reaction was performed in an aqueous solution and was catalyzed by 
CuI generated, in situ, by reduction of CuSO4 with ascorbic acid 
27. An equimolar mixture of 
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NH2-gH625-Pra and azido functions on the liposome surface were used and the expected 
gH625-functionalized liposomes were obtained with a yield higher than 90% after 12 h at 
room temperature. In the absence of the copper catalyst no reaction was observed.  
 
Drug loading 
Doxo was loaded into soy phospholipid mixture/cholesterol/DSPE-PEG/(C18)2L-N3 
liposomes using the well-assessed procedure based on the ammonium sulphate gradient 28; in 
particular, a solution containing Doxo was incubated under stirring for 30 min at 60°C. 
Subsequently, unloaded Doxo was removed using a Sephadex G50 column pre-equilibrated 
with HEPES-NaCl buffer (5 mM-100mM) at pH 7.4. The drug/lipid weight ratio chosen for 
the loading experiments was 0.1. The drug loading content (DLC) was above 90% of the 
total.  
The drug loaded liposomes were then efficiently modified with the gH625-Pra peptide 
according to the click-chemistry procedure used in the case of empty liposomes. 
 
Characterization of liposomes. 
Dynamic light scattering (DLS) measurements were performed on liposomes alone and on 
gH625 functionalized liposomes. Table 1 shows that all liposome solutions present a 
monomodal distribution with a polydispersity index (PDI) < 0.2. indicating a narrow and 
homogenous size distribution, optimal not only for the more effective extravasation of 
liposomes, but also for their longer retention in tumor tissues. The analysis of the zeta-
potential shows a change between Lipo and LipoDoxo compared to LipoDoxo-gH625, which 
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indicates a change in the surface of the liposomes upon functionalization with the peptide. 
 
Release of doxorubicin from liposomes  
The release of Doxo was carried out in HEPES-NaCl buffer or HEPES-NaCl buffer with 
50% FBS and the results are presented in Figure 2. Free Doxo was used as control and its 
release rate was nearly 100% in 2 h, which means that the release of Doxo from dialysis 
membrane to buffer solution is not a restricting factor and the release of Doxo from the 
liposomes is the only rate limiting step. There were no pronounced differences in Doxo 
release (Figure 2) from LipoDoxo and LipoDoxo-gH625 at each time point, indicating that 
the decoration of the surface of the liposomes with gH625 did not substantially change the 
release kinetics of liposomes. The Doxo release from liposomes decorated and not with 
gH625 is less than 30% within 72 h, indicating their good stability.  
 
Effects of liposomes encapsulating doxorubicin conjugated or not with gH625 viral 
peptide on A549 and A549 Dx cell proliferation  
The effects of Doxo, of empty liposomes and liposomes encapsulating Doxo conjugated or 
not with gH625 were evaluated on the proliferation of either parental A549 or Doxo-resistant 
cells (A549 Dx) by MTT assay as reported in “Materials and Methods”. Doxo, LipoDoxo 
and LipoDoxo-gH625 induced a dose-dependent growth inhibition in both cell lines after 72 
h (Figure 3), while treatment with Lipo produced no significant cytotoxic effects in both cell 
lines (Figure 3). In Table 2, results are reported as concentrations inhibiting 50% of cell 
growth (IC50s) after 72 h of treatment. The IC50 was reached with 0.06 µM and 0.2 µM of 
18 
 
Doxo (Figure 3 C, Table 2), with 2.5 µM and 5 µM of LipoDoxo (Figure 3 A and B, Table 2), 
with 0.5 µM and 2.7 µM of LipoDoxo-gH625 (Figure 3 A and B, Table 2) in A549 and A549 
Dx cells, respectively. These data suggested that A549 cells were more sensitive to the 
treatment with Doxo compared to A549 DX, confirming the drug-resistant phenotype of this 
cell line. Both cell lines were more responsive to LipoDoxo-gH625 compared to LipoDoxo. 
These data suggested that the conjugation of liposomes with gH625 probably facilitated the 
entry and retention of doxorubicin in both sensitive and drug-resistant tumor cell lines 
allowing an increase of cell growth inhibition. 
 
Doxorubicin accumulation in A549 and A549 Dx cell lines  
The accumulation of doxorubicin, free or encapsulated in liposomes conjugated or not with 
gH625, was investigated by flow cytometry analysis as reported in “Materials and Methods”. 
A time-dependent accumulation of free and encapsulated Doxo was observed in A549 and 
A549 Dx cells and the maximal levels were reached after 24 h (Figure 4 and 5). Moreover, 
LipoDoxo-gH625 induced in both cell lines a greater doxorubicin accumulation than 
LipoDoxo (Figure 4 and 5). In details, A549 Dx cells showed an early accumulation of 
doxorubicin after 3 h of treatment with both liposomal formulations and the accumulation 
was higher if compared to the one observed in parental A549 cells (Figure 4 and 5). This 
effect was more evident in resistant cells treated with LipoDoxo-gH625 that induced an 
increase of about 86.9 % of MFI against an increase of about 64.3 % of MFI induced in 
parental cells (Figure 5 and 4, respectively). Moreover, after 24 h we observed a two-fold 
increase of percentage of MFI in A549 Dx cells treated with LipoDoxo-gH625 if compared 
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to those exposed to LipoDoxo (Figure 5). Similar data were also obtained in parental cells 
but to a lesser extent (Figure 4). Therefore, these data suggested that the conjugation of 
liposomes with the viral peptide increased the retention of doxorubicin into the cells 
supporting the data obtained on the growth inhibition. 
 
Evaluation of oxidative stress in A549 and A549 Dx cells 
The effects of doxorubicin and liposomes encapsulating doxorubicin conjugated or not with 
gH625 were also evaluated for analyzing the accumulation of superoxide anions (O2
−) in 
either parental or doxorubicin A549 cells, as reported in “Materials and Methods”. In both 
cell lines free doxorubicin induced a time-dependent accumulation of superoxide anions 
(Figure 6 and 7) significantly lower compared to that induced by both liposomal 
formulations. In details, the maximal O2
− level increase in A549 cell line was detectable after 
48 h of treatment with LipoDoxo. LipoDoxo-gH625 induced an accumulation of O2
− lower 
than LipoDoxo but this effect was maintained up to the end of treatment (72 h) differently 
from LipoDoxo (Figures 6). On the other hand, both formulations induced similar effects on 
A549 Dx cells after 24 h of treatment, but a significant increase of oxidative stress was 
observed after 72 h of treatment with LipoDoxo-gH625 if compared to the one induced by 
LipoDoxo (Figure 7). In both cell lines NAC had no effect on the increase of O2
− levels in 
contrast to H2O2 and acted as a scavenger in combination with H2O2 (Figures 6 and 7) 
decreasing the accumulation of superoxide anions.  The data obtained on oxidative stress 
suggested a greater internalization of LipoDoxo-gH625 than LipoDoxo in A549 Dx after 72h 
of treatment.  
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Evaluation of cell death in A549 and A549 Dx cells 
A further experiment was performed to evaluate the effects of Lipo, LipoDoxo-gH625, 
LipoDoxo and Doxo in inducing apoptosis or necrosis as reported in “Materials and 
Methods”. In agreement with the data obtained from the MTT assay, empty liposomes did 
not induce any significant toxic effects on both cell lines at any time-point tested (Figure 8 
and 9). In contrast, LipoDoxo caused an accumulation of about 27.7% necrotic cells in 
parental A549 and about 21.1% of late apoptotic cells were recorded after 24h. This effect 
was more marked when using LipoDoxo-gH625 with about 41.8% of necrotic cells and 
about 23.3% of apoptotic cells (Figure 8). On the other hand, LipoDoxo induced late 
apoptosis in about 5.5% of A549 Dx cells while necrosis was recorded in about 36.5% of 
A549 DX cells after 24h of treatment (Figure 9). This effect was potentiated also in 
doxorubicin-resistant cells by LipoDoxo-gH625 that caused about 3.8% of late apoptosis and 
about 50.5 % of necrosis (Figure 9). Free doxorubicin induced more significant effects on 
A549 cells than on A549 Dx cells but to a lesser extent. In fact, it caused an accumulation of 
about 25.7% and 16.4% of necrotic cells in A549 and A549 Dx cells, respectively (Figure 8 
and 9, respectively).  
On the basis of these results, it can be suggested that LipoDoxo-gH625 induced more 
significant effects on cell death in both cell lines, but with different mechanisms. In fact, we 
have found that the main mechanism by which LipoDoxo caused cell death in parental A549 
was necrosis while it caused apoptosis in doxorubicin-resistant counterpart. These effects 
were potentiated by LipoDoxo-gH625 in both experimental cell models (Figure 8 and 9). 
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Intracellular distribution of Doxo in A549 and A549 Dx cells  
In order to investigate the intracellular distribution of the different formulations, the Doxo 
fluorescence associated to the cells was evaluated by confocal laser scanning microscopy 
(CLSM). A549 and A549 Dx were incubated with IC50s of free Doxo, LipoDoxo and 
LipoDoxo-gH625 for 6 and 24 h. After 6 h, free Doxo and LipoDoxo-gH625 entered A549 
cells and translocated into the nucleus as indicated by the red fluorescence in the center of 
the cell body (Figure 10 A) while LipoDoxo accumulate in the cytoplasm, without entering 
into the nucleus (Figure10 A). In fact, cell nuclei are dark and only few red fluorescent spots, 
distributed in the cytoplasm, are visible. No fluorescence was observed in A549 treated with 
empty liposome as expected. On the other hand, in A549 Dx free Doxo was not able to enter 
into the nucleus accumulating in perinuclear region while CLSM results showed a 
widespread and intense fluorescence, with intranuclear red spots for cells incubated with 
LipoDoxo-gH625 (Figure 10 B). Cells treated with LipoDoxo evidenced a significant lower 
fluorescence intensity, with visible red spots into the cytoplasm (Figure 10 B). We observed 
a time-dependent uptake of free and encapsulated Doxo and the maximal levels were reached 
after 24 h in both cell lines (Figure 11 A and B) Therefore, the intracellular uptake of 
liposomes armed with gH625 could contribute to overcome resistance in lung 
adenocarcinoma cell lines 
 
Conclusions 
A major challenge in cancer therapy is the inability to deliver the chemotherapeutic agents to 
target tumor cells and tissues selectively, resulting in severe side effects to normal tissues and 
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organs. Nanotechnology has the potential to promote delivery of drugs improving specificity 
and enhancing the uptake.29-31 Moreover, the multidrug resistance (MDR) represents the 
principal mechanism by which many cancers develop resistance to chemotherapy, and poses 
the major obstacle to the successful clinical treatments of cancers.32,33  
Due to these problems, it is highly important to explore alternative strategies for utilizing 
currently available drugs against MDR cancer cells. The mechanism of drug action is an 
important design constraint in defining where the drug must ultimately be delivered. For 
many platforms designed for intracellular delivery, uptake occurs by an endocytic pathway. 
Although endocytic pathways can be very efficient in internalization, drug release and 
endosomal escape are key challenges in achieving high therapeutic efficacy.  
Thus, current challenges include developing platforms with improved biodistribution, 
pharmacokinetic properties, and active targeting. While various active targeting strategies 
have been explored, there are no FDA-approved platforms4,34 highlighting the difficulties in 
reliably improving accumulation at the tumor site with active targeting. 
Doxil is a liposomal formulation of doxorubicin, which was FDA-approved for AIDS-related 
Kaposi's sarcoma in 1995, for ovarian cancer in 1999, and for multiple myeloma in 2007. In 
2013 the use of the generic version Lipodox was approved for treatment of ovarian cancer 
and Kaposi's sarcoma 1. Doxil is formulated from a combination of fully hydrogenated soy 
phosphatidylcholine (HSPC), cholesterol, and a lipid with a polyethylene glycol (PEG) head 
group (DSPE-PEG2k) in a mole ratio of 56.4:38.3:5.3. The DSPE-PEG provides a polymer 
coating that can inhibit protein adhesion and prolong evasion of mononuclear phagocytic 
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system (MPS) 4,12. Such coatings lead to long circulation half-times (3–4 days in humans) 
and are essential to achieve significant passive accumulation at a tumor site.  
Successful design of nanosystems to treat tumor effectively requires the appropriate surface 
modification to enhance the uptake; in fact, the activity of cytotoxic drugs that are 
internalized by cells depends also on their concentration and availability in the cell cytosol 
and nuclei. Peptide gH625 represents a novel opportunity to overcome the known limits of 
classical CPPs and proved to be successful for delivery of several molecules, therefore was 
chosen in our study to increase the cell internalization of liposomes into cells. 
The different  phospholipids used to prepare the liposomes investigated in the present study 
are of paramount importance to determine the uptake and mechanism of internalization. We 
have previously reported preliminary results on the internalization of DOPG liposomes 
decorated on their surface with gH625 and we proved that gH625 allowed to modify the 
mechanism of internalization of Doxo, but the eukaryotic membranes are zwitterionic; thus 
DOPG, being negatively charged, does not well mimics eukaryotic cell membranes. In this 
study we used liposomes with enhanced biomimetics characteristics (phospholipids derived 
by soy) and functionalized on their external surface with PEG.  
The presence of gH625 on the surface of liposomes is favouring their uptake in both 
sensitive and drug-resistant tumor cell lines allowing an increase of cell growth inhibition: in 
fact, a greater quantity of Doxo from functionalized liposomes is accumulated into cells. A 
higher oxidative stress is obtained after treatment with functionalized liposomes for 72 h 
indicating that probably also other mechanisms contribute to the activity in presence of 
gH625. Doxo encapsulated in functionalized liposomes was able to enter in the nuclei of 
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Doxo-resistant cancer cells indicating that the peptide gH625 was probably inducing a 
greater and more rapid internalization also in resistant cells, which could contribute to 
overcome drug resistance 35.  
In conclusion, further details have been shed on the mechanism of internalization promoted 
by gH625 which clearly indicates that this translocating peptide hold promise for the 
development of a platform for cancer therapy. 
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Tables 
 
Table 1. Zeta potential, size, expressed as z-average, as measured by DSL and 
polydispersivity index (PDI). Data are expressed as means±standard deviation (SD) of three 
separate experiments for each of two batch formulations, with at least 13 measurements for 
each. 
Liposomes Average Size (nm) PDI Zeta potential (mV) 
Lipo 104.95±1.63 0.17±0.01 -7.40±1.50 
LipoDoxo 129.85±1.82 0.15±0.03 -7.43±1.84 
LipoDoxo-gH625 143.90±0.64 0.14±0.02 9.43±1.61 
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Table 2. IC50 values of the different formulations Concentration inhibiting 50% of cell 
growth (IC50) reached after 72 h of treatment with Lipo, LipoDoxo, LipoDoxo-gH625, 
Doxo in A549 and A549 Dx cells. Data are shown as mean ± SD. 
Compounds IC50 ± SD A549 IC50± SD A549 DX 
Lipo >5 µM ± 0.02 >5 µM ± 0.01 
LipoDoxo 2.5 µM ± 0.01 5 µM ± 0.02 
LipoDoxo -gH625 0.5 µM ± 0.01 2.7 µM ± 0.04 
Doxo 0.06 µM ± 0.03 0.2 µM ± 0.01 
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Figure 1. Scheme of the functionalization reaction of gH625 to LipoDoxo 
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Figure 2. Release profile of doxorubicin from liposomes at 37 °C in HEPES-
NaCl buffer (a) and in HEPES-NaCl buffer with 50% FBS (b). 
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Figure 3. Evaluation of cell growth in lung adenocarcinoma cell line sensistive 
(A549) and resistant (A549 Dx) to doxorubicin after 72 h of treatment with 
Lipo, LipoDoxo, LipoDoxo-gH625 (A- B) and doxorubicin (DOXO) (C). 
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Figure 4. Doxorubicin accumulation in A549 cells after 3, 6, 12 and 24 h of 
treatment with LipoDoxo, LipoDoxo-gH625 and Doxo. (A) Flow cytometry 
overlay of Doxo fluorescence intensity. (B) Histogram of Doxo mean 
fluorescence intensity (% of control). The bars represent means ± SD of three 
independent experiments. Asterisks indicate significant difference between 
LipoDoxo vs LipoDoxo-gH625 (**P<0.01) (*P<0.05) 
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Figure 5. Doxorubicin accumulation in A549 Dx cells after 3, 6, 12 and 24 h of 
treatment with LipoDoxo, LipoDoxo-gH625 and Doxo. (A) Flow cytometry 
overlay of Doxo fluorescence intensity. (B) Histogram of Doxo mean 
fluorescence intensity (% of control). The bars represent means ± SD of three 
independent experiments. Asterisks indicate significant difference between 
LipoDoxo vs LipoDoxo-gH625 (**P<0.01) (*P<0.05). 
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Figure 6. Evaluation of oxidative stress in A549 cells after 24, 48 and 72 h of 
treatment with LipoDoxo, LipoDoxo-gH625 and Doxo. A) Flow cytometry 
overlay of dihydroethidium (DHE) fluorescence intensity. (B) Histogram of 
DHE mean fluorescence intensity (% of control). The bars represent means ± 
SD of three independent experiments. Asterisks indicate significant difference 
between LipoDoxo vs Doxo and LipoDoxo-gH625 vs Doxo (**P<0.01) 
(*P<0.05). 
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Figure 7. Evaluation of oxidative stress in A549dx cells after 24, 48 and 72 h of 
treatment with LipoDoxo, LipoDoxo-gH625 and Doxo. (A) Flow cytometry 
overlay of dihydroethidium (DHE) fluorescence intensity. (B) Histogram of 
DHE mean fluorescence intensity (% of control). The bars represent means ± 
SD of three independent experiments. Asterisks indicate significant difference 
between LipoDoxo vs Doxo and LipoDoxo-gH625 vs Doxo (**P<0.01). 
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Figure 8. Evaluation of apoptosis in A549 cells by Annexin V/PI assay (flow 
cytometry) after 48 h of treatment with LipoDoxo, LipoDoxo-gH625 and Doxo. 
(A) Flow cytometry dot plots. (B) Histogram of data expressed as percentage of 
viable cells, early/late apoptotic cells and necrotic cells after 3, 6,12 and 24 h. 
The bars represent means ± SD of three independent experiments. Asterisks 
indicate significant difference between LipoDoxo-gH625 vs Doxo (**P<0.01). 
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Figure 9. Evaluation of apoptosis in A549dx cells by Annexin V/PI assay (flow 
cytometry) after 48 h of treatment with LipoDoxo, LipoDoxo-gH625 and Doxo. 
(A) Flow cytometry dot plots. (B) Histogram of data expressed as percentage of 
viable cells, early/late apoptotic cells and necrotic cells 3, 6, 12 and 24 h. The 
bars represent means ± SD of three independent experiments. Asterisks indicate 
significant difference between LipoDoxo-gH625 vs Doxo (**P<0.01). 
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Figure 10. Confocal microscopy images of A549 (A) and A549 Dx (B) cells after 
6 h incubation with free Doxo, LipoDoxo, or LipoDoxo-gH625. On the left, 
merged image (green vimentin; red doxo; blue dapi). On the right, Doxo 
distribution. 
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Figure 11. Confocal microscopy images of A549 (A) and A549 Dx (B) cells after 
24 h incubation with free Doxo, LipoDoxo, or LipoDoxo-gH625. On the left, 
merged image (green vimentin; red doxo; blue dapi). On the right, Doxo 
distribution. 
 
 
